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Community epidemiological surveys that examined the prevalence of psychiatric disorders have been conducted since the end of World War 
II.1,2 We now know that up to half the general population meet criteria for one 
or more lifetime DSM disorder.3 Depressive disorders are the most frequent 
psychiatric problem with a life- time incidence of around 25%. Although 
the published reports of high prevalence estimates initially were met with 
a good deal of scepticism, clinical reappraisal showed that they were accu-
rate.4 Public health experts now acknowledge that depression is one of the 
most important causes of disability world wide. Some expect it to become the 
number one cause of disability and premature death by 2020.5 
More than 100 years ago psychiatrists began to systematically study bio-
logical factors as a cause of late life depression. In 1905 Gaupp, a college 
of Kraepelin in Munich, published the results of a case series of 300 patients 
aged 45 years and above consecutively admitted to the university psy-
chiatric clinic in Heidelberg.6 He delineated a subgroup of 23 patients that 
had “arteriosklerotische depressive Erkrankungen”. Twenty years later the 
German psychiatrist Gilarowsky-Moskau took up the thread and proposed to 
systematically study atherosclerosis in the depressed elderly.7 He concluded 
“es is schwierig, irgendwelche statistischen Schlüsse in bezug auf eine so ger-
inge und schwer differenzierbare Gruppe zu machen”. He also suggested to 
investigate “vasomotorische Störungen” because they reinforced “die mit der 
Arteriosklerose verbundenen psychischen Veränderungen”. The efforts of 
German psychiatrists ended abrupt due to the impact of political despotism 
on individual careers and on the direction taken by scientific research. It was 
the British psychiatrist Post who resumed the study of vascular disease in the 
development of late life depression in the 1960s.8 Another twenty years later, 
the advent of magnetic resonance imaging and other neuroimaging tech-
niques made it possible to evaluate subtle vascular changes of the brain.9 
Vascular factors in late life depression were subsequently rediscovered by 
American psychiatrists.10 
The contributions of immune mediators to the pathogenesis of psychiatric 
disorders have also been studied for over 100 years. In 1927 Wagner-Jauregg 
was the first of three psychiatrists ever to receive the Nobel prize. He had 
noted that the mental status of patients with fever improved and began treat-
ment of dementia paralytica (syphilis) with the malaria virus.11 Thousands of 
patients world-wide were treated with fever therapy until the introduction of 
penicillin. East German psychiatrists in the 1970s still induced local anaphy-
HT1.indd   3 04-02-2003, 19:25:04
BIOLOGICAL FACTORS IN LATE LIFE DEPRESSION
4
lactic reactions in attempts to treat depressive psychoses.12 For decades mood 
disorders were related to a depressed immune system only.13 The first report 
that considered a quantitative measure of the immune system in depressive 
disorders was published in 1978.14 Since then, numerous investigators have 
compared immune markers of depressed persons with apparently healthy 
controls and more recently, showed an immune activation in depressed sub-
jects.15,16
This thesis presents population-based studies of late-life depression. Biological 
correlates of depression were examined in community-dwelling persons. Our 
aim was not to detect a biological marker but to evaluate possible risk factors 
of depression. Many physiological measures have only been studied in clini-
cal samples, others in population-based studies without careful assessment of 
depression and some have never been related to depression - such as arterial 
stiffness or vasomotor reactivity assessed by a Doppler technique. The basic 
idea of the thesis is, that it is possible to learn something about causes of 
depression if correlates are studied carefully. In chapter 2 we examined the 
physical health of depressed persons by constructing a frailty index. Chapter 
3 is devoted to the associations of vascular pathology with depression in the 
elderly. In chapter 4 the role of immunological, nutritional and metabolic 
factors in late life depression are explored. Finally, in chapter 5 the reader 
will find a reappraisal of the formal and material aspects of the study. The 
chapter addresses the hypotheses our studies have generated and gives an 
outlook on future research. 
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ABSTRACT
Depression in the elderly is closely related to physical health. However, methodological 
problems arise when physical health is measured. A comprehensive assessment of somatic 
diseases is complex and possibly ineffi cient and self-reported measures may be biased in 
depressed persons. The aim of this study was to quantify the physical health of depressed 
persons and compare it to non-depressed persons. The authors used data from a large pro-
spective population-based study of 4553 persons aged 55 and over (mean follow-up 9.3 
years) to develop a study-specifi c index of physical health. A multivariate score function 
was derived using baseline information on all available variables independently related to 
mortality. Demographic factors, medical problems, functional disabilities and indicators 
of health service use were included in the index. However, most variables were based on 
physiologic measurements. Another score function was obtained by adding subjective 
items. Physical health of depressed (n=190) and non-depressed (n=2705) persons was 
assessed using data from a subsequent examination round. The association between the 
frailty score and late life depression was calculated with logistic regression. Odds ratio (OR) 
were 1.5 (95% confi dence interval (CI): 1.3, 1.9) per standard deviation of score without 
subjective items and 1.7 (95% CI: 1.4, 2.0) for the score with subjective items. This was only 
moderately less than the association between the frailty score and stroke in older adults 
(OR: 1.7, 95% CI: 1.3, 2.2 and OR: 1.8, 95% CI: 1.4, 2.3, respectively). There was no indica-
tion that poorer health is related to more severe depressive disorders nor that a depressed 
subpopulation without somatic comorbidity can be distinguished in community-dwelling 
elderly. Nevertheless the score can be used to stratify populations into risk-homogenous 
subgroups by quantiles. The authors conclude that a frailty index is an appropriate tool to 
study the mortality risk and etiology of late life depression. 
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INTRODUCTION
Depressive disorders in the elderly are intimately related to physical health.1-3 
Studies comparing the relative impact of risk factors found an overwhelming 
effect of physical illness on late life depression. Poor physical health largely 
explains the increase of depressive syndromes with age.4 Compared to social 
support, life events, stress or genetic factors, physical health has the strongest 
correlation to depression in older community-dwelling adults.5,6 
However, some methodological problems arise when physical health is 
assessed and quantified in depressed persons. Firstly, subjects who become 
depressed may report more negatively about their health.7 This can bias self-
report measures.8 Secondly, depression and somatic disease may exhibit the 
same symptoms such as lack of concentration or appetite. An artificial cor-
relation may result if rating scales are used to measure depression or physical 
health. Other problems encountered in the measurement of physical health 
are not specific for depression. Physical health can be conceptualized as spe-
cific pathology, impairment or functional limitations but combined measures 
are not available.9,10 Furthermore, a comprehensive assessment of somatic 
diseases is very complex and possibly inefficient.
In most studies on late life depression, the investigators relied on self-
reported measures of physical health. Besides assessing functional limita-
tions, the number of comorbid conditions is simply summed and the resulting 
variable categorized.2,4 This limits the understanding of the relation between 
physical health and depression. Weighing a select number of self-reported 
diseases equally makes comparisons of physical health disputable. It has 
remained unclear whether poorer physical health is associated with more 
severe depressive symptoms and whether distinct groups of elderly depressed 
subjects exist, those with ‘pure depression’ and those with somatic comorbid-
ity.11 
In the present study we constructed a study-specific score to assess physi-
cal health using all available correlates of mortality. Our assumption was that 
true comorbidity is related to worse health outcomes, of which mortality is the 
most straightforward and reliably measured. The primary aim of our study 
was to quantify the physical health of depressed subjects in order to examine 
whether subpopulations of depressed persons can be identified. Secondly, 
we wanted to compare the health of persons with different diseases. Finally, 
we give an example to show how a health score can be used in etiological 
HT2.indd   9 04-02-2003, 19:23:57
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research.
METHODS
Study population
This study is part of the Rotterdam Study, a population based cohort study 
of chronic and disabling diseases in the elderly.12 All inhabitants of a district 
of Rotterdam aged 55 years or over were invited. People living in homes for 
elderly were also included. In total, 7983 subjects of those invited participated 
(78% response rate). The Medical Ethics Committee of Erasmus University Rot-
terdam approved the study. Written informed consent was obtained from all 
participants. Baseline measurements were performed from 1990 to 1993 and 
consisted of an interview and two visits to the research center for physical 
examination. 
The frailty index
We constructed a study-specific measure of physical health. Because of the 
absence of a gold standard we assumed that good health is associated with 
survival. All variables that correlate with mortality can thus be considered 
as indicators of poor physical health. To derive specific weights for these 
variables we developed a Cox-regression model with the binary variable 
alive/dead as the outcome. First, we selected all variates of the baseline 
data set that were related to mortality in an age- and gender-adjusted model. 
Secondly, we allowed these variates to compete for entry in a stepwise pro-
cedure. All variates that were not independently associated with mortality 
(p<0.1) were removed. The regression coefficients (betas) of retained variates 
constituted the score function. In the function all variates were entered as 
additive terms. Thus a particular value can be computed for each subject. 
The result is a unidimensional score for physical health. Because the score 
function included items not traditionally considered health indicators we 
termed it ‘frailty index’.
The variates entered into the age-and gender-adjusted survival analyses 
included demographic and social factors, the presence of major medical 
problems, and risk indicators assessed by interview or physiologic measure-
ment. We also tested indicators of functional limitations or disabilities as well 
as variates indicating health service use. The variates included in the score 
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TABLE 1: Selected characteristics of the study subjects in the third examination round 
(Rotterdam Study 1997-1999)
Variates included in the frailty index*
Non-
depressed
(n=2705)
Depressive 
symptoms
(n=190)
Demographic characteristics
     Age, years, mean  73  75
     Gender, % female  56  73
Diagnoses established with physiologic measurements
     Diabetes, %  9  11
     Peripheral arterial disease, %  17  20
     Atrium fi brillation, %  3  1
Diagnoses established by questioning
     Myocardial infarct, %  11  13
     Cancer in last fi ve years, %  10  17
Risk indicators established with physiologic measurements
     Diastolic blood pressure, mmHg ¶  75  73
     Systolic blood pressue, mmHg  144  141
     Cholesterol, mmol/l ¶  5.8  5.8
     Carotid plaques, number  1.8  1.9
     Intima media thickness, mm  0.87  0.88
     Bone mineral density, T score  0.85  0.83
     Cognitive score  28  27
     Body mass index, kg/m2  26.8  26.9
Risk indicators established by questioning
     Smoking current, %
 former, % 
 16
 52
 20
 44
     Dyspnoe, %  34  54
Health service use and medication
    Visits to specialist per year (more than one)  44  55
    Number of medication taken daily (more than one)  42  56
Functional disabilities and limitations
     Problems with riding a bicycle, %  55  77
     Activities of daily life score  0.5  0.9
Personal health assessment‡
     Health compared to members of age groups good, %
 bad, %
 54
 10
 37
 22
     Memory complaints, %  36  63
* Note that C-reactive protein, creatinin, and unintentional weight loss in last three months were not 
included in the index because no data was available from the third examination round. History of 
fractures was not included because of a negative association of the baseline variable with mortal-
ity, whereas the association of a time dependent variable with mortality was positive.
† The category depressive symptoms includes all subjects with a score on the Center of Epidemio-
logical Studies for Depression scale of 16 and above.
¶ Diastolic blood pressure and cholesterol were additionally entered into the index as squared terms. 
This accounted for the fact that both high and low levels were negatively associated with survival.
‡ The primary frailty index was calculated without these subjective variables.
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function are listed in table 1. 
For certain conditions or risk indicators the association with mortality was 
not independent of other variates (e.g. dementia, stroke, left ventricular 
hypertrophy diagnosed by electrocardiogram, albumin level, angina pec-
toris, instrumental activities of daily living score, number of chronic condi-
tions, or use of antihypertensive medications). Consequently, these were 
not included in the frailty function. A second frailty score (with subjective 
items) was obtained by additionally including personal health assessments 
(e.g. subjective memory function), which were possibly related to depression. 
Again only variates were retained that independently predicted survival.
The frailty indexes were based on the data of 4553 subjects who par-
ticipated in the baseline examination and had complete information on the 
selected variables. During 42,479 person years of follow-up (mean follow-up 
9.33 years) 1188 deaths occurred before October 1st 2002, end of follow-up. 
However, assessment of depressive symptoms was added to the study proto-
col only in the third survey (1997-1999). Thus the actual frailty score in the 
present study is calculated with data from the third survey, whereas the func-
tion is derived from baseline data. Three variates, the inflammation marker 
C-reactive protein (CRP), urinary creatinin and unintentional weight loss, that 
were associated with mortality have not been assessed in this 3rd examina-
tion round. Thus the final model was adapted, rerun and the weights of the 
score function changed to account for this.
Assessment of baseline variables
Measurements of all variables have been described in previous publica-
tions.12-14 Information on smoking, history of cancer in the last five years, 
congestive heart failure, number of visits to specialist, medications, ability 
to ride a bike, memory complaints, and personal health judgment were 
obtained during the home interview. We used the Disability Index of the 
Stanford Health Assessment Questionnaire and a 9-item Instrumental Activi-
ties of Daily Living score to establish the functional status and disabilities.15,16 
Cognitive function was measured by the Mini Mental State Examination. His-
tory of myocardial infarction was primarily assessed by direct questioning 
but only self-reported events confirmed by additional information of general 
practitioner or specialist were taken into account. Diabetes was defined as 
random or postload serum glucose higher than 11.1 mmol/l or use of anti-
diabetic medication. Serum cholesterol and CRP levels were assessed by an 
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automated procedure in non-fasting blood, creatinin levels were assessed 
in urine. A standard 12-lead electrocardiogram was recorded and analyzed 
using a computer program to detect atrium fibrillation. Bone mineral density 
measurement of the femoral neck was performed by X-ray absorptiometry. 
Ankle-brachial systolic blood pressure index was used as an indicator of 
peripheral arterial disease. Intima-media thickness and plaques in the carotid 
arteries were determined by an ultrasound technique and used as indicators 
of subclinical atherosclerosis.
Depression assessment
In the third examination we added assessment of depressive symptoms to 
the study protocol. Depressive disorders were diagnosed using a two step 
procedure. First, participants were screened for depressive symptoms with 
the Dutch version of the original Center for Epidemiologic Studies Depression 
scale (CES-D) during the home interview. We used a score of 16 as a cut-off. 
Previous studies in the Netherlands have verified that this score represents 
clinically significant depressive symptoms and has a very high sensitivity for 
major depression in older subjects.17 As a second step, screen positive subjects 
had a semi-structured psychiatric interview with the Schedules for Clinical 
Assessment in Neuropsychiatry.18 Psychiatric disorders were classified accord-
ing to the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) 
criteria.19 The diagnostic categories include major depression and dysthymia 
in addition to minor depression (as defined in the appendix of the DSM-IV).
Of the 4703 subjects who participated in the home interview of the third 
examination, 2973 had information on all variables included in the frailty 
index. Of these, 197 (6.6%) were screen-positive on the CES-D and in 184 
(93%) psychiatric interviews had been conducted. The psychiatric interviews 
revealed that 78 cases had a depressive disorder according to DSM IV crite-
ria. The remaining 106 subjects were diagnosed as having either anxiety or 
another psychiatric disorder (n=18) or did not meet criteria for an axis I psy-
chiatric disorder (n=88, subthreshold depressive symptoms). 
Assessment of stroke and age-related maculopathy
The frailty index was used to compare the physical health of persons with 
depression to those with a history of stroke and those with age-related macu-
lopathy. Neither stroke nor indicators of eye disease were included in the 
frailty index, because they did not predict mortality independent of other 
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variates. Stroke is a leading cause of death and disability in the Netherlands. 
Subjects participating in the Rotterdam Study were continuously monitored 
for stroke through automated linkage of the study database with the files 
from general practitioners. Additional information is obtained by scrutinizing 
hospital discharge records.20 Age-related maculopathy is the most important 
cause of incurable blindness in the elderly. A positive association of eye dis-
eases with mortality has been reported.21 Like depression, the presence of 
age-related maculopathy was established in the third examination round. 
The screening and diagnostic procedure have been described in detail else-
where.22 Color transparencies were taken of the macula area and graded in a 
detailed manner to identify all features of age-related maculopathy. Subjects 
with early stages of the disease were also included.
Data analysis
The frailty score was logistically transformed after adding 4.7 to avoid 
negative values. Through this computation a normal distribution in the non-
depressed persons was achieved. Thereafter we divided the score by its stan-
dard deviation, which yields more meaningful values. Secondly, we assessed 
the association of frailty with depressive symptoms, depressive disorders and 
subthreshold depressive symptoms using age- and gender-adjusted logistic 
regression. Thirdly, the distribution of the frailty score in subjects with depres-
sive symptoms was examined in order to study whether latent subpopula-
tions with depression exist. For the graphical presentation the frailty score 
was categorized in 25 categories with equal ranges. Next, the association 
of the frailty score with stroke and age-related maculopathy was quantified 
with logistic regression. Finally, we illustrate the use of the frailty score in etio-
logic research. For this aim, we stratified the population at the median of the 
frailty score in two groups more homogenous for physical health. The relation 
between cytokine interleukin-6 and depression was examined in the resulting 
strata. Interleukin-6 is an inflammatory protein that indicates immune acti-
vation and can be measured in plasma. Numerous small hospital and two 
population-based studies have reported an association between depression 
and interleukin-6.23,24 
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RESULTS
The characteristics selected for the frailty score in persons with and without 
depressive symptoms are presented in table 1. All indicators of frailty were 
found to be more frequent or had higher levels in the depressed persons 
except atrium fibrillation and male gender. 
Table 2 shows the relation of the frailty scores with depressive symptoms. 
The odds ratio of depressive symptoms increased by 50% per standard devia-
tion of frailty score without and by 70% of the score with subjective items. In 
a further analysis, screen positive subjects were classified according to the 
severity of the depressive symptoms. Persons with subthreshold depressive 
symptoms and subjects with DSM-IV depressive disorders were analyzed 
as distinct groups. Estimates for the association of the two frailty scores with 
depressive disorders and subthreshold depressive symptoms symptoms (data 
not shown) were exactly the same as for depressive symptoms (table 2). Thus 
we found no indication that more severe depressive disorders were associ-
ated with poorer health.
Figure 1 gives a graphical representation of the distribution of the frailty 
score in subjects with depressive symptoms. The distribution is normal 
(median: 5.5, interquartile range 4.9 to 6.1). No bimodal distribution was 
found and we could not identify latent classes in the group with depressive 
symptoms.
TABLE 2: The association of physical health with depression, stroke and age-related 
maculopathy assessed with a study-specifi c frailty index
Frailty score (per SD)
Depressive
symptoms*
(n=190)
History of stroke
(n=90)
Age-related
maculopathy*
(n=341)
OR (95% CI) OR (95% CI) OR (95% CI)
Without subjective items 1.5 (1.3, 1.9) 1.7 (1.3, 2.2) 1.1 (0.9, 1.3)
With subjective items† 1.7 (1.4, 2.0) 1.8 (1.4, 2.3) 1.0 (0.9, 1.3)
Results were obtained with logistic regression adjusted for age-and gender. See table 1 for list of 
variates included in the frailty index.
*The category depressive symptoms includes all subjects with a score on the Center of Epidemiolog-
ical Studies for Depression scale of 16 and above. The category age-related maculopathy includes 
subjects in early stages of the disease.
† This frailty index additionally includes memory complaints and judgement of health compared to 
members of same age group.
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The association of the frailty score with stroke was slightly stronger than 
with depressive symptoms (table 2). The unadjusted odds ratios (OR) of the 
frailty scores also suggested a relation between physical health and age-
related maculopathy (both OR were 1.5, 95% confidence interval (CI): 1.4, 
1.7). However, the association disappeared after adjustment for age and 
gender. 
Finally, we illustrate the use of the frailty score with an example of etio-
logical research. In a previous paper we reported on associations between 
depressive disorders and plasma concentrations of inflammatory proteins in 
the present study population.25 There was an association between cytokine 
interleukin-6 and depressive disorders after adjustment for age, gender, his-
tory of stroke, smoking and functional disability (OR per standard deviation: 
1.5, 95% CI: 1.2, 1.9). This odds ratio remained unchanged after exclusion of 
subjects in whom no frailty score could be calculated. We used the median of 
the frailty score to stratify the population according to subjects with relatively 
good (n=256, of which 36 subjects with depressive disorders) or relatively poor 
physical health (n=248, of which 38 with depressive disorders). Subsequently, 
we reran the analyses. There was no relation between interleukin-6 and 
depressive disorders in subjects with good health (OR: 1.2, 95% CI: 0.7, 1.9), 
only in those with relatively poor health (OR: 1.9, 95% CI:1.1, 3.3). In accor-
dance with this, we found that the interaction term between the frailty score 
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Figure 1   Distribution of physical health in persons with depressive symptoms
For this graphical representation the frailty score was divided in 25 categories with equal ranges. No 
subjects with depressive symptoms were found in the fi rst three categories.
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and interleukin-6 concentrations was associated with depressive disorders 
(p=0.04).
DISCUSSION
In this large population-based study we quantified physical health by con-
structing a study-specific frailty index. A multivariate score function was 
derived using baseline information on all available variables related to 
mortality. The score function was then used to assess the physical health of 
depressed and non-depressed persons with data from a following examina-
tion round. We found that persons with poor physical health were more likely 
to have depressive symptoms even when subjective measures of health 
were excluded. The association of the frailty score with depression was only 
moderately weaker than the association with stroke. There was no indication 
that poorer health was related to more severe depressive disorders nor that a 
depressed subpopulation without somatic comorbidity can be distinguished 
in community-dwelling elderly. 
Previous population-based studies of depression mostly relied on self-
reported measures of physical health only. Besides functional limitations, 
the number of chronic conditions was assessed. Participants were explicitly 
asked whether they have certain diseases.4,26 The result may be biased and 
‘number of co-occurring conditions’ is not considered an overall measure of 
physical health.8 This may explain why some investigators found an asso-
ciation between severity of depressive symptoms and poor physical health.27 
On the other hand, our observations are in line with the strong evidence that 
depressive symptoms in the elderly are frequently accompanied by very 
poor health.5,6,28 
It is a challenge to formalize the identification and measurement of 
physical disease for research purposes and different approaches exist.29 
Comorbidity scores are increasingly used in population-based research.30-32 
The popular instruments use a grading system which weigh either specific 
diseases or the severity of comorbidity within each organ system. For some 
diseases agreement between questionnaire and general practitioner data is 
poor (e.g. peripheral atherosclerosis).33 A recent review questioned the use of 
standardized comorbidity scores in epidemiological research.34 The indexes 
performed reasonably well in the setting they were developed for but added 
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little to adjustment or stratification for age in other populations. 
More recently epidemiologists have also developed frailty indexes to sum-
marize individual differences in health status.35-37 There is no common con-
cept of frailty but the aim of the indexes is to predict mortality.38 Most frailty 
indexes use items traditionally included in measures of functional limitations 
such as grip strength, gait abnormality or visual problems. These measures 
are frequently superior to ‘number of co-occurring conditions’ in the ability to 
control for morbidity risks in community-dwelling populations.35,39 However, 
functional limitations and disabilities capture only one aspect of disease and 
specific pathology is important for future health.
Another approach is to derive study specific weights to aggregate comor-
bidity information instead of using a standardized instrument. The outcome 
is modeled as a function of all comorbid conditions and regression scores 
are used to weigh individual diseases.34 In the present study we decided to 
aggregate all variables available related to mortality. The main advantages 
are that an overall measure of health is derived and different dimensions of 
health can be incorporated. Furthermore all available information is used 
and specific weights account for the quality of diagnostic data. We are not 
aware of a risk function or a index that has taken this approach to quantify 
physical health. 
However, the items used in our score to measure frailty are known to be 
related to mortality in older adults. In a seminal paper on the 5-year mortal-
ity in older adults the Cardiovascular Health Study Collaborative Research 
Group (CHS) identified 20 independent risk factors.40 The overlap is striking, 
14 of these characteristics were the same as in our study population. Minor 
differences originate from the availability of data, e.g. lung function was 
not assessed quantitatively in the Rotterdam Study. Other differences may 
be due to the population studied, the measurement technique, allowance 
for quadratic terms and the health care system. This probably explains why 
albumin, cholesterol, not being able to ride a bicycle or income are indepen-
dent risk factors of mortality in our or in the CHS study. 
Few clinical diseases that were assessed by history independently pre-
dicted mortality. Most of the conditions that characterize comorbidity scores 
compared badly to the variates incorporated in our index. We retained only 
cancer and myocardial infarction and included mostly objective, non-inva-
sive measures in our score. This is a strong argument to use a study-specific 
score if physiological measurements are available. Using only diagnoses 
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as established by interview leads to more misclassification. Further, many 
conditions are correlated, because of shared risk factors, common patho-
logical processes or their relation to health care use. Moreover, quantitative 
measures indicate both subclinical and clinical disease and do not dichoto-
mize diseased and non-diseased. They do not rely on arbitrary cut-offs and 
self-report, which is especially appealing if the physical health of depressed 
subjects is examined. 
There are some limitations to our study. The frailty score lacks a clear bio-
logical interpretation. Persons with the same score are at a similar mortality 
risk but with possibly very different patterns of risk factors.41 When persons are 
grouped on biological or functional characteristics they may seem relatively 
risk-homogenous. We have seen, however, that there are a large number of 
independent risk factors for mortality. Meaningful groups cannot be defined 
without data aggregation. Thus a score function is useful if exposure and out-
come are related to a large number of variates. However, it should be derived 
from an outcome relevant to the subject matter. In case a cardiovascular risk 
factor is studied one may want to use cardiovascular mortality as an out-
come, provided that there is no substantial misclassification of this outcome. 
Furthermore, the weights and the combination of items in our frailty index 
were study specific. The score function cannot be used across studies. How-
ever, only age and gender, the most simple and widely used “comorbidity 
scores”, are ubiquitously and accurately recorded in all studies. 
It should also be pointed out that our approach is less feasible if the psy-
chosocial impact of somatic diseases is the issue. There is good evidence 
that lack of controllability and functional limitations have a strong impact 
on mood in chronically diseased persons.42,43 This is a major conceptual dif-
ference between frailty and comorbidity. Comorbidity refers to co-occurring 
disease,29 frailty to mortality risk.38 Measures of subclinical disease fit better 
into the frailty concept. On the other hand, this makes it questionable to use 
mortality as the gold standard of a comorbidity index.44
Our approach is related to Miettinen’s multivariate confounder score and 
Rubin’s propensity score.45,46 All variates associated with an outcome or an 
exposure are summarized in these score methods. Diseases, functional and 
personal characteristics are aggregated with study specific weights. The mul-
tivariate confounder score appears to have fallen into disuse. It was shown 
to be flawed as a test of confounding.47 However, it was developed to enable 
stratification in fairly risk-homogenous subgroups. Indeed, with our frailty 
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index we could show that inflammatory proteins are only associated with 
depression in persons of relatively poor health. This suggests that immune 
activation may have a stronger effect in the presence of other pathological 
processes.
In summary, our frailty index allowed useful descriptive comparisons. 
Depressed persons have a much poorer health than persons with age-related 
maculopathy. They have a mortality risk which is comparable to persons who 
survived a stroke. This is consistent with the results of longitudinal studies that 
documented an increased mortality in depressed persons.48-50 However, quan-
titative assessments of disease were not performed in the population-based 
cohort studies. Control for disease severity was only possible in clinical stud-
ies that showed a high risk of depressed symptoms for further events.51,52 Thus 
two questions arise, (a) does confounding by subclinical disease explain the 
increased mortality in depressed community dwelling subjects, and (b) does 
depression increase the mortality risk predominantly in persons with poor 
health. This study showed that both possibilities must be investigated and that 
a frailty score may be an appropriate tool to study the latter question.
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ABSTRACT
Context: Depression in late life has been associated with vascular pathology. Several stud-
ies have demonstrated that persons with brain infarcts or cerebral white matter lesions are 
more likely to have depressive disorders. Furthermore, depression is related to the subse-
quent development of ischemic heart disease. However, whether atherosclerosis is related 
to depression in the general population has not yet been investigated.
Objective: To investigate the relation between atherosclerosis at different locations and 
depression.
Design: Cross-sectional population-based study.
Setting: The Rotterdam Study, a population-based cohort study.
Participants: 4019 men and women aged 60 and above in whom we assessed atheroscle-
rosis at different locations, including common carotid intima-media thickness, plaques in 
the carotid arteries, the ankle-brachial blood pressure index, and aortic atherosclerosis. 
An overall measure of extracoronary atherosclerosis was obtained in 3747 persons by 
computing the principal component of these extracoronary atherosclerosis measures. In a 
subgroup of 1874 persons we additionally measured coronary calcifi cations. 
Main Outcome Measure: All subjects were screened for depressive symptoms. Screen posi-
tive subjects had a psychiatric interview to diagnose depressive disorder. Logistic regres-
sion controlled for age, gender, cognitive score and cardiovascular risk factors was used to 
examine the association of the atherosclerosis measures with depression. 
Results: More severe extracoronary atherosclerosis was associated with a higher preva-
lence of depressive disorders. For every standard deviation increase the prevalence 
increased with 30%. Further, we found a strong relation of severe coronary and aortic cal-
cifi cations with depressive disorders (odds ratio: 3.8, 95% confi dence interval [CI]: 1.5-9.3 
and 2.0, 95% CI: 1.0-3.9, respectively).
Conclusions: Atherosclerosis and depression are associated in the elderly. Our population-
based study supports the existence of vascular depression. It suggests that in some elderly 
depressed persons a treatment more akin to the management of cardiac disease needs 
to be investigated.
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INTRODUCTION
Several lines of evidence suggest that there is a relation between vascular 
factors and late life depression. Both symptomatic and silent brain infarcts 
are associated with subsequent depression.1 Further, subtle white matter and 
deep grey matter abnormalities were found more frequently in depressed 
than in non-depressed persons.2 A vascular depression hypothesis has been 
proposed. It postulates that structural changes in the brain due to atheroscle-
rosis are of primary importance in late life depression.3,4 
On the other hand, depressive symptoms are also related to subsequent 
cardiovascular disease. Several prospective population-based studies of 
depressed persons showed an increased risk of myocardial infarct.5-8 How-
ever, none of these studies included measurements of vascular pathology 
that might underlie the observed association. Most clinical studies on the car-
diovascular risk associated with depressive symptoms did not assess athero-
sclerosis either but focussed on other measures like platelet function or heart 
rate variability.9  Epidemiological evidence for a link between atherosclerosis 
and depression in the general population is lacking. Moreover, the vascular 
depression hypothesis is mainly supported by neuroimaging studies. 
We examined the association between atherosclerosis at different loca-
tions in the body and depression in the Rotterdam Study, a large, community-
based population of the elderly subjects.  
METHODS
Subjects
The study was conducted as part of the Rotterdam Study, a population based 
cohort study ongoing since 1990 for which all inhabitants aged 55 and over 
of a suburb of Rotterdam were invited. The Medical Ethics Committee of the 
Erasmus University approved the study and written informed consent was 
obtained from all participants. In the third survey (1997 to 1999) we added 
assessment of depressive symptoms to the study protocol. Of the 5901 subjects 
that were invited, 4,730 persons (response rate 80%) participated in the home 
interview. Of these, 4019 came to the research center for non-invasive assess-
ments of atherosclerosis. The 711 subjects with no assessment of atherosclero-
sis were on average older (78 versus 72 years), more likely to be female (69% 
HT31.indd   29 04-02-2003, 19:22:41
BIOLOGICAL FACTORS IN LATE LIFE DEPRESSION
30
versus 58%) and had more depressive symptoms (11.8% versus 6.9%, overall 
prevalence 7.8%). 
Additionally, non-institutionalized participants younger than 85 years who 
had completed the third survey were invited for a coronary atherosclerosis 
scan at a second research site. Of the 3371 eligible subjects, 2263 agreed to 
undergo electron-beam computer tomography (CT). Because of archiving 
problems the scores of only 1986 participants were available for analysis.
Assessment of depression
Depressive disorders were assessed using a two step procedure. First, par-
ticipant completed the Dutch version of the original Center for Epidemiology 
Studies Depression scale (CES-D) during the home interview. The CES-D is a 
20-item self-reported measure of symptoms scored on a scale of 0 to 3 points.10 
We used a score of 16 as a cut-off to indicate depressive symptoms. This cut-off 
had a very high sensitivity for major depression in a random sample of older 
subjects in the Netherlands.11 Previous studies have verified that a score of 
16 and above on the CES-D represents clinically significant depressive symp-
toms.12 In a second step, screen positive subjects had a psychiatric work-up. 
They were evaluated by the Dutch version of the Present State Examination 
(PSE-10), a semi-structured psychiatric interview included in the Schedules for 
Clinical Assessment in Neuropsychiatry.13 All interviews were conducted by 
one or other of two experienced clinicians. Psychiatric disorders were classi-
fied according to the DSM-IV criteria with an algorithm based on the PSE-10 
scores. The diagnostic criteria include minor depression as defined in the 
appendix of the DSM-IV.
Of the 4019 subjects included in the analyses, 285 (7.1%) were screen-posi-
tive for depressive symptoms as measured by the CES-D. A psychiatric work-
up was performed in 259 (93 %) of these participants. Twelve subjects refused 
to participate in this evaluation; four screen positive subjects could not be 
reached. A depressive disorder as defined by the DSM-IV criteria was estab-
lished in 119 cases. The remaining subjects were either classified as anxiety 
disorders or other psychiatric diseases (n=30) or did not meet the criteria for 
an Axis I psychiatric disorder (n=110, subthreshold depressive symptoms).
Assessment of atherosclerosis
We measured atherosclerosis non-invasively with four established methods, 
i.e. the ankle-brachial blood pressure index, intima-media thickness in the 
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common carotid arteries, the presence of plaques in the carotid arteries and 
aortic atherosclerosis. These four measures assess extracoronary atheroscle-
rosis at different locations in the body. Furthermore, in a subgroup of partici-
pants we measured coronary atherosclerosis.
Ankle-brachial blood pressure index is an indicator of peripheral arterial 
disease.14 Systolic blood pressure at the right brachial artery was calculated 
as the mean of two consecutive measurements with a random-zero sphyg-
momanometer. A single systolic blood pressure reading was taken both at 
the left and the right posterior tibial artery with a Doppler ultrasound 8 MHZ 
transducer (Huntleigh 500 D, Huntleigh Technology, Bedfordshire, UK) while 
the subject was in supine position. In agreement with the approach followed 
by Fowkes et al., peripheral arterial disease was considered present when 
the ankle-brachial blood pressure index was lower than 0.90 in at least one 
leg.14 
Intima-media thickness was measured by recording of ultrasonographic 
images of both the left and right carotid artery, using a 7.5-MHz linear-array 
transducer (ATL Ultra-Mark IV, Advanced Technology Laboratories, Bethel, 
Washington, USA).15 The lumen-intima interface and the media-adventitia 
interface of the distal common carotid artery were measured off-line. The 
common carotid intima-media thickness was determined as the average of 
near and far wall measurements of both left and right side. 
The presence of plaques in the carotid artery was assessed by evaluating 
the ultrasonographic images of the common, internal, and bifurcation sites of 
the carotid artery for the presence of atherosclerotic lesions.16 Plaques were 
defined as a focal widening relative to adjacent segments and composed of 
calcified or non-calcified components. The total carotid plaque score of each 
subject was defined by summation of the presence of plaques at far and near 
walls of left and right sides at 3 locations. For the analyses we used four cat-
egories of plaque scores (no, 1, 2-3, and 4 or more plaques).
Atherosclerosis of the abdominal aorta was determined with a lateral x-
ray of the lumbar spine. Calcified plaques were considered present when 
linear densities were clearly visible in an area parallel and anterior to the 
lumbar spine.17 Values for the extent of calcification were scored according to 
the length of the involved area (<1 cm, 1-2.5 cm, 2.5-5cm, and >5 cm)
We used coronary calcifications as a measure of coronary atherosclerosis. 
Imaging of the epicardial coronary arteries was performed with an electron 
beam CT-scan (C-150, Imatron, San Francisco, USA). From the root of the 
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aorta through the heart 38 images were obtained with 3 mm slice thickness. 
Using Agatston’s method a calcium score was obtained by multiplying each 
area of interest with a factor indicating peak density within the area. We 
summated the scores for the calcifications to obtain a score for the entire epi-
cardial system.
Other measurements
Age, gender, cognitive function, education, cigarette smoking, total cho-
lesterol, blood pressure, history of myocardial infarction and stroke were 
considered as possible confounders. Cognitive function was assessed by the 
Mini Mental State examination. Education was measured on an ordinal scale 
and later dichotomized into low (primary education only) and high educa-
tion. Cigarette smoking was analyzed in categories of non-smoker, current 
and former smoker. Fasting blood samples were obtained from all subjects 
in this analysis and serum total cholesterol was determined using an auto-
matic enzymatic procedure. A history of myocardial infarction and stroke 
were obtained by direct questioning and computerized linkage with general 
practitioner medical records. It was considered positive when verified by a 
physician. 
Statistical analysis
The association of atherosclerosis with depression was analyzed in two ways. 
First, we assessed the relation of individual atherosclerosis measures with 
depressive disorders using logistic regression. Subjects who were screen posi-
tive for depressive symptoms but did not fulfill the DSM-criteria for depressive 
disorders were excluded. Intima-media thickness was entered into the model 
as a continuous variable divided by one standard deviation. Ankle-brachial 
blood pressure index, carotid plaques and aortic calcifications were analyzed 
in the categories defined above. For the coronary calcifications three calcium 
score categories were defined as described previously: 0 to 100, 101 to 500, 
and above 500.18
Second, we used the different extracoronary atherosclerosis measures to 
obtain an overall atherosclerosis score. A principal component analysis was 
performed. This is a standard procedure to combine related measures.19 Origi-
nal variables were replaced with a linear combinations of these variables. 
For this aim we used the continuous measure ankle-brachial blood pressure 
index, intima-media thickness, plaques in the carotid arteries and aortic ath-
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erosclerosis. We were able to reduce the four measures in our original data 
set to one principal component. The association with extracoronary athero-
sclerosis was studied by regressing depressive disorders on this continuous 
measure divided by its standard deviation. A principal component analysis 
increases the power to reveal relationships. Unlike other methods – such as 
the construction of a composite score – it does not rely on arbitrary cut-off 
points (categorizations). 
To check whether confounding existed we added the potential confound-
ers into the basic model, which already contained age (continuous) and 
gender. The variables were included in further analysis if the result differed 
meaningfully.20 The analyses were run with and without additional adjust-
ment for a history of stroke and myocardial infarction because they can be 
seen as an intermediate in the relation between atherosclerosis and depres-
sive disorders.
Of all 3747 subjects who had at least three measures of atherosclerosis 
performed, 742 had a missing value on the fourth measure. To decrease pos-
sible bias these missing atherosclerosis values can be filled in (imputed) using 
the multiple imputation method.21 Imputation is based on the correlation 
between the missing variable and other variables including the atheroscle-
rosis measures. This correlation can be estimated using the subjects in whom 
the measurement was performed. We followed the method described by Van 
Buuren et al.,22 which accounts for the uncertainty around estimated values. 
Imputations were performed with the Multivariate Imputations by Chained 
Equations (MICE©) statistical package. For the present analyses, imputed 
values were used for the principal component analyses only.
RESULTS
Table 1 presents characteristics of the non-depressed reference subjects and 
the cases with depressive disorders.
In table 2 the associations of the extracoronary atherosclerosis measures 
with depressive disorders are shown. There was a consistent pattern across 
the four locations at which atherosclerosis was measured. The persons with 
a more severe disease process were more likely to be depressed. For intima 
media thickness and severe aortic calcifications the relation with depressive 
disorders reached statistical significance.
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TABLE 1: Characteristics of the study subjects 
Non-depressed
(n=3734)
Depressive
disorders†
(n=119)
Age, years‡ 72.2 (61-97) 74.3** (61-87)
Gender, % female 56.7 72.3***
Primary education only, % 47.5 57.1
MMSE-score‡ 27.7 (2.0) 26.5*** (3.4)
History of stroke, % 2.8 8.4**
History of MI, % 11.3 17.4
Smoking: current smoker, %
 ex-smoker, %
15.9
50.4
19.3
39.5
Diastolic blood pressure (mmHg)‡ 
Systolic blood pressure (mmHg)‡
75 (11)
144 (21)
73 (12)
139* (24)
Total cholesterol‡ (mmol/l) 5.8 (1.0) 5.8 (1.0)
Common carotid intima-media thickness‡ (mm) 0.87 (0.15) 0.90 (0.16)
Peripheral arterial disease, % 16.8 21.8
Carotid plaques, % 70.2 73.8
Aortic calcifi cations, % 78.1 82.8
Coronary calcifi cations,¶ % 54.3 75.0
*p < 0.05; **p<0.01, ***p<0.001 for comparison with reference group; Continuous variables analyzed 
by Ancova and categorical variables by logistic regression, adjusted for age and gender were 
appropriate.
† The category “depressive disorders” includes persons with major or minor depression and dysthy-
mia. 
‡ Values are means and ranges for age, and means and standard deviations for MMSE-score and 
blood pressure, cholesterol, and intima-media thickness.
¶ Numbers for coronary calcifi cations were 1871and 36 in non-depressed and depressive disorder 
group, respectively
Table 3 shows that subjects with higher levels of coronary calcifications 
have substantially more depressive disorders than subjects without extracoro-
nary atherosclerosis do.
In table 4 we present the results based on the overall measure of athero-
sclerosis. Extracoronary atherosclerosis is related to depressive disorders if dif-
ferent measures are combined. The associations were very similar if imputed 
data of subjects with a missing atherosclerosis measurement were included. 
The odds ratio for this all case analysis was 1.27 (95% confidence interval: 
1.02, 1.59; p=0.03 with 102 cases with depressive symptoms and 3491 non-
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TABLE 2: Relation between different extracoronary measures of atherosclerosis and 
depression expressed as odds ratios*
Depressive disorders†
Cases/ Controls  Odds ratio (95% CI)
Intima-media thickness (per SD‡ increase) 102/3588 1.22 (1.01, 1.48)
Peripheral arterial disease$ 110/3580 1.15 (0.70, 1.88)
Carotid plaques: none
 mild 
 moderate
 severe
25/1037
19/ 646
29/1137
21/ 661
1.0
1.16
1.19
1.52
Referent
(0.64, 2.13)
(0.70, 2.03)
(0.83, 2.82)
Aortic calcifi cations: none
 mild 
 moderate
 severe
15/ 686
29/1112
13/ 699
29/635
1.0
1.20
0.86
1.99
Referent
(0.63, 2.29)
(0.40, 1.87)
(1.01, 3.94)
* Odds ratios were calculated with logististic regression adjusted for age, gender, total cholesterol, 
blood pressure, cognitive score, smoking and history of stroke and myocardial infarction. To test 
statistical signifi cance of the categorical variables we calculated overall p values for depressive dis-
orders with a test for trend. For carotid plaques we obtained p=0.20, for aortic calcifi cations p=0.06.
† The category “depressive disorders”includes cases with major or minor depression and dysthymia. 
Screen positive subjects with subclinical depressive symptoms, other psychiatric disorders or without 
a psychiatric work-up were excluded.
‡ SD = Standard deviation.
$ Peripheral arterial disease was defi ned as an ankle-brachial index below 0.90.
TABLE 3: Relation between coronary calcifi cations and depression expressed as odds 
ratios*
Depressive disorders†
Cases/ Controls  Odds ratio (95% CI)
Coronary calcifi cation: (0-100)
 (101-500) 
 (>500)
9/865
11/463
16/511
1.0
2.42
3.74
Referent
(0.97, 6.02)
(1.51, 9.25)
* Odds ratios were calculated with logististic regression adjusted for age, gender, total cholesterol, 
cognitive score, blood pressure, smoking and history of stroke. To test statistical signifi cance of the 
association between coronary calcifi cations and depressive disorders we calculated the overall p 
value with a test for trend: p=0.004.
† The category “depressive disorders” includes cases with major or minor depression and dysthymia. 
Screen positive subjects with subclinical depressive symptoms, other psychiatric disorders or without 
a psychiatric work-up were excluded.
depressed persons). Additional adjustment for stroke and myocardial infarc-
tion moderately changed estimates. 
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TABLE 4: The association between the measure of generalized extracoronary athero-
sclerosis and depression
Principal component (per SD) of extra-
coronary atherosclerosis measures
Depressive disorders*
Cases/ Controls OR (95% CI) p-value
Adjusted† 77/2798 1.30 (1.01, 1.66) 0.04
Additionally adjusted for stroke and
myocardial infarction
77/2798 1.28 (1.01, 1.66) 0.05
CI = confi dence interval, OR = Odds ratio, SD = Standard deviation. 
In this complete case analysis only subjects with all four measurements of atherosclerosis were 
included.
* The category “depressive disorders” includes cases with major or minor depression and dysthymia. 
Screen positive subjects with subclinical depres   sive symptoms, other psychiatric disorders or no 
psychiatric work-up were excluded. 
† Odds ratio and 95% CI were calculated with logististic regression adjusted for age, gender, total 
cholesterol, cognitive score, systolic blood pressure, smoking.
DISCUSSION
In this population-based study we found that subjects with atherosclerosis 
were more likely to be depressed. A combined measure of extracoronary ath-
erosclerosis was related to depressive disorders although at some of the differ-
ent locations the association was only moderate and non-significant. Further, 
we found a substantial relation of severe coronary and aortic calcifications 
with depressive disorders.
The strengths of this study are the large number of elderly people partici-
pating and its population-based design. Furthermore, the psychiatric work-
up in subjects who were screen positive on the CES-D enabled us to determine 
in which group depressive symptoms were due to depressive disorders. A pre-
vious study in an elderly Dutch population reported a high sensitivity using 
the same cut off point and misclassification of disease is therefore unlikely to 
have influenced our results.11
Some methodological issues of this study must be discussed. First, this is a 
cross-sectional study and cannot demonstrate the chronology of the observed 
relationship. Second, the prevalence of subjects with depressive symptoms in 
this study (7.8%) was relatively low. However, it is comparable to the commu-
nity prevalence observed by Blazer et al (1991) in the US (9.0%) who also used 
the CES-D.12 Furthermore, the rate falls within the variable range recently 
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reported in a review of depressive symptoms in the elderly (2.8% to 35%).23 
To our knowledge the present study is the first to examine the relation 
between measures of atherosclerosis and depressive disorders in community 
dwelling subjects. Many clinical studies have been performed in patients 
with pre-existing vascular disease.24-26 These studies generally show a high 
risk of comorbid depression on survival after a cardiovascular event. So far 
few studies were conducted in community dwelling subjects.27,28 A recent 
study in US Army personnel using electron beam tomography observed no 
correlation between psychological factors and coronary atherosclerosis.28 We 
studied an elderly population which encompassed a very broad spectrum 
of the degree of atherosclerosis. This may help to detect an association not 
found in a homogenous population of middle aged men. Further, the previous 
population-based research, which investigated potential pathophysiological 
mechanisms, concentrated on personality traits rather than specific mood 
states.27-29 It is not clear in how far a single trait (e.g. negative affectivity) can 
account for the associations of depressive disorders with increased cardiovas-
cular morbidity. This makes it even more difficult to relate previous findings 
to the present study. Moreover, personality traits are much more stable than 
specific mood states such as depression. Studying distinct diseases has been 
advocated in order to identify potential treatments.9,30
Data from mostly cross-sectional studies suggest that cerebrovascular 
disease contributes to the development or persistence of depression.31 These 
studies, few of which were population based, have utilized different neuro-
imaging techniques.2,4,32-35 It is assumed that the observed neuroradiological 
findings in depressed patients are due to vascular disease.3 Our findings con-
firm the postulated link between vascular factors and depression. The present 
study cannot establish a causal role of atherosclerosis but provides evidence 
that a generalized atherosclerotic process accompanies late life depression. 
Although there are gaps in knowledge, the vascular depression hypothesis 
potentially has wide clinical implications.31 Assessment of atherosclerosis in 
persons with late life depression and a treatment more akin to the manage-
ment of cardiac disease and vascular dementia need to be investigated.36 
Another explanation for our results needs to be discussed. Previously, lon-
gitudinal population-based studies established depression as a risk factor for 
cardiovascular disease. Depressive status at baseline was an independent 
risk factor for ischemic heart disease and death.5-7,37 Numerous biological pro-
cesses that have been associated with depression may underlie this increased 
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cardiovascular risk: decreased myocardial perfusion, abnormalities in plate-
let reactivity, cardiac arrhythmia, inflammatory processes and noradren-
ergic hyperactivity.38-40,41 These pathophysiological changes are generally 
accompanied by increased atherosclerosis. Even if behavioral factors such 
as difficulties in smoking cessation or poor adherence to medical treatment 
account for the relation of depression with vascular disease one would expect 
to find increased levels of atherosclerosis in depressed persons. Our results are 
compatible with this notion. Increased cardiovascular mortality in depressed 
persons can be envisaged because depression was associated with general-
ized atherosclerosis in the present study population. The observed association 
was somewhat more marked for coronary calcifications. But this should be 
interpreted carefully because electron beam CT was not available in all sub-
jects. Moreover, it may reflect the good assessment of atherosclerosis rather 
than indicating a specific cardiac process.
In summary, in this large study of community-dwelling elderly subjects we 
found that depression and atherosclerosis were related. Like other cardiovas-
cular risk factors such as cholesterol or blood pressure, depressive disorders 
may be accompanied by a generalized atherosclerotic process. This suggests 
that intensive treatment of atherosclerosis or cardiovascular risk factors may 
prevent depressive disorders in late life. However, to further elucidate the 
pathophysiology underlying the association between depressive disorders 
and vascular disease prospective studies are needed that include different 
biological measures and psychiatric interviews.
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ABSTRACT
Objective: Neuroimaging studies suggest that vascular pathology may be a causal factor 
in late life depression. This study was performed to determine whether arterial stiffness is 
associated with depression in the elderly.
Design: Population-based cross-sectional study.
Setting: Ommoord, a suburb of Rotterdam, Netherlands.
Participants: 3704 subjects of the Rotterdam Study aged 60 years and over.
Measurements: We assessed arterial stiffness by the distensibility of the carotid artery and 
the carotid-femoral pulse wave velocity. All participants were screened for depressive 
symptoms with the Center of Epidemiological Studies Depression Scale. Those with depres-
sive symptoms had a psychiatric work-up to establish a diagnosis of depressive disorders 
according to the Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) crite-
ria.
Results: Participants with increased arterial stiffness were more likely to have depressive 
symptoms. Odds ratios for depressive symptoms were 1.24 (95% confi dence interval [CI]: 
1.01, 1.52) per standard deviation decrease in carotid distensibility, and 1.17 (95%CI: 1.00, 
1.38) per standard deviation increase in aortic pulse wave velocity. The association was 
stronger for depressive disorders meeting DSM-IV criteria (odds ratios 1.44 (95%CI: 1.03, 
2.03) and 1.48 (95%CI: 1.16, 1.90), respectively). Control for atherosclerosis, as measured by 
the ankle-to-brachial index or presence of plaques in the carotid artery, did not change 
the associations.
Conclusions: This study shows an association between arterial stiffness and depression in 
the elderly. The fi ndings are compatible with the vascular depression hypothesis. Our data 
suggest that the proposed relation between vascular factors and depression may partly 
be caused by arterial stiffness.
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INTRODUCTION
Depression is an important health problem in older people. The causes of 
depression in the elderly are poorly understood but current research puts 
particular emphasis on biological risk factors. It has been suggested that 
vascular pathology may cause depression in the elderly.1 A “vascular 
depression hypothesis” was introduced by Alexopoulos.2 He postulated that 
late life depression encompasses a high percentage of patients with cere-
brovascular disease. While few clinical differences exist between early and 
late-onset depression the hypothesis has been supported by neuroimaging 
studies showing that persons with late-onset depression have more vascular 
abnormalities than non-depressed.3 Research on measures of atherosclerosis 
and cerebrovascular risk factors has yielded mixed results.4 Factors such as 
smoking, hypertension and atrial fibrillation were not found more frequently 
in late onset depression.
The level of arterial stiffness is an important characteristic of the vascular 
system and increased arterial stiffness is related to cerebrovascular disease 
independent of atherosclerosis.5,6 Furthermore, increased arterial stiffness is a 
determinant of blood pressure. Low blood pressure has repeatedly been asso-
ciated with depressive symptoms in the elderly, but the underlying mecha-
nism remains unclear.7,8 We hypothesized that arterial stiffness could mediate 
the associations between vascular pathology and depression. Therefore, we 
investigated the relation between arterial stiffness and depression in a large 
population-based study among elderly subjects.
SUBJECTS AND METHODS
Study population
This study was conducted as part of the Rotterdam Study, a population based 
study that is ongoing since 1990. All inhabitants aged 55 years and over of 
a district of Rotterdam were invited at baseline; 7983 persons participated. 
In the third survey (1997-1999) we added assessments of depressive symp-
toms and arterial stiffness to the study protocol. Measurements included a 
home interview and a visit to the research center. Of the 4703 persons (80% 
response) who participated in this examination round, 3704 were screened 
for depressive symptoms and had at least one measurement of arterial 
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stiffness performed. Common carotid artery distensibility was measured in 
3014 and carotid-femoral pulse wave velocity in 3374 participants. The 999 
subjects in whom arterial stiffness was not assessed were on average older 
(77.2 vs. 72.1 years), more likely to be female (67% vs. 58%), and had more 
depressive symptoms (11.0% vs. 6.7%, overall prevalence 7.8%). The Medical 
Ethics Committee of the Erasmus University approved the study and written 
informed consent was obtained from all participants.
Depression assessment
Depressive disorders were assessed using a two step procedure. First par-
ticipants completed the Dutch version of the original Center for Epidemiology 
Studies Depression scale. This is a 20-item self-reported measure of symptoms 
scored on a scale of 0 to 3 points. We used a score of 16 as a cut-off to indi-
cate clinically relevant depressive symptoms. Beekman et al. (1997) reported 
a very high sensitivity of this cut-off for major depression in older subjects in 
the Netherlands.9 Second, screen positive subjects had a psychiatric work-up 
using the Dutch version of the Present State Examination (PSE-10), a semi-struc-
tured psychiatric interview included in the Schedules for Clinical Assessment 
in Neuropsychiatry.10 All interviews were conducted by two experienced 
clinicians. Psychiatric disorders were classified according to the Diagnostic 
and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria. Of the 3704 
subjects included in this study 250 (6.7%) were screen-positive. Psychiatric dis-
orders were subsequently assessed in 234 (93.6%) participants. The diagnostic 
categories of depression included dysthymia, major and minor depression as 
defined in the appendix of the DSM-IV. 
Measures of arterial stiffness
Both common carotid arterial and aortic stiffness were measured at the 
research center. The distensibility coefficient of the right common carotid 
artery was used as a measure of common carotid arterial stiffness. The vessel 
motion was measured by means of Doppler scanner (Ultramark IV, ATL, Both-
ell, Washington, USA). The arterial wall distensibility coefficient was calcu-
lated by dividing the relative stroke change in the diameter of the arterial 
wall through the pulse pressure.11 Pulse pressure was defined as systolic blood 
pressure minus diastolic blood pressure. 
Carotid-femoral pulse wave velocity was assessed using an automatic 
device (Complior, Colson, Garge-lès-Gonesse Cx, France). The time delay 
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between the rapid upstroke of simultaneously recorded pulse waves in the 
carotid artery and the femoral artery was measured. Pulse wave velocity was 
calculated as the ratio between the distance traveled by the pulse wave and 
the time delay.12 It was expressed in meters per second. The average of at 
least 10 successive measurements was used in the analyses.
Other measurements
The following variables were considered as possible confounding variables: 
age, gender, education, smoking, cognitive function, antihypertensive, anti-
depressant medication, body mass index, total and HDL-cholesterol, diabetes 
mellitus and a history of stroke. Educational level was assessed on an ordinal 
scale but dichotomized for analysis according to whether only primary edu-
cation was attained. Cigarette smoking was analyzed in categories of current 
and former smoker. Cognitive function was measured by the Mini Mental 
State Examination. Information on current antidepressant or antihypertensive 
medication was obtained during the home interview and included a cabinet 
check, but treatment indication was not ascertained. Body mass index was 
computed as weight in kg divided by height in m2. Overnight fasting blood 
samples were taken and serum total and HDL-cholesterol was measured 
using an automated procedure. Diabetes mellitus was defined as the use of 
insulin or oral blood glucose lowering drugs, or serum glucose concentrations 
of more than 11.0 mmol/l. A history of stroke was obtained from all subjects 
through direct questioning and computerized linkage with general practitio-
ner medical records, and verified by a neurologist. 
Because the effects of arterial stiffness might depend on those of atheroscle-
rosis and blood pressure as risk factors for depression we included measures of 
atherosclerosis and blood pressure in the present study. Atherosclerosis was 
assessed by three different measures: ankle-to-brachial index, the presence 
of plaques in the carotid arteries assessed by ultrasonography,13 and pres-
ence of aortic atherosclerosis, which was determined on a lateral abdominal 
x-ray.14 Ankle-to-brachial index was dichotomized using a threshold value of 
0.90 that indicates peripheral arterial disease.15
Statistical analysis
The association of arterial stiffness with depressive symptoms and depressive 
disorders was assessed using logistic regression and expressed as odds ratios 
with 95% confidence intervals. Age (continuously in years), gender, mean 
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arterial blood pressure (in mm Hg) and heart rate were controlled for in all 
analyses. We assessed measures of arterial stiffness in quartiles of the dis-
tribution. Common carotid distensibility and pulse wave velocity were also 
entered into the logistic regression model as a continuous variable divided 
by one standard deviation. For analyses on depressive disorders according 
to DSM-IV criteria screen positive subjects who did not fulfil the criteria were 
excluded. Additionally we performed an analysis excluding subjects on 
anti-depressant medication without depressive symptoms from the reference 
group.
To check for confounding we added all potential confounders to the 
basic model. In further analysis we additionally adjusted for measures of 
atherosclerosis. A change in estimate may indicate that part of the effect 
of arterial stiffness can be attributed to atherosclerosis. Subsequently we 
studied whether any relation between atherosclerosis and depression was 
independent of arterial stiffness. We also performed analyses stratified for 
gender. Finally, the relationship between blood pressure and depression was 
assessed by logistic regression. In an additional analysis we checked whether 
this association was curvilinear by entering a quadratic term in the model.
RESULTS
Of the 234 screen positive subjects with a psychiatric work-up 96 had a depres-
sive disorder as defined by the DSM-IV. The remaining subjects either had an 
anxiety disorder or other psychiatric disease (n=20), or did not meet criteria 
for an Axis I psychiatric disorder (n=118, subclinical depressive symptoms). 
Table 1 presents characteristics of the reference subjects, the screen positive 
subjects with depressive symptoms and the subjects with DSM-IV depressive 
disorders. Female gender, low cognitive score, smoking, low diastolic blood 
pressure, use of antidepressant medication and aortic calcifications were 
more frequently observed in subjects with depressive symptoms.
Depressive symptoms as defined by a score of 16 and above on the Center 
for Epidemiology Studies Depression scale were significantly associated with 
a decrease in distensibility of the common carotid artery; the association with 
pulse wave velocity was borderline significant. Subjects with increased arte-
rial stiffness (upper quartiles) were more likely to have depressive symptoms. 
Table 2 shows the odds ratios per quartile of arterial stiffness adjusted for age, 
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TABLE 1: Characteristics of the study subjects 
Variables
Reference 
subjects:
no depressive 
symptoms
(n=3454)
Depressive
symptoms†
(n=250)
Depressive
disorders†
(n=96)
Age, years, mean (range) 72.0 (61-101) 73.5** (61-93) 72.7 (61-87)
Gender, % female 56.5 73.2*** 71.9**
Primary education only, % 46.8 55.6 53.1
MMSE-score, mean (± SD) 27.7 (2.0) 26.9* (2.7) 26.5** (3.3)
History of stroke, % 2.8 6.0** 5.2
Smoking current smoker, %
 ex-smoker, %
15.5
51.0
19.6*
42.0
19.8
40.6
Peripheral arterial disease, % 16.7 20.3 18.5
Antidepressant medication, % 2 10*** 13***
Diabetes mellitus, % 8.6 10.4 8.3
Carotid plaques, % 0
 1-4
 5-8
 >9
30
50
17
3
29
52
18
2
26
54
16
4
Aortic calcifi cations, % <1 cm
 1-2,5 cm
 2.5-5 cm
 >5 cm
22
35
38
  4
18*
30
49
  4
19
32
44
  5
Heart rate, mean (± SD) 75 (14) 77 (15) 75 (13)
Total cholesterol, mmol/l, mean (± SD)
HDL-cholesterol, mmol/l, mean (± SD)
5.8 (1.0)
1.4 (0.4)
5.9 (0.9)
1.5 (0.4)
5.9 (1.0)
1.4 (0.4)
Body mass index, kg/m2, mean (± SD) 26.8 (4.0) 26.9 (4.9) 26.4 (3.8)
Diastolic blood pressure, mmHg, (± SD)
Systolic blood pressure, mmHg, (± SD)
Pulse pressure, mmHg, mean (± SD)
 75 (11)
143 (21)
 68 (17)
73* (11)
142 (22)
 69 (18)
 73 (12)
141 (23)
 68 (19)
Distensibility coeffi cient of common 
carotid artery, 10-3/kPa, mean (± SD)
Pulse wave velocity, m/s, mean (± SD)
10.6 (4.4)
13.5 (3.0)
9.5* (3.9)
13.9 (3.4)
9.2* (3.7)
14.3** (3.6)
* p < 0.05, ** p < 0.01, *** p < 0.001; ANCOVA or logistic regression adjusted for age and gender 
were appropriate; carotid plaques and aortic calcifi cations were tested for overall signifi cance and 
not per category.
SD = Standard deviation, MMSE = Mini Mental State Examination
† The category depressive symptoms includes all subjects with a Center of Epidemiological Studies 
Depression scale (CES-D) score ≥ 16.  The category depressive disorders includes only the cases with 
major or minor depression and dysthymia.
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gender, blood pressure heart rate, smoking, history of stroke and cognitive 
score. Entering any other covariate into the models did not alter the estimates. 
The analyses using the categorical variables did not suggest substantial 
threshold effects.
In the analyses shown in table 3 arterial stiffness is used as a continuous 
variable. Odds ratios for depressive symptoms were 1.27 (95% confidence 
interval [CI]: 1.03, 1.57, p=0.03) per standard deviation decrease in carotid 
distensibility, and 1.19 (95% CI: 1.00, 1.40, p=0.05) per standard deviation 
increase in aortic pulse wave velocity. Table 3 also shows that this association 
was independent of peripheral arterial disease and atherosclerosis as mea-
sured by carotid plaques, but controlling for aortic calcifications reduced the 
point estimates. The association of both measures of arterial stiffness with DSM-
IV depressive disorders was stronger than with depressive symptoms (Tables 
2 and 3). Further, we observed only a modest reduction in estimates for 
depressive disorders when we adjusted for atherosclerosis (Table 3). Exclud-
ing subjects with antidepressant medication did not change the results (data 
not shown). To further explore our data we subsequently checked whether 
the relation of aortic calcifications with depressive symptoms (odds ratio for 
moderate and severe calcifications: 1.60, 95% CI: 1.05, 2.35; p=0.03) was 
independent of arterial stiffness. We observed a substantial reduction of the 
association after adjustment for carotid-femoral pulse wave velocity as well 
as after adjustment for common carotid artery distensibility. The respective 
odds ratios of aortic calcifications did not reach significane anymore (1.30, 
95% CI: 0.83, 2.04, p=0.24 and 1.41, 95% CI: 0.93, 2.14, p=0.10). 
Subjects with low diastolic blood pressure had an increased risk to be 
depressed. However, this relation reached significance only for depressive 
symptoms and not for depressive disorders. Odds ratios were 0.88 per 10 
mmHg (95% CI: 0.78, 0.99, p=0.04) and 0.84 (95% CI: 0.70, 1.02, p=0.07), 
respectively. Furthermore, we also computed the odds ratios of systolic blood 
pressure (0.94 per 10 mmHg, 95% CI: 0.89, 1.00, p=0.06 for depressive symp-
toms and 0.92, 95% CI: 0.84, 1.02, p=0.12 for depressive disorders). We found 
no curvilinear associations and observed no difference in pulse pressure 
between subjects with and without depression (data not shown).
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DISCUSSION
This large population based study showed that arterial stiffness is associated 
with depressive symptoms in the elderly. The strongest associations were 
found in subjects who fulfilled criteria for a DSM-IV depressive disorder. Par-
ticipants with a reduced common carotid artery distensibility or an increased 
carotid-femoral pulse wave velocity were more likely to have a depressive 
disorder after the effects of age, sex, history of stroke, smoking and cognitive 
function were controlled for.
Some limitations of the present study need to be discussed. Firstly, the 
prevalence of subjects with depressive symptoms in this study (7.8%) was rel-
atively low. However, it is within the range (2.8% to 35%) reported in a recent 
review16 and is comparable to the prevalence in the US (9.0%) observed by 
Blazer (1991).17 Further, subjects with depressive disorders were slightly under-
represented in the analytical sample because they were less likely to visit the 
research center. This reduced the power to detect significant associations, but 
we think it is unlikely that the observed relation between arterial stiffness and 
depression was due to this selection effect.
Secondly, in analyses with arterial distensibility adequate correction for 
blood pressure is of utmost importance.12 Higher blood pressure stretches the 
arterial wall and makes arteries less distensible. Because of the association of 
mean arterial blood pressure with stiffness we adjusted all analyses for this 
variable. However, high blood pressure also leads to structural changes in the 
arterial wall and therefore is an important determinant of arterial stiffness. 
Possibly, adjustment for mean arterial pressure is an over-correction. This 
might have attenuated the association between arterial stiffness and depres-
sive disorder.
Strength of the present large, population-based study is the psychiatric 
work-up in subjects who were screen positive on the depression scale. We 
were able to determine in which group depressive symptoms were due to 
depressive disorders and perform analyses along the worsening spectrum 
of affective illness. Moreover, misclassification of disease is unlikely to have 
influenced our results. Studies in psychiatric epidemiolgy are frequently 
based on measurements of depressive symptoms only and include an inho-
mogeneous group of subjects with subclinical depressive symptoms and other 
psychiatric diseases.
One possible explanation for the association of arterial stiffness with 
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depressive disorder is the relation between arterial stiffness and atherosclero-
sis.18 Atherosclerosis has been suggested as a risk factor for depression in late 
life and depressive symptoms itself are related to subsequent cardiovascular 
disease.19,20 The vascular depression hypothesis postulates that structural 
changes in the brain due to atherosclerosis are of primary importance in 
late life depression.21 However, indicators of extracerebral vascular changes 
have not been studied in this context. Research on depressive symptoms as 
a risk factor for cardiac morbidity, on the other hand, has concentrated on 
altered heart rate variability, platelet function, immunological factors and 
associations with other cardiac risk factors such as smoking.22 The few studies 
investigating atherosclerosis have reported conflicting results and have not 
included a diagnosis of depression.23,24 Likewise, the association found in the 
present study is not explained by atherosclerosis alone. Neither correction 
for carotid plaques nor correction for peripheral arterial disease changed the 
point estimates. Subclinical atherosclerosis as indicated by carotid plaques 
may actually reduce stiffness.25 In our study only the adjustment for aortic 
calcifications reduced the observed association between arterial stiffness 
and depressive symptoms. However, aortic calcifications may reflect arterial 
stiffness as well as atherosclerosis. The presence of atheromatous plaques 
in the aorta is strongly correlated with vessel stiffness.26 Moreover, the asso-
ciation of aortic calcifications with depressive symptoms found in this study 
was not independent of arterial stiffness. We may thus have overadjusted by 
adding aortic calcifications to the model. Adjusting for carotid plaques and 
peripheral arterial disease was probably adequate to control for the effect of 
atherosclerosis.
Another possible factor that could explain our findings is increased pulse 
pressure. Arterial stiffness leads to an increase in systolic blood pressure and 
simultaneously a decrease in diastolic blood pressure, hence increased pulse 
pressure. A high pulse pressure is a strong risk factor for cerebrovascular 
disease.27 However, we did not observe a relation between pulse pressure 
and depressive symptoms. Instead, both a low diastolic and a low systolic 
blood pressure were associated with depressive symptoms. This could be 
explained by the fact that a high degree of medical comorbidity is reported 
in elderly depressives, which is frequently associated with low mean blood 
pressure.7,8,28
This is a cross-sectional study that can not demonstrate the chronology of 
the observed relationship. The etiological arrow may go from arterial stiffness 
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to depressive symptoms as well as the other way round. However, the pres-
ent study sheds light on a possible mechanism underlying the association 
between vascular pathology and depression. Further studies on the mecha-
nism may help identify the elderly depressed patients in whom vascular 
disease is important and who might benefit from specific interventions.1 To 
measure pulse wave velocity may be the most practical approach in view 
of technical convenience, the cost of equipment and manpower, whereas 
measurement of aortic calcifications involves x-rays. If arterial stiffness plays 
a role, ACE inhibitors and calcium channel blockers, which decrease stiff-
ness, may prevent late onset depression. Furthermore, drugs that increase 
endothelial nitric oxide and thus arterial compliance are of potential benefit. 
In this context a link between blood pressure, arterial stiffness and vascular 
depression is especially relevant. On the one hand, intensified antihyperten-
sive treatment as a secondary prevention of vascular depression is discussed 
in the USA.29 On the other hand, a sizeable proportion of doctors in European 
countries treat a “hypotensive syndrome”. Patients with fatigue, depressive 
symptoms and low blood pressure are prescribed ephedrine, derivatives of 
ergot or amphetamine.7,8
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ABSTRACT
Background: Evidence from epidemiological and neuroimaging studies suggests that 
cerebrovascular disease is associated with depressive disorders in the elderly, but the 
extent to which it contributes to the pathogenesis of late life depression is unclear. 
Objective: To investigate the relation between cerebral haemodynamics and depression 
in a population based study, using transcranial Doppler ultrasonography. 
Methods: Cerebral blood fl ow velocity and CO2 induced vasomotor reactivity in the middle 
cerebral artery were measured in 2093 men and women who participated in the Rotter-
dam study. All subjects were screened for depressive symptoms using the Center of Epide-
miological Studies Depression scale, and those with a score of 16 or over had a psychiatric 
work up. In a semistructured interview, diagnoses of depressive disorders according to the 
DSM-IV and subthreshold depressive disorder were established. Analyses of covariance 
controlled for age, sex, stroke, cognitive score, and cardiovascular risk factors were used 
to compare means of haemodynamic variables. 
Results: Subjects with depressive symptoms had reduced blood fl ow velocities (mean dif-
ference, -2.9 cm/s; 95% confi dence interval (CI), -5.0 to -0.8; p = 0.008) and lower vasomo-
tor reactivity (mean difference -0.5%/kPa; 95% CI, -1.0 to -0.05; p = 0.03). Blood fl ow velocity 
was reduced most in subjects suffering from a DSM-IV depressive disorder (mean differ-
ence, -4.9 cm/s; 95% CI, -8.5 to -1.4; p = 0.006). The overall reduction in vasomotor reactivity 
was accounted for by subjects with subthreshold depressive disorder. 
Conclusions: Depression in late life is associated with cerebral haemodynamic changes 
that can be assessed by transcranial Doppler ultrasonography. The observed reduction 
in cerebral blood fl ow velocity could be a result of reduced demand in more seriously 
depressed cases with a DSM-IV disorder, whereas reduced CO2 induced cerebral vasomo-
tor reactivity is a possible causal factor for subthreshold depressive disorder. 
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INTRODUCTION
The “vascular depression” hypothesis postulates that in late life vascular 
pathology contributes significantly to the pathogenesis of depression.1 Evi-
dence from epidemiology, genetics, and neuropsychology suggests that cere-
brovascular changes may lead to depressive disorders.2-6 Strong evidence 
comes in particular from neuroimaging studies.2,7 These studies have focused 
on magnetic resonance imaging (MRI) hyperintensities, but single photon 
emission tomography (SPECT) and positron emission tomography (PET) have 
also been used to provide information on the function of the brain in depres-
sive disorders.8-10 In studies using MRI, white matter hyperintensities in the 
basal ganglia and the frontal lobes were reported. These lesions are attrib-
uted to vascular disease, but other causes cannot be ruled out.1 In clinical 
studies employing SPECT, regional differences in cerebral blood flow were 
reported between subjects with depressive disorders and clinical controls.11-14 
It remains unclear whether low blood flow is a result of depression, reflects 
cerebrovascular disease, or marks neuronal loss predisposing to depres-
sion.15 
With transcranial Doppler ultrasonography it is possible to assess the intra-
cranial circulation directly. Aaslid et al first described a non-invasive Doppler 
ultrasound technique in 1982, which took advantage of the relatively thin 
temporal bone.16 Transcranial Doppler is a useful tool for detecting the hae-
modynamic changes resulting from cerebrovascular impairment, despite the 
limitation that the temporal bone often cannot be passed by ultrasound.17,18 
Changes in both vasomotor reactivity and blood flow velocity are commonly 
measured in the basal cerebral arteries by transcranial Doppler. Vasomo-
tor reactivity is reduced in patients with cerebral microangiopathy,17 while 
changes in cerebral artery blood velocities reflect changes in blood flow and 
brain tissue perfusion.19-21 
The Rotterdam study provided an opportunity to examine the relation 
between cerebral haemodynamics and depression in a population based 
sample of older adults. We conducted this study to evaluate whether cere-
brovascular impairment, as measured by transcranial Doppler, is related to 
depression. Our a priori hypothesis was that subjects with depressive disor-
ders have a reduced flow velocity and reduced vasomotor reactivity.
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METHODS
Subjects
The investigation was conducted as part of the Rotterdam study, a popula-
tion based cohort study ongoing since 1990, in which all inhabitants aged 55 
and over in a suburb of Rotterdam were invited to participate.22 In the third 
survey we added assessments of depressive symptoms and cerebral haemo-
dynamics to the protocol. Measurements were conducted between 1997 and 
1999. Screening for depressive symptoms was carried out during the home 
interview part of the survey, in which 4730 subjects participated. 
In 3101 consecutive participants we attempted to perform transcranial 
Doppler ultrasonography as part of the standard clinical investigation at the 
research centre. No transcranial Doppler measurements were carried out 
in the remainder (n = 1629), owing to the unavailability of a technician. In 
990 subjects (32%), transcranial Doppler was undertaken but no results were 
obtained. In most cases this was because of window failure on both sides 
(n = 771) or because restlessness or discomfort prevented the study being 
done (n = 36). In 183 participants haemodynamic measurements could not 
be carried out for other reasons, such as ambiguous flow direction or lack of 
time.19,23 Subjects in whom no transcranial Doppler data were obtained were 
older (p < 0.001) and more likely to be female (p < 0.001). The prevalence of 
psychiatric symptoms in the analytical sample was found to be lower than 
in the study population as a whole (5.5% v 7.8%). A further 18 subjects were 
excluded because they did not have complete screening for depression. The 
final study sample consisted of 2093 participants in whom adequate depres-
sion and haemodynamic indices were obtained. 
The Rotterdam Study was approved by the medical ethics committee of 
Erasmus University Medical School. After complete description of the study to 
the subjects, written informed consent was obtained. 
Depression assessment
Depressive disorders were assessed using a two step procedure. First, par-
ticipants completed the Dutch version of the original Center for Epidemiology 
Studies Depression scale (CES-D) during the home interview. The CES-D is a 20 
item self reported measure of symptoms experienced in the past week, scored 
on a scale of 0 to 3 points. The validity of the CES-D has been well estab-
lished.24 We used a score of >16 as a cut off point, as this has been found to 
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have a high sensitivity for major depression in a random sample of older sub-
jects in the Netherlands.25 Previous studies have verified that a score of 16 and 
above on the CES-D represents clinically significant depressive symptoms.26 
In a second step, screen positive subjects had a psychiatric work up. They 
were evaluated by the Dutch version of the present state examination (PSE-
10), a semistructured psychiatric interview included in the Schedules for Clini-
cal Assessment in Neuropsychiatry.27 All interviews were conducted by two 
experienced clinicians. Psychiatric disorders were classified according to the 
DSM-IV criteria, with an algorithm based on the PSE-10 scores. The diagnostic 
categories include minor depression, as defined in the appendix of DSM-IV. 
Of the 2093 subjects included in the analyses, 116 (5.5%) were screen 
positive for depression as measured by the CES-D. A psychiatric work up was 
performed in 111 of these participants (95.6%). Four subjects refused to partici-
pate in this evaluation, and one screen positive subject could not be reached. 
A depressive disorder as defined by the DSM-IV criteria was established in 42 
cases. The remaining subjects were either classified as having anxiety disor-
ders or other psychiatric disease (n = 8) or did not meet criteria for an axis I 
psychiatric disorder (n = 61, subthreshold depressive disorder). 
To define late onset depression we used the data from the baseline inter-
view with a physician. All subjects in the present analysis responded to the 
questions about psychiatric history. Participants who reported a history of 
depression before the age of 60 were considered to be suffering from early 
onset depression. 
Transcranial Doppler assessment
Transcranial Doppler ultrasonography was done using a Multi-Dop X-4 instru-
ment (DWL, Sipplingen, Germany), and the cerebral blood flow velocity (cm/
s) was measured in the middle cerebral artery on both sides if possible. End 
diastolic, peak systolic, and mean cerebral blood flow velocity were recorded 
automatically. 
CO2-induced cerebral vasomotor reactivity measurements were done as 
follows. The cerebral blood flow velocity was measured continuously and the 
participants first breathed room air through an anaesthetic mask, tightly fitted 
over mouth and nose, until a steady expiratory end tidal CO2 was obtained. 
Next, participants inhaled a mixture of 5% carbon dioxide in 95% oxygen for 
two minutes. Cerebral vasomotor reactivity was defined as the percentage 
increase in cerebral blood flow velocity occurring during inspiration of 5% CO2, 
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divided by the absolute increase in end tidal CO2 in the same period (%kPa). 
End tidal pCO2 (kPa) was recorded continuously with a CO2 analyser (Multi-
nex, Datascope, Hoevelaken, Netherlands). End expiratory CO2 was assumed 
to reflect arterial CO2. TCD-8 DWL special software (VMR-CO2) was used. All 
transcranial Doppler data were stored on hard disc for off-line analysis. The 
mean of the right and left haemodynamic variables was used for analyses 
if both middle cerebral arteries could be insonated adequately. A one sided 
haemodynamic variable was used if there was unilateral window failure. 
Measurements of other covariates
The following were considered to be possible confounding variables: age, sex, 
education, cognitive function (measured by the mini mental state examina-
tion (MMSE)), antihypertensive treatment, and antidepressant treatment. 
Education was measured on an ordinal scale and later dichotomised into low 
and high. Information on current antidepressant or antihypertensive drug 
treatment was obtained during the home interview. The following cardiovas-
cular risk factors were assessed: stroke, smoking, systolic and diastolic blood 
pressure, diabetes mellitus, and total cholesterol. A history of stroke was 
obtained from all subjects through direct questioning and computerised link-
age with general practitioner medical records. The history was considered 
positive when confirmed by a physician. Cigarette smoking was analysed in 
categories of current and former smoker. Sitting blood pressure was measured 
twice on the right arm with a random zero sphygmomanometer. Diabetes 
mellitus was defined as the use of insulin or oral blood glucose lowering drugs, 
or serum glucose concentrations of more than 11.0 mmol/l. Fasting blood 
samples were taken and serum total cholesterol was measured using an 
automated enzymatic procedure. The ankle to brachial index was used as an 
indicator of peripheral atherosclerosis. We assessed ankle to brachial index 
by taking the ratio of the systolic blood pressure measured at the tibial artery 
to that measured at the right arm. Subjects with an ankle to brachial index of 
less than 0.9 were considered to suffer from peripheral arterial disease.28 
Statistical analysis
The associations between haemodynamic variables and depressive disorders 
were addressed in three ways. 
First, analysis of covariance (ANCOVA) was used to calculate means of the 
screen positive subjects and the reference group, adjusted for age and sex. 
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Haemodynamic indices were entered as continuous variables. In addition, 
we controlled these analyses for education, antihypertensive and antide-
pressant drug treatment, cognitive function, and cardiovascular risk factors. 
We also performed an ANCOVA to evaluate possible differences between 
subjects with depressive disorders and subjects with subclinical depressive 
symptoms. Subjects without a psychiatric work up and those with other psy-
chiatric disorders were excluded from subgroup analyses. Analyses were run 
both excluding and adjusting for subjects with a history of stroke (n = 7 in 
the screen positive group, including two subjects with depressive disorder) or 
taking antidepressant drugs. 
Second, logistic regression analysis was used to calculate the odds ratios 
for the association between haemodynamic variables and the presence of 
depressive disorders. We assessed tertiles of haemodynamic variables to 
allow for a non-linear relation. Because of the relatively small number of 
cases we did not use more categories. In this model we included only the vari-
ables associated with haemodynamic indices to avoid an overfitted model. 
Third, we used stratified analyses to study possible effect modification by 
peripheral arterial disease and a history of depression. 
TABLE 1: Characteristics from participants with and without depressive symptoms.†
Non-depressed (n=1977) CES-D-score ≥ 16 (n=116)
Age, years 71.1 (6.5) 72.8 (6.6)**
Male 54.1% 41.4%**
Primary education only 58% 42%**
Previous stroke 2.3% 6.0%*
Diabetes 6% 5%
Smoking : current smoker
 former smoker
16%
56%
21%
47%
MMSE‡ score 27.9 (1.8) 27.1 (2.6)**
Systolic blood pressure (mmHg) 143 (18) 142 (20)
Diastolic blood pressure (mmHg) 75 (11) 74 (12)
Total cholesterol (mmol/L) 5.8 (1.0) 5.8 (1.0)
Antidepressant medication 1.7% 10.5%**
Antihypertensive medication 35% 33%
Peripheral arterial disease 17% 25%
Major depression before age 60 3.5% 6.9%*
* p < 0.05; ** p < 0.001 adjusted for age and sex were appropriate.
† Values are unadjusted means (SD) or percentages.
‡ MMSE, Mini Mental State Examination
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RESULTS
Table 1 compares the demographic characteristics and confounding variables 
of the 116 participants who were screen positive and the 1977 participants 
who were screen negative for depression. Age, sex, education, a history of 
major depression before age 60, previous stroke, and cognitive function were 
all associated with current depressive symptoms. However, the cardiovascu-
lar risk factors smoking, diabetes, systolic and diastolic blood pressure, and 
total cholesterol were not related to depressive symptoms.
Subjects with depressive symptoms as determined by the CES-D had a 
lower mean cerebral blood flow velocity (age and sex adjusted mean dif-
ference, -2.9 cm/s; 95% confidence interval (CI), -5.0 to -0.8; p = 0.007) and 
reduced vasomotor reactivity (age and sex adjusted mean difference, -0.7 %/
kPa; 95% CI, -1.2 to -0.2; p = 0.008). Table 2 shows the relation between cere-
bral haemodynamic variables and depressive symptoms, with additional 
adjustment for education, history of stroke, antidepressant and antihyperten-
sive drug treatment, cognitive function, and cardiovascular risk factors.
In a further analysis, screen positive subjects were classified according to 
the severity of the depressive symptoms (table 3). Subjects with subthreshold 
depressive disorder and DSM-IV depressive disorders were included as dis-
TABLE 2: Association between cerebral hemodynamic parameters and depressive 
symptoms*
Non-depressed
(n=1977)
CES-D score ≥ 16
(n=116)
mean mean
adjusted
difference 
(95% CI)
p-value
Blood fl ow velocity (cm/s)
  - end diastolic 32.5 29.6 -2.3 (-3.9; -0.7) p=0.005
  - mean 50.5 47.8 -2.9 (-5.0; -0.8) p=0.008
  - peak systolic 86.5 82.5 -4.2 (-7.6; -0.7) p=0.02
Vasomotor reactivity (%/kPa) 3.9 3.1 -0.5 (-1.0;-0.05) p=0.03
*Analysis of covariance with hemodynamic parameters entered as continuous variables and 
adjusted for age, gender, education, cognitive function, smoking, systolic and diastolic blood 
pressure, antidepressant and antihypertensive medication, total cholesterol, diabetes mellitus, and 
history of stroke.
Values represent unadjusted means and adjusted differences (95% CI), pairwise comparison with 
non-depressed reference group.
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tinct groups. The results showed a consistent pattern for end diastolic, mean, 
and peak systolic blood flow velocity. Blood flow velocity of subjects with 
depressive disorders was significantly lower than in the reference group. 
The mean values of subjects with a subthreshold depressive disorder lay in 
between. A different pattern was observed for vasomotor reactivity. Subjects 
with subthreshold depressive disorder had a lower vasomotor reactivity than 
non-depressed reference subjects, whereas there was no clear cut difference 
between subjects with depressive disorders and the reference group. Very 
similar estimates were observed if we excluded subjects with a history of 
stroke or those taking antidepressant drugs, rather than adjusting for those 
variables. 
Table 4 shows the odds ratios for depressive symptoms per tertile of hae-
modynamic variables adjusted for age, sex, and cognitive function. The 
particular contributions of subjects with subthreshold depressive disorder and 
subjects with DSM-IV depressive disorders are also presented in the table. It 
can be seen that more subjects with depressive disorders were found in the 
lowest tertile of blood flow velocity. For vasomotor reactivity, the middle 
and the lower tertiles were associated with an increased risk of subthreshold 
depressive disorder.
The observed relations between depressive status and cerebral hae-
modynamic variables were not altered after we controlled for a history of 
major depression before age 60 and peripheral arterial disease. There were 
more subjects with peripheral arterial disease in the group with subthreshold 
depressive disorder (28.8%) and the group with depressive disorders (25.0%) 
than in the reference group (16.5%). However, the relation between blood 
flow velocity or vasomotor reactivity and depression was neither explained 
by nor modified by peripheral arterial disease (data not shown). 
DISCUSSION
This study shows that haemodynamic changes as assessed by transcranial 
Doppler ultrasonography are associated with depressive symptoms. Both 
cerebral blood flow velocity and vasomotor reactivity were found to be lower 
in subjects with depressive symptoms, after the effects of age, sex, education, 
history of stroke, cognitive function, and cardiovascular risk factors were con-
trolled for. These results support the view that cerebrovascular impairment 
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may be a cause of depressive symptoms in the elderly. To our knowledge this 
study is the first to report results of transcranial Doppler ultrasound measure-
ments and depression. Most studies using transcranial Doppler ultrasonogra-
phy in psychiatric settings have looked at dementia or panic disorders.20,29-33 
The strength of the present large population based study is the psychiatric 
work up in subjects who were screen positive on the CES-D. A previous study 
in an elderly Dutch population reported high sensitivity using the same cut off 
point, and misclassification of disease is thus unlikely to have influenced our 
results.25 Furthermore, we were able to determine in which group depressive 
symptoms were caused by depressive disorders. The prevalence of depres-
sive symptoms in the Rotterdam study (7.8%) falls within the range reported 
in a recent review of community prevalence of depressive symptoms in 
the elderly and is comparable with the prevalence of 9.0% reported in the 
USA.26 
The term “vascular depression” was introduced by Alexopoulos.1 He pos-
tulated that geriatric depression encompasses a high percentage of patients 
with cerebrovascular disease. While there are few clinical differences 
between early and late onset depression,7 the hypothesis has been supported 
by studies showing that persons with late onset depression have more neu-
roradiological abnormalities than non-depressed individuals.34 This finding 
could only partially be replicated in a population based study. Steffens et al 
reported hyperintensities in the basal ganglia, but other white matter lesions 
were not related to depressive symptoms as measured by a shortened version 
of the CES-D.2 
Different mechanisms for altered cerebral blood flow velocity as mea-
sured by transcranial Doppler have been postulated.35 Reduced blood flow 
may reflect altered cerebral metabolism, an intrinsic property of the vascular 
smooth muscle, or a neuronal dysfunction of sympathetic nerve fibres. Meta-
bolic autoregulation is probably of key importance and explains the increased 
flow velocity during cognitive activity.36,37 As reduced cognitive activity is a 
well recognised symptom of depressive disorder, a reduction of blood flow 
velocity might be an epiphenomenon of depression. The decreased blood 
flow velocity in our study could reflect the diminished demand in depressive 
states and does not necessarily support the vascular hypothesis. 
Vasomotor reactivity, on the other hand, is probably a good indicator of 
microangiopathy. A reduced vasomotor reactivity indicates that the cerebral 
arterioles are unable to dilate in order to compensate for increased demand.38 
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In patients with stroke or transient ischaemic attacks reduced vasomotor 
reactivity has often been reported.17,39 In a subset of 73 patients with MRI 
scans who participated in this study, we previously observed that vasomotor 
reactivity was related to deep subcortical and periventricular white matter 
lesions.40 However, in the present study we did not confirm our hypothesis 
that reduced vasomotor reactivity is associated with depressive disorders. 
The observed impairment of vasomotor reactivity in subjects with depressive 
symptoms was accounted for by cases with subthreshold depressive disorder. 
If this is not a chance finding, it suggests that cerebral microangiopathy may 
be less important in the more severely diseased and more often cause sub-
threshold depressive disorder. Interestingly, a recent neuropathological nec-
ropsy study also found no evidence of microvascular disease either locally or 
generally in the brain of depressed patients.41 
Limitations
Some limitations of the study must be discussed. This was a cross sectional 
study and it cannot show whether the observed association with cerebro-
vascular changes precipitates or results from the depressive symptoms. Fur-
thermore, we should consider whether selection influenced the outcome of 
the study. In the first place, transcranial Doppler measurements were not 
performed in all subjects participating in the third survey of the Rotterdam 
study; however, this omission was entirely random so it did not introduce bias. 
Second, transcranial Doppler measurements were unsuccessful in nearly one 
third of the subjects, and participants in whom transcranial Doppler measure-
ments were unsuccessful were on average older and more often female. This 
was expected, as temporal bone acoustic thickness increases with age and 
in postmenopausal women,42 and this adversely affects the transmission of 
ultrasound. Hyperostosis, which is predominantly found in women, is also 
thought to preclude transcranial Doppler measurements.43 As old age and 
female sex are positively associated with depressive symptoms, persons with 
mood disorders were underrepresented in our study. This selection may have 
impeded the detection of modest associations. However, we think it unlikely 
that the observed relations between cerebral haemodynamic variables and 
depressive symptoms were a result of selection. There is no indication that 
haemodynamic changes differ in women or very old depressed subjects. 
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Conclusions
We have shown that depressive symptoms are associated with changes in 
both blood flow velocity and vasomotor reactivity. Our finding of reduced 
vasomotor reactivity suggests that vascular pathology may be a causal 
factor in subjects with subthreshold depressive disorder but not in DSM-IV 
depressive disorders. Furthermore, our data indicate that reduced cerebral 
blood flow velocity could be caused by reduced demand in depressed sub-
jects and does not necessarily reflect microangiopathy. 
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ABSTRACT
Context: Vascular pathology may contribute to late-onset depression. Cross-sectional stud-
ies showed that elderly patients with depression more frequently have cerebral infarcts 
and white matter lesions on MRI. The relationship between cerebrovascular disease and 
depressive disorders has not been studied in the general population longitudinally.
Objective: To prospectively examine the association between symptomatic and asymp-
tomatic brain infarcts, white matter lesions and the risk of depressive disorders.
Design and Setting: The Rotterdam Scan Study, a large population-based prospective 
cohort study conducted in the Netherlands.
Participants: 1077 elderly people, aged 60 to 90 years, who all underwent MRI of the brain 
in 1995-1996. Presence of infarcts and severity of white matter lesions at baseline was 
scored. Participants were followed for on average 3.6 years.
Main Outcome Measure: Depressive disorders, assessed by psychiatric work-up of partici-
pants with CES-D score > 16 and monitoring of medical records of all 1077 participants for 
the development of depressive disorders during follow-up.
Results: Seventy-eight participants developed a depressive disorder during follow-up. The 
presence of brain infarcts at baseline nearly doubled the risk of depressive disorders (odds 
ratio 1.8, 95% confi dence interval 1.1-3.1). This risk increase of depressive disorders was 
restricted to participants with baseline infarcts who acquired new infarcts during follow-
up. Severity of subcortical white matter lesions was associated with an increased risk of 
incident depressive disorders (odds ratio per ml increase in subcortical lesions 1.08, 95% 
confi dence interval 1.00-1.17).
Conclusions: The presence of brain infarcts and white matter lesions increases the risk of 
depressive disorders in elderly people. Our fi ndings support the hypothesis that cerebrovas-
cular disease plays an important role in late-onset depression.
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INTRODUCTION
Late-onset depression may have a different etiology than early-onset depres-
sion. It has been postulated that vascular factors may play a role in the onset 
of depression in elderly people.1 Epidemiological and neuroimaging studies 
have shown that cerebrovascular lesions are more frequently present in 
depressive elderly patients than in controls.2,3 We showed earlier that white 
matter lesions on MRI were associated with depressive symptoms.4 Further-
more, one third of hospitalized stroke patients develop a major depression.5 
These findings support the ‘vascular depression’ hypothesis6 that cerebrovas-
cular disease contributes to the pathogenesis of late-onset depression. How-
ever, most of these studies were cross-sectional and hospital-based. Recently, 
a longitudinal population-based study found that cerebrovascular disease 
was related to depressive symptoms.7 Whether cerebrovascular disease 
increases the risk of depressive disorders in the general population has not 
been studied prospectively. We therefore examined the association between 
brain infarcts, white matter lesions and the risk of depressive disorders in an 
elderly population-based follow-up study. Because the risk of depression may 
be related to lesion location,5,8 we additionally investigated if this relation-
ship was influenced by different locations of these cerebrovascular lesions 
on MRI.
METHODS
Participants
The Rotterdam Scan Study was designed to study causes and consequences 
of brain changes in the elderly. The study design has been described in 
detail.9 In 1995-1996, we randomly selected participants aged 60 to 90 years 
in strata of age (5 years) and sex from two large ongoing population-based 
studies, the Zoetermeer Study and the Rotterdam Study.10,11 A total of 1077 
non-demented elderly participated in our study (overall response 63%). The 
medical ethics committee of the Erasmus Medical Center approved the study 
and each participant gave informed consent.
Baseline examination in 1995-1996 comprised a structured interview, 
screening for depressive symptoms, physical examination, blood sampling, 
and neuropsychological tests at the research center, as well as a cerebral 
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MRI scan. All 1077 participants were continuously monitored after baseline 
for mortality and major morbidity including depressive and other psychiatric 
disorders, dementia, stroke, and TIA. Follow-up was virtually complete until 
March 1st, 2000 (99.4%; of 7 participants we had no information on depres-
sion). In 1999-2000, we re-examined 787 of the participants at the research 
center with a protocol similar to the baseline examination (response 81%). 
Participants who were non-eligible (n=104) or those who refused the second 
examination (n=186) were significantly older and less educated compared 
to those who did participate; those who refused had also more depressive 
symptoms at baseline. In total, 668 underwent a second MRI scan in 1999-
2000 (response 70%).
Cerebral infarcts and white matter lesions
All participants underwent MRI of the brain in 1995-1996. We made axial T1-, 
T2-weighted, and proton-density scans on 1.5 Tesla MRI scanners (for partici-
pants from Zoetermeer: MR Gyroscan, Philips, Best, the Netherlands and for 
participants from Rotterdam: MR VISION, Siemens, Erlangen, Germany). The 
slice thickness was 5 or 6 mm with an interslice gap of 20%. In 1999-2000, 
participants underwent a second MRI using the MR VISION with the same 
sequences and protocol as at baseline.
The presence of infarcts was rated similarly at baseline and at follow-up. 
Infarcts were defined as focal hyperintensities on T2-weighted images, 3 mm 
in size or larger. Proton-density scans were used to distinguish infarcts from 
dilated perivascular spaces. Lesions in the white matter also had to have 
corresponding prominent hypointensities on T1-weighted images, in order to 
distinguish them from cerebral white matter lesions. A single trained physi-
cian (S.E.V.) scored infarcts both on baseline and second MRI, including their 
location and size. An intrarater study (n=110) for detecting infarcts showed 
good agreement (κ=0.80).12 We obtained a history of stroke and transient 
ischemic attack (TIA) by self-report, and by checking medical records in all 
1077 participants. An experienced neurologist (P.J.K.) subsequently reviewed 
the medical history and scans and categorized the infarcts as silent or symp-
tomatic. We defined silent brain infarcts as evidence of one or more infarcts 
on MRI, without a history of a (corresponding) stroke or TIA. Participants with 
both symptomatic and silent infarcts were categorized in the symptomatic 
infarct group.
White matter lesions were considered present if visible as hyperintense on 
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proton-density and T2-weighted images, without prominent hypointensity on 
T1-weighted scans. Two raters scored periventricular and subcortical located 
white matter lesions independently. Both intrareader and interreader studies 
(n=100) showed a good to excellent agreement (κ=0.79-0.90, r=0.88-0.95). A 
detailed description of the scoring method has been reported previously.9 
Briefly, severity of periventricular white matter lesions was rated semi-quanti-
tatively at three regions (grade range 0-9). A total volume of subcortical white 
matter lesions was approximated based on number and size of lesions in the 
frontal, parietal, occipital, and temporal lobes (volume range 0-29.5 ml).
Assessment of depressive disorders
We assessed whether participants had a psychiatric history in 1995-1996 by 
interview and by checking medical records and indications of prescribed 
drugs in all 1077 participants. We also screened the participants for depressive 
symptoms with a validated Dutch version of the original Center for Epidemio-
logic Studies Depression (CES-D) scale (range 0-60).13,14 A history of depression 
was defined as a depressive episode before the baseline examination lasting 
for more than two weeks, diagnosed by a psychiatrist, clinical psychologist, 
or general practitioner and treated with antidepressant medication.
Information on persistent and incident depressive disorders was obtained 
in two ways. Firstly, we re-examined 787 participants for depressive symp-
toms with the CES-D scale in 1999-2000. Participants with a CES-D score of 16 or 
more were considered screen-positive,14 and received a psychiatric work-up. 
A psychiatrist visited these participants at home and evaluated them with the 
Dutch version of the Present State Examination, a semi-structured psychiatric 
interview included in the Schedules for Clinical Assessment in Neuropsychia-
try.15 Psychiatric disorders including major depression, minor depression, and 
dysthymia were classified according to the DSM-IV criteria. Six participants 
were screen-positive on the CES-D scale, but received no psychiatric work-up 
and were subsequently excluded. Secondly, we continuously monitored the 
medical records of all 1077 participants at the general practitioner’s office 
and the Regional Institute for Ambulatory Mental Health to obtain informa-
tion on depressive episodes. Depressive disorders were diagnosed either 
by our screening and psychiatric work-up or by information from medical 
records if diagnosed by a psychiatrist, clinical psychologist, or general practi-
tioner and treated with antidepressant medication. Persistent depression was 
defined as a depressive disorder during follow-up, with depressive symptoms 
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(CES-D score > 16) or antidepressant medication at baseline. If participants 
did not have depressive symptoms or antidepressant medication at baseline, 
the depressive disorder during follow-up was considered to be incident.
Other measurements
Neuropsychological tests at baseline included the Mini-Mental State Exami-
nation (MMSE) (score range 0-30) as a measure of global cognitive function. 
All participants were followed for the development of dementia, which was 
diagnosed according to standardized criteria.
Data analysis
We first examined the cross-sectional association between the presence of 
brain infarcts and depressive symptoms at baseline (defined as CES-D > 16 or 
antidepressant medication at baseline) by estimation of the odds ratio and 
95% confidence interval with multiple logistic regression analyses. For the 
longitudinal analyses, we excluded participants of whom we had no infor-
mation on depression (n=7), those who were screen-positive but received 
no psychiatric work-up (n=6), and those who were diagnosed with another 
psychiatric disorder than a depressive disorder during follow-up (n=8). We 
examined whether the presence of brain lesions on MRI was predictive of a 
depressive disorder, persistent or incident, with multiple logistic regression 
analyses. In all analyses we adjusted for age, sex, education, and baseline 
MMSE score. We used separate models for presence of symptomatic and silent 
brain infarcts, and for severity of periventricular and subcortical white matter 
lesions. For the analyses with brain infarcts, the reference group comprised 
participants without brain infarcts and no distinction was made between 
participants with one or more infarcts on MRI. Periventricular and subcorti-
cal white matter lesions were analyzed in tertiles of their distribution, and 
continuously if the association was linear. In addition, we examined the risk 
of incident depressive disorders by excluding all participants on antidepres-
sant medication and those with depressive symptoms at baseline, defined as 
CES-D score of 16 or over (n=92). In order to investigate the risk of incident 
late-onset depression, we additionally excluded all participants with a his-
tory of early-onset depression (n=21). Early-onset depression was defined as a 
depressive episode with an onset before the age of 60 years. Because depres-
sive symptoms often precede dementia and this might confound the associa-
tions of interest, we repeated the analyses after exclusion of participants who 
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became demented during follow-up (n=34).
We further investigated the relationship between location of MRI lesions 
and risk of depressive disorders. According to some studies, patients with 
basal ganglia lesions in the left hemisphere have a higher risk of post-stroke 
depression.5,8 We examined if the relationship with the risk of depressive dis-
orders was different for infarcts located in the left basal ganglia compared to 
infarcts located elsewhere. In this respect, we also looked at subcortical white 
matter lesions in the frontal, parietal, occipital, and temporal lobes in relation 
to the risk of depressive disorders.
Finally, we explored the contribution of incident brain infarcts on the 
second MRI to the onset of depressive disorders during follow-up, because we 
hypothesized that a new infarct might result in depression.
RESULTS
The baseline characteristics of the study population are shown in Table 1. 
Brain infarcts on baseline MRI were associated with depressive symptoms at 
baseline in cross-sectional analysis (adjusted odds ratio 1.9, 95% confidence 
TABLE 1. Baseline characteristics of all participants.
All participants
n=1077
Age, years 72.2 ± 7.4
Women 555 (52%)
Primary education only 375 (35%)
History of depression 67 (6%)
Use of antidepressant medication 23 (2%)
CES-D score, range 0-60 5.9 ± 6.2
CES-D score > 16 79 (7%)
MMSE score, range 0-30 27.4 ± 2.2
Brain infarcts on MRI:
   Symptomatic
   Silent
259 (24%)
42 (4%)
217 (20%)
Periventricular white matter lesions, grade 2.4 ± 2.2
Subcortical white matter lesions, ml 1.4 ± 2.9
Values are unadjusted means ± standard deviation or number of participants (percentages).
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interval 1.2-3.0). Participants with symptomatic infarcts more often had 
depressive symptoms than those with silent brain infarcts when compared 
with participants without infarcts on baseline MRI, although this difference 
was not statistically significant (adjusted prevalence odds ratio for symptom-
atic infarcts 2.9, 95% confidence interval 1.2-7.0 and for silent infarcts 1.7, 95% 
confidence interval 1.0-2.8).
Seventy-eight participants (7%) were diagnosed with a depressive disorder 
during a mean follow-up of 3.6 years, of whom 30 had a persistent and 48 
had an incident depressive disorder. In 39 participants the depressive disor-
der was assessed by information from medical records and in 39 participants 
the depressive disorder was diagnosed during re-examination, of whom 18 
had a major depression, 18 a minor depression, and 3 dysthymia. The mean 
age of the 78 participants with a depressive disorder during follow-up was 
72.1 years and 55 (71%) were women. Twenty-six of these 78 participants 
had a history of a treated depression before baseline. Twenty-seven (35%) 
of them had one or more brain infarcts present on baseline MRI, of whom 23 
had silent brain infarcts only. They also had more severe periventricular and 
subcortical white matter lesions than participants without a depressive disor-
der during follow-up.
The presence of brain infarcts at baseline nearly doubled the risk of a 
persistent or incident depressive disorder (Table 2). Risks were similar for 
participants with symptomatic and those with silent brain infarcts, although 
the risk increase for symptomatic infarcts was not significant due to small 
numbers. The risk of a depressive disorder increased linearly with increasing 
periventricular and subcortical white matter lesions, which was borderline 
significant (Table 2). When analyses were restricted to those participants 
without antidepressant medication and depressive symptoms at baseline, the 
relationship between brain infarcts and the risk of depressive disorders disap-
peared (Table 2). Subcortical white matter lesions remained associated with 
incident depressive disorders, whereas the association with periventricular 
lesions diminished (Table 2). Additional exclusion of participants with early-
onset depression in history did not change any of the results (data not shown). 
None of the above risk estimates changed after exclusion of participants who 
developed dementia during follow-up, of whom 6 were diagnosed with a 
depressive disorder before the dementia diagnosis (data not shown).
Participants with basal ganglia infarcts in the left hemisphere at base-
line (n=62) had a nearly threefold-increased risk of depressive disorders 
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compared with participants without infarcts on MRI (adjusted odds ratio 2.9, 
95% confidence interval 1.4-6.2). This was higher than for participants with 
brain infarcts located elsewhere when compared with those without infarcts 
(adjusted odds ratio 1.5, 95% confidence interval 0.8-2.7), although these risk 
estimates were not significantly different. The risk of depressive disorders was 
similar for subcortical white matter lesions in the frontal lobes as for lesions in 
the parietal, occipital, and temporal lobes (data not shown).
Participants with infarcts on baseline MRI who acquired new infarcts 
during follow-up (n=35) had a threefold-increased risk of depressive disorders 
compared with those without infarcts and those with baseline infarcts only 
(adjusted odds ratio 3.4, 95% confidence interval 1.3-8.9). These participants 
had twice the risk of incident depressive disorders, although no longer sig-
nificant, after exclusion of participants with antidepressant medication or 
depressive symptoms at baseline (adjusted odds ratio 1.9, 95% confidence 
interval 0.5-7.2).
DISCUSSION
We found that elderly people with brain infarcts, both symptomatic and silent, 
TABLE 2. Association between presence of brain infarcts (symptomatic and silent) and 
white matter lesions (periventricular and subcortical) on baseline MRI and the risk of 
depressive disorders during follow-up, estimated by odds ratios (OR) with 95% confi -
dence intervals (CI) adjusted for age, sex, education, and cognitive function.
Persistent or incident 
depressive disorder*
OR (95% CI)
Incident depressive 
disorder†
OR (95% CI)
Infarcts (yes/no):
All infarcts
Symptomatic infarcts
Silent infarcts
1.8 (1.1-3.1)
1.9 (0.6-5.8)
1.8 (1.0-3.1)
1.0 (0.5-2.1)
1.4 (0.3-6.2)
1.0 (0.4-2.1)
White matter lesions:
Periventricular (per grade increase)
Subcortical (per ml increase)
1.11 (0.99-1.24)
1.06 (0.99-1.13)
1.09 (0.95-1.25)
1.08 (1.00-1.17)
* Analyses are based on 1056 participants with complete follow-up of depressive disorders.
† Analyses are restricted to 969 participants without antidepressant medication and without depres-
sive symptoms (CES-D score < 16) at baseline.
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have twice as frequent a depressive disorder compared with those without 
infarcts in the general population. Brain infarcts on baseline MRI did not 
predict the risk of incident depressive disorders in people without depressive 
symptoms at baseline, nor did periventricular white matter lesions. Severity of 
subcortical white matter lesions predicted the risk of incident depressive disor-
ders, both in persons with and without depressive symptoms at baseline.
The strengths of this study are the large number of participating elderly 
people and its prospective population-based design. Furthermore, we hardly 
had any losses to follow-up. However, a potential methodological limitation of 
our study is misclassification. Despite good agreement, we may have system-
atically over- or underrated infarcts or white matter lesions on MRI. Misclassifi-
cation may also have occurred in the diagnosis of depressive disorders during 
follow-up. Participants tend to underreport depressive symptoms and physi-
cians probably underdiagnose depressive disorders, which will have resulted 
in an underestimation of the true number of events. However, in addition to 
information from medical records we actively screened participants for the 
presence of depressive symptoms, and this will have reduced the underdi-
agnosis of depression. Furthermore, the raters and neurologist who identified 
and classified white matter lesions and infarcts and the psychiatrist who diag-
nosed the depressive disorders were blinded to all other data. If anything, this 
non-differential misclassification will have attenuated the associations and 
will not have introduced a major bias in our study.
We report an increase of persistence and incidence of depressive disorders 
in elderly people with brain infarcts and severe white matter lesions on MRI in 
the general population. We found that both people with symptomatic infarcts 
and those with asymptomatic lesions, i.e. silent brain infarcts or white matter 
lesions, had an increased risk of a depressive disorder. This suggests that in 
elderly people depression may be a direct consequence of vascular brain 
damage and is not only a psychological reaction to physical disability or per-
ceived disease. Ischemic damage of striatal and prefrontal cortical systems 
may disrupt neurotransmitter circuitry involved in mood regulation.16 Several 
hospital-based studies found that 30% of the stroke patients develop a depres-
sion,5 and this is three times higher than the 10% of the participants with 
symptomatic brain infarcts that acquired a depressive disorder in our study. 
We have to keep in mind that participants with symptomatic brain infarcts in 
our study have less severe stroke symptoms than patients in hospital-based 
studies. Furthermore, our participants with symptomatic infarcts may have 
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experienced their stroke or TIA years before the baseline examination and 
it could well be that people who developed a depression directly after their 
stroke did not participate in our study. Therefore, our study cannot unravel 
the psychological impact of experiencing a stroke on the development of 
depression after a stroke. Still, the increased risk in neurologically asymptom-
atic participants with silent brain infarcts and white matter lesions suggests 
that brain lesions themselves play a role in late-onset depression, extending 
our earlier cross-sectional findings.4 We found that severity of subcortical 
white matter lesions did increase the risk of incident depressive disorders, 
while the presence of brain infarcts did not. This is in line with the Cardiovas-
cular Health Study that recently reported that MRI infarcts were associated 
with persistence of depressive symptoms, whereas white matter lesions were 
associated with worsening of depressive symptoms.7 Infarcts are acute events 
and perhaps a depressive disorder develops directly after an infarct has 
occurred due to total cell loss in the infarcted area. White matter lesions on 
the other hand may represent a more gradual process of brain damage that 
might result in a depressive disorder after the damage has reached a certain 
threshold. This implies that many people with baseline infarcts already have 
a depression at baseline, which is supported by our cross-sectional findings 
and those of the Cardiovascular Health Study.17,18 Our finding that the risk 
of depressive disorders was confined to people with baseline infarcts who 
acquired new infarcts during follow-up supports this. As for lesion location, 
we found a stronger relationship of depression with subcortical than with 
periventricular white matter lesions. But the frequency of depressive disorders 
did not differ for any specific location of these subcortical lesions. This can be 
explained by the involvement of many brain structures, with subcortically 
located connecting fibers, in mood regulation. The risk of depressive disor-
ders seemed to be higher for people with basal ganglia infarcts in the left 
hemisphere, but this was not significantly different from that for persons with 
elsewhere located infarcts.
Silent brain infarcts, of which the majority is lacunar,12,19 and white matter 
lesions reflect mainly small-vessel disease.20 Both are related to an increased 
stroke risk21 and are thought to be risk factors for dementia and cognitive 
decline.22 Depressive symptoms often precede the development of demen-
tia.23 The relationship between depressive symptoms and silent brain infarcts 
disappeared after adjustment for physical disability and cognitive impair-
ment in the Cardiovascular Health Study.18 In our study, the risk increase of 
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depressive disorders with the presence of brain lesions remained both after 
adjustment for cognitive function and after exclusion of participants who 
developed dementia during follow-up.
In conclusion, we found an increased risk of depressive disorders in elderly 
people with cerebrovascular lesions in the general population. The asso-
ciations were present for symptomatic and asymptomatic brain lesions. This 
supports that vascular brain damage plays an important role in late-onset 
depression. Whether prevention of brain infarcts and white matter lesions 
will diminish the number of depressive disorders in elderly people needs to 
be examined.
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Inflammatory proteins
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ABSTRACT
Background: Clinical studies suggest that depression may be accompanied by an activa-
tion of the infl ammatory response system. We investigated the relation of cytokine inter-
leukin-6 (IL-6) and the acute phase proteins α1-antichymotrypsin (ACT) and C-reactive 
protein (CRP) with depression in a population-based study.
Methods: We screened 3,884 adults at age 60 and older living in a district of Rotterdam for 
depressive symptoms, and performed a psychiatric work-up on those who were screened 
positive. All subjects had blood drawn. We compared levels of infl ammation markers 
adjusted for smoking, stroke, functional disability and cognitive score for 263 cases with 
depressive symptoms (including 106 subjects with depressive disorders) and 461 randomly 
selected reference subjects. 
Results: Age- and gender-adjusted analyses suggested associations of ACT and CRP with 
depressive disorders, but these associations disappeared after adjustment for additional 
confounding factors. Even after adjustment, increased levels of IL-6 were related to 
depressive disorders (odds ratio per standard deviation increase IL-6 = 1.47; 95% confi -
dence interval = 1.15 – 1.89). Further analyses demonstrated that this relation was mainly 
due to the subjects with high IL-6 concentrations, suggesting a threshold effect. 
Conclusions: IL-6 levels were strongly increased in some subjects with depressive disorders, 
possibly indicating a specifi c immunological process. However, the associations of acute 
phase proteins with depression in this population-based study could be explained by con-
founding. 
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INTRODUCTION
Clinical studies have shown that depression is associated with increased 
levels of circulating cytokines and acute phase proteins.1-4 However, critics 
argue that the increased levels of acute phase proteins such as C-reactive 
protein (CRP) are not specific for depression but mainly reflect the effects of 
other associated variables such as hospitalization, tobacco dependence, and 
co-morbidity.4-6 Indeed, some studies have not been able to reproduce the 
findings of immune activation.7-9
The present study explored the relation of cytokine IL-6 and the acute 
phase proteins CRP and α1-antichymotrypsin (ACT) with depressive disorders. 
IL-6 is a central mediator of the acute phase response and CRP is the classic 
acute phase reactant.10,11 Our aim was to investigate whether the reported 
associations with depression can be found in a population-based study after 
controlling for a variety of demographic and medical variables.
METHODS
Study population
This study is based on the Rotterdam Study, an ongoing population-based 
cohort study in which all inhabitants age 55 and over, living in a defined 
geographic area of Rotterdam, had been invited to participate.12 The base-
line response rate was 78%. The Medical Ethics Committee of the Erasmus 
University approved the study and written informed consent was obtained 
from all participants. In the third survey (1997-1999) we added assessment of 
depressive symptoms to the study protocol. Of the 4703 persons who partici-
pated in that survey, 3,884 visited the research center and had venous blood 
samples drawn. In the present analysis we compared inflammatory proteins 
in 263 cases with depressive symptoms and 461 randomly selected reference 
subjects.
Depression assessment
Depressive disorders were assessed using a two-step procedure. First, partici-
pants completed the Dutch version of the original Center for Epidemiological 
Studies Depression scale (CES-D) during a home interview.13,14 We used a score 
of 16 as a cut-off, which indicates clinically significant depressive symp-
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toms.15 Secondly, screen-positive subjects had a psychiatric work-up using 
the Present State Examination, a semi-structured psychiatric interview.16 All 
interviews were conducted by two experienced clinicians. Psychiatric dis-
orders were classified according to the Diagnostic and Statistical Manual of 
Mental Disorders-IV criteria. The diagnostic categories include major depres-
sion, dysthymia and minor depression.
Of the 3884 subjects who visited the research center, 263 (7%) were screen-
positive for depressive symptoms. Of these, 250 (95%) had a psychiatric 
work-up. In total, 106 cases had a depressive disorder. These subjects were 
classified as having major depression (n=47), dysthymia (n=13) or minor 
depression (n=46). The remaining 144 subjects were diagnosed as having 
another psychiatric disorder (n=29), or they did not meet criteria for an Axis I 
psychiatric disorder (n=115, subclinical depressive symptoms). Eight subjects 
declined to undertake the interview, and five subjects could not be reached.
Blood specimens
Overnight fasting blood was collected, put on ice directly, and centrifuged 
at 2000g for 10 min. Plasma was separated and dispensed into two 1.5 ml 
aliquots and then frozen within three hours at -80°C. Both ACT and CRP were 
assessed by means of a nephelometric method (BN 100, Dade Behring, Mar-
burg, Germany). The IL-6 concentrations were determined with quantitative 
enzyme-linked immunosorbent assay with a test kit from R&D systems (Minne-
apolis, USA). The intra-assay and interassay coefficients for all measurements 
were < 5% and < 8%, respectively.
Other measurements
The following variables were considered as possible confounding variables: 
age, sex, education, stroke, cognitive function (as measured by the Mini 
Mental State Examination), smoking, body mass index, antidepressant drug 
use and functional disability. Education was measured on an ordinal scale 
and later dichotomized at the median of the sample into low and high edu-
cation. A history of stroke was obtained through direct questioning and com-
puterized linkage with general practitioner medical records. Smoking was 
coded as number of cigarettes currently smoked per day and in categories 
of current, former and never smoker. Functional status was assessed using 
the Stanford Health Assessment Questionnaire.17 In an additional analysis we 
adjusted for atherosclerosis as measured by the intima-media thickness in the 
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carotid arteries.18
Statistical analysis
We used logistic regression to estimate odds ratios (OR) and 95% confidence 
intervals (CI) of inflammation markers for depressive symptoms, depressive 
disorders and major depression. Inflammation markers were entered into 
separate models as a continuous variable (divided by its standard deviation). 
To further explore the relation we checked whether there was a threshold 
effect. For this, we calculated the odds ratios for each decile of the inflamma-
tion marker. We plotted the odds ratios at the median of each decile using the 
unit of inflammation markers on the x-axis. 
Age (continuous) and sex were controlled for in all analyses. To check 
for confounding we added potential confounders to the basic model. If this 
changed the effect estimate meaningfully the variables were included in 
further analyses.19 
TABLE 1: Selected characteristics of the study subjects, Rotterdam Study, 1997-1999
Non-
depressed
(n=461)
Depressive 
symptoms*
(n=263)
Depressive
disorder*
(n=106)
Age (yrs) (mean, range) 72.4 (61-101) 73.7 (61-97) 73.6 (61-97)
% female 59 74 73
Primary education only (%) 49 57 57
Body mass index (kg/m2)
 (mean, SD)
27.7 (8.3) 27.9 (9.4) 27.9 (10.6)
Smoking
-cigarettes per day (mean, range) 
-current smoker (%)
-ex-smoker (%)
1.7 (0-30)
15
50
2.7 (0-30)
19
42
2.8 (0-25)
21
41
History of stroke (%) 2 7 8
MMSE-score (mean, SD) 27.6 (2.2) 26.8 (2.9) 26.2 (3.7)
Functional disability (%) 30 56 60
Antidepressant medication (%) 2 11 17
Interleukin-6 (pg/ml) 3.19 3.80 4.56
α1-Anti-chymotrypsin (mg/dl) 39.6 40.3 41.5
C-reactive protein (mg/l) 3.08 3.36 3.80
CES-D = Center of Epidemiologic Studies Depression scale; MMSE = Mini Mental State Examination; 
BMI = Body Mass Index.
*The category ‘depressive symptoms’ includes all subjects who were screen positive, the category 
‘depressive disorder’ includes only the subjects with major or minor depression and dysthymia.
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TABLE 2: The association between infl ammatory proteins and depression, Rotterdam 
Study, 1997-1999
Infl ammatory proteins
Depressive symptoms*
(263 cases)
Depressive disorder*
(106 cases)
Odds ratio  95% CI Odds ratio  95% CI
Interleukin-6, per SD
  Model 1† 
  Model 2‡ 
  Model 3§ 
1.23
1.18
1.11
0.99, 1.53
0.94, 1.47
0.86, 1.43
1.46
1.47
1.38
1.15, 1.85
1.15, 1.89
1.04, 1.83
α1-Anti–chymotrypsin, per SD
  Model 1 
  Model 2 
  Model 3 
1.12
0.99
0.93
0.95, 1.32
0.83, 1.18
0.77, 1.11
1.21
1.08
0.93
0.98, 1.50
0.86, 1.37
0.72, 1.20
C-reactive protein, per SD
  Model 1 
  Model 2 
  Model 3 
1.06
1.01
0.97
0.91, 1.23
0.86, 1.18
0.80, 1.16
1.16
1.09
1.00
0.96, 1.39
0.90, 1.33
0.76, 1.29
SD = standard deviation; CI = confi dence interval
*The category ‘depressive symptoms’ includes all subjects who were screen positive, the category 
‘depressive disorder’ includes only the subjects with major or minor depression and dysthymia.
† Model1: Logistic regression analyses adjusted for age and gender; subjects (n=461) without 
depressive symptoms were used as the reference group. Infl ammation markers were analyzed as a 
continuous variable divided by one standard deviation.
‡ Model 2: As model 1 and additionally adjusted for smoking, history of stroke and functional dis-
ability.
§ Model 3: As model 2 and additionally adjusted for atherosclerosis as measured by intima-media 
thickness in the carotid arteries. These analyses were based on 96 subjects with depressive disorders, 
240 subjects with depressive symptoms and 433 reference subjects due to missing atherosclerosis 
data.
RESULTS
Table 1 presents characteristics of the reference subjects, the cases with 
depressive symptoms, and the subgroup of cases with depressive disorders. 
No strong associations between inflammation markers and depressive 
symptoms were observed (Table 2). The odds ratios for DSM-IV depressive 
disorders were higher than those for depressive symptoms. Adjustment for 
general confounders did not change the association with IL-6: Control for ath-
erosclerosis had a moderate effect, but even after this adjustment, subjects 
with increased levels of IL-6 were more likely to have a depressive disorder. 
In contrast, the odds ratios associated with ACT and CRP decreased substan-
tially after adjustment. Age, sex, smoking, stroke, functional disability and 
atherosclerosis were entered into the model; no other covariate altered the 
estimates. Furthermore, we compared the subjects with major depression and 
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the reference group. Results were essentially the same as for the group of 
depressive disorders as a whole (data not shown).
Figure 1 shows the odds ratios of deciles of IL-6. Over a broad range of 
Il-6 levels an association between IL-6 and depressive disorders was hard to 
discern. However, visual inspection suggested a threshold at high levels of 
IL-6; subjects in the upper decile of IL-6 (above 9.3 pg/ml) were at a high risk 
to have a depressive disorder. If the upper decile of IL-6 is chosen as a cut-off 
(dichotomous variable), the odds ratio was 3.9 (95% CI = 1.5 – 9.9).
DISCUSSION
In this population-based study of elderly subjects we found that high levels of 
cytokine IL-6 were associated with depressive disorders. After controlling for 
confounders, the acute phase proteins ACT and CRP were not increased in 
depressed subjects.
Some methodologic issues of the present study need to be considered. 
0,1
1
10
0 5 10 15 20
Interleukin-6
Od
ds
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Figure 1: The association between deciles of interleukin-6 and depressive disorders.
Logistic regression analysis adjusted for age, gender, history of stroke, smoking and func-
tional status. Odds ratios for depressive disorders (triangles) and 95% confi dence intervals 
(vertical lines) are plotted at the median of the interleukin-6 decile. 
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Firstly, residual confounding may explain our findings. Cardiovascular risk, 
medical co-morbidity or treatment may be incompletely controlled for.4,20 Sec-
ondly, the prevalence of subjects with depressive symptoms in this study (7%) 
was relatively low and this could impede the detection of modest associations. 
However, it is comparable to the community prevalence of depressive symp-
toms in the elderly reported by Blazer et al. in the US (9%) in a study that also 
used the CES-D.15 A strength of the study is the psychiatric work-up; hence, 
misclassification of disease is unlikely to have influenced our results.
For many years the finding that increased levels of acute phase proteins 
may occur in association with depression primarily emanated from one 
research group studying hospitalized patients and healthy controls.1,21-23 
Several confounding factors such as severity of symptoms, co-morbidity and 
tobacco dependence might have accounted for the heterogeneity in obser-
vations reported by other investigators.4 In the present study smoking status 
as measured by cigarettes currently smoked per day, as well as stroke, were 
strongly related to the acute phase proteins. Only a weak association of ACT 
and CRP with depressive disorders remained after adjustment, whereas IL-6 
may be independently related to depression. Our findings concerning the 
ACT and CRP are in contrast to some previous observations, but these were 
comparisons of clinical samples with healthy controls.8,21,24,25 On the other 
hand, a recent population-based study of IL-6 reported a moderate associa-
tion with depressive symptoms as measured by the CES-D.26 Further research 
is needed to establish whether only specific inflammatory proteins are ele-
vated in depression or whether our results were a chance finding.
The observed relation between IL-6 and depression in the present study 
was not linear. To our knowledge previous studies did not investigate the 
nature of the association with IL-6. However, our results are compatible with 
observations in experimental studies. Pollmächer and coworkers27 stimulated 
an IL-6 response by applying endotoxins intravenously. Negative emotions 
were observed at IL-6 levels more than 20 times higher than those in our 
study. In contrast, moderately increased levels had a positive effect on mood. 
In another study endotoxin also elicited a dose-dependent effect of on sleep.28 
Low doses enhanced sleep and high levels resulted in a disrupted sleep pat-
tern typical for psychiatric illnesses. Thus there may be a threshold above 
which IL-6 has a negative effect on mood, and high concentrations could 
directly cause the depressed affect in a small group of community dwelling 
subjects. Furthermore, part of the relation between inflammation markers 
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and depression was explained by atheroslerosis. Inflammation is related to 
atherosclerosis, and atherosclerosis in turn is a possible cause of depression 
in the elderly.29,30 However, the present study cannot demonstrate whether 
atherosclerosis actually is part of the causal pathway between inflamma-
tion and depression. Cardiovascular disease and depression could be related 
independent of inflammatory processes, in which case atherosclerosis must 
be seen as a confounder. 
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ABSTRACT
Background: It has been hypothesized that n-3 polyunsaturated fatty acids (PUFAs) are 
involved in mood regulation, but epidemiological evidence for such a link in the general 
population is lacking. 
Objective: This study examined whether community dwelling elderly persons with depres-
sion have a different fatty acid composition than the non-depressed.
Design: As part of the Rotterdam Study we screened 3,884 adults aged 60 years and over 
for depressive symptoms. Screen positive subjects had a psychiatric interview to diagnose 
depressive disorders. All eligible subjects had blood drawn and concentrations of plasma 
phospholipids were determined. We compared percentage of n-3 and n-6 PUFAs and their 
ratio between 264 cases with depressive symptoms, including 106 subjects with depressive 
disorders, and 461 randomly selected reference subjects. We also investigated whether 
atherosclerosis or infl ammatory response as measured by C-reactive protein (CRP) underlie 
the relationship between fatty acid composition and depression.
Results: Subjects with depressive disorders had a higher ratio of n-6/n-3 PUFAs, but differ-
ences in individual PUFAs were mostly small. However, the depressed subjects with normal 
CRP concentrations had a substantially altered fatty acid composition; n-3 PUFA percent-
age was lower and n-6/n-3 ratio higher in subjects with depressive disorders as compared 
to controls (5.2% vs. 5.9%, p=0.02 and 7.2 vs. 6.6, p=0.01, respectively). This relation was not 
due to atherosclerosis.
Conclusions: In community dwelling persons fatty acid composition is related to depression. 
Because this was not secondary to infl ammation, atherosclerosis or possible confounders 
this association suggests a direct impact of fatty acid composition on mood.
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INTRODUCTION
The long chain polyunsaturated fatty acids (PUFAs) fall into two main fami-
lies: omega-3 (n-3) and omega-6 (n-6). The n-3 PUFAs are derived from fish 
and some plants, the n-6 PUFAs mainly from vegetable oil. The principal pre-
cursors of the n-3 and n-6 PUFAs cannot be endogenously synthesized from 
carbohydrates. The specific concentrations of the n-3 and n-6 PUFAs in blood 
or cell membranes thus reflect dietary intake.1 Long term changes of dietary 
habits in Western societies are believed to have altered the ratio between n-
6 and n-3 PUFAs. In ecological studies it has been postulated that the rise in 
the incidence of coronary heart disease and depressive disorders in the last 
century was related to a diet change, which was characterized by a slightly 
increased intake of total and saturated fats, and a two- to threefold increase 
in oils from seeds.2-5 
Different mechanisms may underlie the relation found in the ecological 
studies. Fatty acid composition determines the biophysical properties of 
neuronal membranes and influences neurotransmission.6 Higher n-3 PUFA 
concentrations lead to higher membrane fluidity, which in turn increases 
serotonin transport.3,7 These biochemical mechanisms connect fatty acids 
to the current receptor- and neurotransmitter-based hypothesis of depres-
sion. But other mechanisms are also discussed, dietary intake of n-3 PUFAs 
decreases the risk of atherosclerosis,8 whilst increased n-6 PUFAs result in an 
overproduction of prostacyclins and inflammatory markers.9 Both inflamma-
tion and atherosclerosis have been associated with depression and could link 
fatty acids and depression.10-12
A few small hospital studies have investigated the relation between the 
fatty acid composition and depressive disorders.10,13-16 They reported low n-3 
PUFA concentrations in subjects with depression as compared to healthy con-
trols. However, since the studies thus far have been restricted to psychiatric 
patients, it is unknown whether fatty acid composition affects mood in the 
general, community dwelling population. Various factors such as chronic dis-
eases, cigarette smoking or cholesterol levels are related to both depression 
and fatty acid composition.17 These confounders might explain the associa-
tions observed in earlier studies. The present population-based study investi-
gates the relation between fatty acid composition of plasma phospholipids 
and depressive disorders in elderly persons controlling for a number of demo-
graphic and biological variables. Nutrient intake in elderly persons usually 
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shows less day-to-day variation18 and fatty acid concentrations presumably 
reflect long-term intake under the assumption of fairly consistent dietary pat-
terns. 
SUBJECTS AND METHODS
Study population
This study is based on the Rotterdam Study, an ongoing population based 
cohort study for which all inhabitants aged 55 and over of a suburb of Rot-
terdam were invited in 1990 to 1993.19 A total of 7983 men and women (78% 
percent of those eligible) entered the study. The Medical Ethics Committee 
of the Erasmus University approved the study and written informed consent 
was obtained from all participants. In the third survey we added assessment 
of depressive symptoms to the study protocol. Measurements took place 
between March 1997 and December 1999 and included a home interview 
and a visit to the research center. Of the 4703 persons who participated in 
the home interview, 3884 visited the research center and had venous blood 
samples drawn. The 819 subjects who were not seen at the research center 
were on average older (77.5 versus 72.3 years), more likely to be female (70 % 
versus 58 %) and had more depressive symptoms (12.2% versus 6.8%, overall 
prevalence 7.8%). In the present analysis we compared fatty acid composi-
tion between all subjects with depressive symptoms and randomly selected 
reference subjects.
Depression assessment
Depressive disorders were assessed using a two step procedure. First partici-
pants completed the Dutch version of the original Center for Epidemiologic 
Studies Depression scale (CES-D) during the home interview. The CES-D is 
a 20-item self-reported measure of symptoms experienced in the last week. 
Each item is scored on a scale of 0 to 3 points. The criterion validity of the 
CES-D version is well established.20 We used a score of 16 as a cut-off, which 
had a very high sensitivity for major depression in a random sample of older 
subjects in the Netherlands.21 Moreover, previous studies have verified that a 
score of 16 and above on the CES-D represents clinically significant depres-
sive symptoms.22 As a second step, screen positive subjects had a psychiatric 
work-up using the Dutch version of the Present State Examination (PSE-10), a 
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semi-structured psychiatric interview included in the Schedules for Clinical 
Assessment in Neuropsychiatry (SCAN).23 The psychometric properties of the 
SCAN have been studied in Dutch patients. An excellent agreement on the 
syndrome level and a substantial test-retest reliability were found.24 One or 
other of two experienced clinicians conducted all interviews. Psychiatric dis-
orders were classified according to the Diagnostic and Statistical Manual of 
Mental Disorders-IV (DSM-IV) criteria with an algorithm based on the PSE-10 
scores. The diagnostic categories include major depression and dysthymia in 
addition to minor depression (as defined in the appendix of the DSM-IV).
Of the 3884 subjects who visited the research center and had blood taken, 
264 (6.8%) were screen-positive on the CES-D and were included in the analy-
sis of depressive symptoms. Nine subjects refused the subsequent psychiatric 
interview, and five screen positive subjects could not be reached. Psychiatric 
disorders and duration of symptoms were thus defined in 250 (95.1%) par-
ticipants according to DSM IV criteria. Psychiatric work-up revealed that 106 
cases had a depressive disorder as defined by the Diagnostic and Statistical 
Manual of Mental Disorders-IV. The remaining 144 subjects were diagnosed 
as having either an anxiety (n=20) or another psychiatric disorder (n=9) or 
did not meet criteria for an Axis I psychiatric disorder (n=115, subclinical 
depressive symptoms).
Selection of reference subjects
A sample of 461 participants ranging in age from 61 to 101 years, served 
as the reference group. They were randomly selected from the participants 
of the Rotterdam Study who were screen-negative for depression. A large 
number of controls increase statistical efficiency but financial constraints did 
not permit determination of fatty acid composition in all subjects. We did 
not match on possible confounding variables in order to be able to study the 
effect of several of these variables on the relation between fatty acids and 
depression. 
Blood specimens
Overnight fasting blood was collected under standardized conditions in a 10 
ml tube of citrate-anticoagulated blood, put on ice directly and centrifuged 
at 2000g for 10 min. Plasma was separated and dispensed into two 1.5 ml 
aliquots and frozen within three hours at -80°C until analyzed. The concen-
tration of fatty acids originating from the phospholipid fraction of plasma 
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was determined. The total lipid extracts of plasma were prepared accord-
ing to a standard method.25 The plasma lipids were extracted from 0.25 ml 
plasma with chloroform and methanol after addition of internal standard 
(Nonadecanoyl 1,2-Diacyl-sn-Glycero-3-Phosphocholine, Avanti Polar Lipids 
Inc Alabaster, USA). Thereafter, solid phase extraction was used to separate 
the phospholipids from the other lipid classes in the extract by NH2 columns 
(Bond Elut 500mg 3ml, Varian, Middelburg, the Netherlands). After separa-
tion, the phospholipids are methylated via reaction with 14% boron trifluoride 
in methanol at 100ºC for one hour. Butylated hydroxytoluene was added 
as anti-oxidant to all organic solvents. Fatty acid methyl esters present in 
the phospholipid fraction were determined via high-resolution capillary 
gas-liquid chromatography (Shimadzu GC17A chromatograph, Shimadzu 
Benelux ’s-Hertogenbosch, The Netherlands) with split injection (1:15) and a 
flame ionization detector using a 50m fused silica column (CP-SIL 88 for FAME, 
0.25mm ID, 0.2 µm film, Chrompack, Varian, Middelburg, the Netherlands). 
The temperature program was as follows: an initial temperature of 160°C for 
10 min, followed by a temperature increase of 3.2°C/min up to 190°C, a 15-
min isotherm period, a temperature increase of 5.0°C/min up to 230°C, a 
7-min isotherm period.
Fatty acid amounts present in the phospholipid fraction were quantified 
based on the amount of 19:0 internal standard fatty acid methyl ester recov-
ered, and expressed as mg/l plasma and percentage of total fatty acids 
(based on the mg/l). Total phospholipid fatty acid concentrations did not 
differ between depressed and reference subjects (1139 mg/l v 1140 mg/l). 
Therefore, a difference in percentage of individual fatty acids between the 
groups also reflects a difference in absolute amounts. The data were trans-
ferred electronically to minimize transcription errors.  
Other measurements
The following variables were considered as possible confounding variables: 
age, gender, level of education, history of stroke, cognitive function as mea-
sured by the Mini Mental State Examination, disabilities in activities of daily 
living and the cardiovascular risk factors cigarette smoking, blood pressure, 
serum total and HDL cholesterol. Education was measured on an ordinal 
scale and later dichotomized at the median of the baseline sample into 
low and high education. A history of stroke was obtained from all subjects 
through direct questioning and computerized linkage with general practitio-
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ner medical records. We assessed cholesterol concentration in fasting blood 
by an automated enzymatic procedure. Cigarette smoking was scored in cat-
egories of current, former and never smoker. Functional status was assessed 
using the Disability Index of the Stanford Health Assessment Questionnaire.26 
This measure reflects the consequences of disease in terms of functional per-
formance and activities. 
We also measured the inflammation marker C-reactive protein (CRP) by a 
nephelometric method and intima-media thickness as an indicator of athero-
sclerosis. The latter was assessed by recording ultrasonographic images of the 
common carotid artery; in the analyses we used the average of near and far 
wall measurements of both left and right side. 
Statistical analysis
We used the individual fatty acids percentages (% of total fatty acids) in the 
analyses. Further, we calculated the ratio between n-6 and n-3 PUFAs as 
well as the ratios between arachidonic acid to eicopentaenoic acid (AA/EPA) 
and arachidonic acid to docosahexaenoic acid (AA/DHA). Previous work 
focussed on AA/EPA, whereas DHA is believed to be important in mental 
function.10,15 The association of fatty acids with depressive symptoms, sub-
clinical depressive symptoms and depressive disorders was quantified with 
analysis of covariance (ANCOVA). Fatty acid percentages and ratios were 
entered into separate models as continuous variables. Equal variance of fatty 
acid percentages in case and referent subjects was tested with Levene’s Test 
for Equality of Variances. No significant differences in variance were found. 
Age (continuous) and gender were controlled for in all analyses. To check 
for confounding we added potential confounders to the basic model. If this 
changed the effect estimate meaningfully (defined as more than 5%) the 
variables were included in further analyses.27 In the tables we present the 
unadjusted means and the fully adjusted mean differences. 
Finally, we investigated whether C-reactive protein and intima-media 
thickness were intermediates or effect modifiers of the association between 
fatty acid ratios and depression. To study possible intermediates we exam-
ined whether associations changed when these variables were entered 
into the model as covariates and calculated the non-parametric correla-
tion (Spearman’s) of CRP and intima-media thickness with fatty acids. Effect 
modification was formally tested by putting the product terms into the model. 
Furthermore, we stratified the analyses by the median of CRP.
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We used SPSS for Windows 9.0 in all our analyses.
RESULTS
The characteristics of the reference subjects and the cases with depressive 
disorders are presented in table 1. Subjects with depressive disorders were 
more likely to be female, to have had a stroke and had lower activities of 
daily living and cognitive scores.
We found no difference in plasma phospholipid fatty acid composition 
between the reference group and the 264 subjects that had depressive symp-
toms as determined by the CES-D (data not shown). The comparisons of the 
115 subjects with subclinical depressive symptoms and the 106 cases who 
fulfilled criteria for a DSM-VI depressive disorder with the reference subjects 
are shown in table 2. Subjects with subclinical depressive symptoms had the 
same percentages of fatty acids in phospholipids and the same ratios as the 
non-depressed reference subjects.
In the analyses restricted to persons with DSM-IV depressive disorders and 
the reference subjects we observed moderate differences in average percent-
ages of only two individual PUFAs. Mean arachidonic acid percentage was 
higher and docosahexaenoic acid percentage was lower in subjects with 
depressive disorders. However, we observed a borderline significant differ-
ence in the ratio of n-6/n-3 as well as the AA/EPA and the AA/DHA ratios. 
This was due to the higher percentage n-6 and less n-3 PUFAs depressed sub-
jects had compared to reference subjects.
The results shown in table 2 were adjusted for age, gender, smoking, blood 
pressure and activities of daily living score. Neither adjusting for any other 
of the possible confounders that we measured, CRP nor intima-media thick-
ness changed the results.Thus there was no evidence that the inflammation 
marker CRP or atherosclerosis as measured by intima-media thickness medi-
ate the relation between fatty acids and depressive disorders. Moreover, all 
Spearman’s correlation coefficients for the relation of both variables with 
the fatty acids were below 0.01 except for percentage saturated fatty acids. 
However, a formal test for interaction demonstrated that the relation between 
n-6/n-3 ratio and depressive disorders depended on the CRP concentration 
(interaction term included in ANCOVA, p=0.02). The difference in n-6/n-3 
ratio between depressed and non-depressed subjects increased with lower 
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TABLE 1: Selected characteristics of the study subjects
No depressive 
symptoms
n=461
Subthreshold depres-
sive
symptoms1
n=115           p-value2
Depressive
disorders
n=106          p-value2
Age, years3  72.5 (61-101) 73.9 (61-93) 0.10 73.7 (61-97) 0.16
Gender (% female)  58.6 77.3 0.01 72.6 0.05
Primary education 
only (%)
 48.8 58.2 0.44 56.6 0.52
MMSE4-score3  27.6 (2.2) 27.2 (2.1) 0.55 26.2 (3.7) 0.001
History of stroke (%)   2.0 7.8 0.01  7.5 0.03
Smoking
   - current smoker
   - ex-smoker
 15.0
 49.5
17.3
44.3
0.21
0.49
20.8
40.6
0.06
0.16
Blood pressure
   - systolic
   - diastolic
144 (21)
 75 (12)
141 (20)
72.2 (11)
0.17
0.06
139 (24)
73 (12)
0.03
0.23
Total cholesterol
(mmol/L)
  5.9 (0.9) 5.8 (1.0) 0.37  5.8 (1.0) 0.40
HDL cholesterol
(mmol/L)
  1.4 (0.4) 1.4 (0.4) 0.12  1.4 (0.4) 0.88
Activities of daily
living score5
  0.5 (0.5) 0.7 (0.6) 0.01  0.8 (0.6) 0.001
C-reactive protein
(mg/l)
   - mean
   - median
  3.1 (4.6)
  1.5
3.1 (5.2)
1.6
0.95  3.8 (5.3)
 1.6
0.16
1 Subjects with subthreshold depressive symptoms were screen positive on the Center of Epidemio-
logical Studies Depression Scale but did not fulfi l the DSM-IV criteria for depressive disorders or for 
any other psychiatric disease. 
2  p values were calculated performing analysis of covariance or logistic regression adjusted for 
age and gender were appropriate.
3 Values are unadjusted means and ranges for age, and unadjusted means and standard devia-
tions for MMSE-score, blood pressure, cholesterol, activities of daily living score and C-reactive 
protein.
4 MMSE = Mini Mental State Examination, HDL = high density lipoprotein.
5 Higher scores indicate a higher degree of functional disabilities in activities of daily living.
concentrations of CRP. Therefore we stratified the analysis between fatty 
acids and depressive disorders at the median of CRP (1.5 mg/l). We found 
no significant difference in fatty acid composition between non-depressed 
and depressed subjects with a CRP concentration above 1.5 mg/l (data not 
shown). The analysis of subjects with a CRP concentration below 1.5 mg/l is 
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presented in table 3. Depressed subjects had a significantly lower n-3 PUFA 
percentage and both ratios showed an altered fatty acid distribution as com-
pared to the reference subjects with CRP below 1.5 mg/l.
To further investigate whether a substantially different fatty acid compo-
sition is seen in all depressed subjects with a normal CRP, we repeated the 
analyses and excluded all subjects (cases and referents) with a CRP above 
the normal range (upper limit 5 mg/l). Depressed subjects with normal CRP 
concentrations had significantly lower total n-3 PUFA percentage and a 
higher n-6/n-3 ratio in plasma phospholipids than the non-depressed sub-
jects with normal CRP concentrations (mean percentage: 5.2 vs. 5.9, p = 0.02, 
mean ratio: 7.2 vs. 6.6, p = 0.01).
TABLE 3: Association of fatty acids and fatty acid composition in plasma phospholipids 
with depression in subjects with low C-reactive protein concentrations1
Percentage fatty acids
Non-
depressed
(n=232)
Depressive disorders
(n=51)
mean  mean
adjusted
difference 
(95% CI)
p-value
Saturated fatty acids 45.8 46.1 0.3 (-0.2; 0.7)  0.2
Monounsaturated 11.6 11.5 -0.1 (-0.7; 0.5)  0.6
Polyunsaturated (PUFA)
  n-6
      Linoleic (18:2)
      Dihomogammalinolenic (20:3)
      Arachidonic (AA; 20:4)
      Total n-6 PUFA
  n-3
      Eicosapentaenoic (EPA, 20:5)
      Docosapentaenoic (22:5)
      Docosahexaenoic (DHA, 22:6)
      Total n-3-PUFA
22.1
3.2
9.0
35.6
0.9
1.0
3.7
5.9
22.4
3.2
9.3
36.1
0.7
0.9
3.2
5.2
0.3 (-0.6; 1.2)
-0.1 (-0.3; 0.1)
0.3 (-0.4; 1.0)
0.6 (-0.3; 1.4)
-0.2 (-0.4; 0)
0 (-0.1; 0)
-0.4 (-0.8; -0.1)
-0.7 (-1.2; -0.1)
 0.6
 0.5
 0.4
 0.2
 0.05
 0.1
 0.02
 0.01
Ratios
  n-6/n-3 PUFA
  AA/EPA
  AA/DHA
6.6
13.2
2.7
7.6
16.4
3.1
0.9 (0.3; 1.6)
3.3 (0.9; 5.7)
0.4 (0.1; 0.7)
 0.006
 0.007
 0.02
1Analyses of covariance with percentage fatty acid entered as continuous variables and adjusted 
for age, gender, smoking, systolic blood pressure and activities of daily living.
Values represent unadjusted means and adjusted differences (95% CI). Low C-reactive protein was 
defi ned as values below 1.5 mg/l (median).
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DISCUSSION
This population-based study showed that fatty acid composition is associated 
with depressive disorders in the elderly after adjustment for demographic and 
biological variables. Subjects with depressive disorders had a moderately 
higher ratio of n-6/n-3 PUFAs, but differences in individual fatty acids were 
mostly small. However, depressed subjects with a normal CRP had a much 
more substantial shift in fatty acid composition. No difference in fatty acid 
composition was found between subjects with subclinical depressive symp-
toms and reference subjects.
Some methodological issues of the present study need to be discussed 
before we can interpret the findings. First, this is a cross-sectional study and 
cannot demonstrate whether depression precedes or follows from altered 
fatty acid composition. Although depressed subjects generally have less 
appetite it is not very likely that our results reflect this. Diet change would 
have to selectively affect percentage n-3 PUFAs and n-6/n-3 ratio but leave 
percentage saturated and monounsaturated fatty acids unaffected. However, 
the possibility that the intake of PUFAs changed after the onset of depression 
(e.g. eating less oily fish) cannot be ruled out. 
Secondly, the prevalence of subjects with depressive symptoms in this 
study (7.8%) was relatively low, but within the range (2.8% to 35%) reported 
in a recent review.28 It is also comparable to the prevalence in the US (9.0%).22 
Further, subjects with depressive disorders were slightly underrepresented 
in the analytical sample because they were less likely to visit the research 
center. However, we think it is unlikely that the observed relation between 
fatty acids and depression was due to a selection effect.
Strengths of the present study are its size, the population base and the psy-
chiatric work-up in subjects who were screen positive on the depression scale. 
We determined which depressive symptoms were due to depressive disor-
ders. Therefore, misclassification of disease is unlikely to have influenced our 
results. Also, we controlled for numerous confounders. Furthermore, we were 
able to separate the effects of smoking and atherosclerosis. To our knowl-
edge only three hospital studies investigated the n-6/n-3 ratio comparing 
depressed subjects with controls. Maes et al. repeatedly found a shift in the 
n-6/n-3 ratio10,16, in a recent study by Peet et al. the n-3/n-6 ratio did not differ 
between cases and controls.13 In the latter study concentrations of both total 
n-3 and n-6 PUFAs were higher in controls as compared to depressed subjects. 
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Others examined fatty acid composition along the worsening spectrum of 
depressive disorders, compared depressed to other psychiatric inpatients or 
focussed on n-3 PUFAs only.14,15,29 
Several mechanisms may be responsible for the observed association 
between fatty acid composition and depression. There is a large body of evi-
dence showing that fatty acid composition influences the biophysical proper-
ties of neuronal membranes.30 Via this pathway fatty acids have an impact 
on receptor function, neurotransmitter re-uptake and signal transmission. In 
animal models of depression it has been shown that diet can influence mem-
brane properties, n-3 PUFA enriched food for example augmented serotonin 
receptor sensitivity.3
Furthermore, a low ratio of n-6/n-3 PUFAs reduces the risk for vascular dis-
ease, presumably by affecting platelet aggregation, blood pressure or direct 
atherogenic effects.8,31,32 According to the vascular depression model vascu-
lar factors contribute significantly to the pathogenesis of depression. However, 
in the present study we found no indication that atherosclerosis is an interme-
diate between fatty acid composition and depression. The same holds for the 
immune activation. Our data suggest that acute phase proteins do not link 
fatty acids and depression, unless CRP is not specific enough to measure the 
immune process. Immune activation is associated with depression and an 
unfavorable n-6/n-3 ratio most probably stimulates the production of proin-
flammatory cytokines and other signs of the inflammatory response system.9 
It is assumed that high n-6 PUFA concentrations (especially arachidonic acid) 
can increase the production of proinflammatory prostaglandins whereas high 
n-3 PUFA concentrations (especially eicosapentaenoic and docosahexaenoic 
acid) may inhibit the formation of prostaglandine E2.
10,33 Indeed, the differ-
ences in PUFAs between depressed and reference subjects in our study were 
mainly due to the fatty acids associated with immune response. However, if 
immune modulation underlies the relationship we should have found more 
subjects with depression among those with both a high n-6/n-3 PUFA ratio 
and a high CRP.
Rather, the association between fatty acids and depression became stron-
ger with lower CRP concentrations. Different explanations for this interaction 
are possible. The acute phase response signaled by CRP is characterized by 
lipolysis.34 Fatty acids are mobilized from adipocytes and hepatocytes. It 
has been shown that the acute phase high-density lipoproteins have a dif-
ferent phospholipid composition than normal ones.35 This suggests that the 
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serum phospholipid fatty acid composition in the present study could be less 
informative with respect to long term dietary intake in the presence of high 
CRP. Another possible explanation is, that high CRP concentrations identify a 
subpopulation with more health problems, which in turn are associated with 
depressive disorders in late life. Biological risk factors for depression such as 
fatty acid composition could be relatively less important. On the other hand, 
low CRP values indicate the more healthy subjects and in them the relation 
of depression with fatty acid composition may not be diluted by other health 
related factors. 
In summary, we showed a different fatty acid composition in commu-
nity dwelling subjects with depressive disorders. Our data suggest that this 
is not secondary to smoking or cardiovascular risk factors and not linked 
to depression by atherosclerosis or the inflammatory marker CRP. The find-
ings make it more credible that relatively low concentrations of n-3 PUFAs 
have a direct impact on mood disorder. Specific diets might thus influence 
mood. Ultimately, clinical trials are necessary to prove whether diet change 
or fatty acid supplementation may play a role in prevention or treatment of 
depressive disorders. So far a positive effect of supplementation with the n-3 
PUFAs has only been shown for the short-term course of bipolar and recurrent 
depression.36-39
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ABSTRACT
Objective: To investigate the reported association between low vitamin E levels and 
depressive symptoms in a population based study.
Methods: The study is based on a cohort of 3,884 adults aged 60 years and over who par-
ticipated in the third survey of the Rotterdam Study, were screened for depressive symp-
toms with the Center of Epidemiological Studies Depression Scale and from whom blood 
was drawn. All screen positive subjects had a psychiatric work up. Blood levels of vitamin E 
were compared between 262 cases with depressive symptoms and 459 randomly selected 
reference subjects. All analyses were stratifi ed by sex, and adjusted for age, cholesterol, 
cognitive score, smoking, dietary supplement use, marital status, living alone, and func-
tional disability score.
Results: Vitamin E levels in men with depressive symptoms were lower than in non-
depressed men after adjusting for age, whereas no such difference was found in women. 
This association in men was substantially weakened after controlling for biological factors, 
and disappeared with additional adjustment for nutritional behaviour and social factors. 
No differences were observed when the analyses were restricted to cases with depression 
as defi ned in the Diagnostic and Statistical Manual of Mental Disorders IV.
Conclusions: After control for several biological and behavioural factors relating to health 
we found no association between low vitamin E levels and depressive symptoms or depres-
sion in the elderly.
HT43.indd   116 05-02-2003, 14:20:37
VITAMIN E
117
INTRODUCTION
Vitamin E is a dietary compound that functions as an antioxidant prevent-
ing lipid peroxidation.1,2 High levels of antioxidants have been reported to 
slow processes related to atherosclerosis, ageing, and selective neuronal 
damage.3,4 The role of oxidative stress in neurological diseases has received 
much attention in experimental studies.5 Depression, like dementia and stroke 
has been associated with impaired antioxidant defences, neuronal damage 
and vascular changes.6
On the basis of this argument the relationship of vitamin E and depression 
was investigated in two recent epidemiological studies by Maes et al.7 and 
Shibata et al.8 The first was a cross-sectional study in a psychiatric setting, 
whereas the latter was a population based study in the elderly with cross-
sectional and longitudinal analyses. Both studies reported an association 
between low vitamin E levels and depressive symptoms, although in the 
Japanese study this association was only observed in men. The relationship 
between vitamin E and depression, however, may also be explained by other 
biological and behavioural factors. Nutrition, cognitive and physical func-
tion are possible variables that are related to depression and might influence 
Vitamin E levels. Both quoted studies considered only biological variables 
and their approach may not have been adequate.
The aim of the present study was to examine the relation of vitamin E and 
depression with adequate control for possible confounding.
METHODS
Study population
This study is based on the Rotterdam Study, an ongoing population-based 
cohort study in the elderly. The Medical Ethics Committee of the Erasmus 
University approved the study and written informed consent was obtained 
from all participants. Measurements for the present study took place during 
the third examination, between March 1997 and December 1999 in which 
4,730 persons participated. Of these, 3,884 visited the research centre and 
had fasting venous blood samples drawn. In the present study, levels of vita-
min E were compared between 262 cases with depressive symptoms and 459 
randomly selected reference subjects.
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Depression assessment
Depressive symptoms were assessed using the Dutch version of the original 
Center for Epidemiology Studies Depression scale (CES-D). We used a cut-off 
(a score of 16), which had a very high sensitivity for major depression in a 
random sample of older subjects in the Netherlands.9 Screen positive subjects 
had a psychiatric work-up as a second step. They were evaluated with the 
Dutch version of the Present State Examination (PSE-10)10 and psychiatric dis-
orders were classified according to the Diagnostic and Statistical Manual of 
Mental Disorders-IV.
Of the 3884 subjects who visited the research centre and had blood taken, 
265 (6.8 percent) were screen-positive on the CES-D. Psychiatric disorders 
were defined in 249 (94 percent) of these participants. Six subjects were lost to 
follow-up or refused to participate in the psychiatric work-up. These subjects 
were excluded in the analyses that took the psychiatric work-up into account. 
Furthermore, blood samples of three screen-positive subjects could not be 
retrieved.
Laboratory assessment
Vitamin E was determined in plasma using a high pressure liquid chromatog-
raphy method.11,12 The intra-assay and interassay coefficients were 3.7 and 
3.2 percent, respectively.
Other measurements
The following variables were considered as possible confounders: age, 
gender, cholesterol levels, cognitive score, smoking, antidepressant drug use, 
dietary intake of antioxidants, dietary supplement use, marital status, living 
alone, level of education, and functional disability score. Dietary intake of 
antioxidants and dietary supplement use were assessed with a semiquantita-
tive food frequency questionnaire at baseline examination (1990-1993) only. 
Subjects who used supplement preparations that contained at least one of the 
antioxidants β-carotene, flavonoids, vitamin C or vitamin E, were classified as 
users of antioxidative supplements. The data for all other measurements was 
obtained during the third survey. Cholesterol was measured as total choles-
terol and HDL cholesterol in mmol/l, cognitive function was assessed with the 
Mini Mental State Examination. Functional status was assessed with the Dis-
ability Index of the Stanford Health Assessment Questionnaire which includes 
questions as whether subjects are able to do the shopping.13 All remaining 
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variables were measured with a dichotomised categorical variable. Marital 
status expresses whether the participant is widowed and living status whether 
the participant lives in a home for the elderly.
Statistical analysis
To assess the association between vitamin E and depressive disorders we 
used analysis of covariance. Vitamin E was entered as a continuous variable 
into the model. All analyses were also stratified for sex. To check whether 
confounding existed we compared the crude and the adjusted estimate of 
the association. The confounding variables were included if this affected the 
estimates.14 The results are presented in different models with adjustment for 
confounding by biological factors, nutritional behaviour and social factors. 
Next, we performed an analysis of covariance making a distinction between 
subjects with depressive disorders and subjects with subclinical depressive 
symptoms. Finally, a regression model was used to evaluate whether a pos-
sible sex difference in vitamin E levels could be explained by the confounders 
measured.
RESULTS
The mean age of the study population was 73.0 years (range 61 to 101). Sixty-
four percent of the sample was female.
We found lower levels in vitamin E in men with depressive symptoms as 
compared to men without depressive symptoms after controlling for age 
(Table 1). No such difference was found in women (Table 2). This association 
in men was substantially weakened after controlling for smoking, cognitive 
score and cholesterol levels. Additional adjustment for nutritional behaviour 
related variables further reduced the association and rendered it non-signifi-
cant. (Table 1)
To further examine the relationship between depression and vitamin E 
we performed separate analyses for cases with depressive syndromes and 
subclinical depressive symptoms and excluded subjects with psychiatric 
co-morbidity. The fully adjusted difference for depressed men (n=28) was -
0.09 µmol/l; 95% confidence interval (CI): -2.1, 1.9; p = 0.93 if compared to 
men without depressive symptoms. Male subjects with subclinical depressive 
symptoms (n=35) had lower vitamin E levels. The difference was -0.96 µmol/l 
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TABLE 2: Association between vitamin E levels and depressive symptoms in women 
(adjusted mean levels, adjusted differences and 95% confi dence intervals)a
Vitamin E levels (µmol/l) in women
Reference 
group
n=269
Subjects with
depressive symptoms
n=194
Difference 95% CI       p-values
Model 1b 28.4 28.7 0.2 -1.0, 1.4     p=0.70
Model 2c 28.4 28.8 0.4 -0.5, 1.4     p=0.37
Model 3d 28.4 28.9 0.5 -0.5, 1.4     p=0.33
Model 4e 26.0 24.9 0.4 -0.6, 1.4     p=0.41
a Analysis of covariance with vitamin E entered as a continuous variable.
b Model 1: Ancova adjusted for age, values represent mean differences, pairwise comparison with 
non-depressed group.
c Model 2: Ancova adjusted for age, smoking, cognitive score, total cholesterol and HDL choles-
terol.
d Model 3: As model 2 but additionally adjusted for dietary supplement use and functional disability 
score.
e Model 4: As model 3 but additionally adjusted for marital status and living situation.
TABLE 1: Association between vitamin E levels and depressive symptoms in men 
(adjusted mean levels, adjusted differences and 95% confi dence intervals)a
Vitamin E levels (µmol/l) in men
Reference 
group
n=190
Subjects with
depressive symptoms
n=68
Difference 95% CI       p-values
Model 1b 26.4 23.8 -2.6 -4.3, -1.0    p=0.002
Model 2c 26.2 24.6 -1.6 -2.9, -0.3     p=0.02
Model 3d 26.1 24.8 -1.4 -2.7, -0.02   p=0.05
Model 4e 26.0 24.9 -1.1 -2.5,  0.2     p=0.11
a Analysis of covariance with vitamin E entered as a continuous variable.
b Model 1: Ancova adjusted for age, values represent mean differences, pairwise comparison with 
non-depressed group.
c Model 2: Ancova adjusted for age, smoking, cognitive score, total cholesterol and HDL choles-
terol.
d Model 3: As model 2 but additionally adjusted for dietary supplement use and functional disability 
score.
e Model 4: As model 3 but additionally adjusted for marital status and living situation.
(95%CI: -2.65, 0.74; p = 0.27) compared to men without symptoms.
The sex difference in vitamin E levels observed in our data set (see Table 
1) was explained by the differences in cholesterol between men and women. 
If only gender is entered into the regression model the estimate for gender 
is highly significant (regression coefficient = 2.95; 95%CI: 2.0, 3.9; p < 0.001) 
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but it sharply drops and becomes non-significant if total cholesterol and HDL 
cholesterol are added (regression coefficient = 0.40; 95%CI: -0.40, 1.20; p = 
0.33).
DISCUSSION
We found no indication for a relation between vitamin E levels and depres-
sive symptoms in the present population-based study.
This is in contrast to the findings of Maes et al.7 who observed marked dif-
ferences in vitamin E levels in a clinical sample and the findings of Shibata 
et al.8 in men with depressive symptoms in the Tokyo Metropolitan Institute 
of Gerontology study.
We considered several possible explanations for these discrepant findings. 
Firstly, the populations were not alike with respect to age and severity of 
depression. The average age of the cases in the study of Maes et al. was 54 
years and although not explicitly mentioned we assume that all cases had a 
major depressive episode. However, in our study lower vitamin E levels were 
observed in less severely depressed men and women.
Secondly, Shibata et al. reported a positive association in the longitudinal 
but not in the cross-sectional analysis. They included the baseline depressive 
symptom score in the model of symptom change. This approach - although 
not uncommon in studies of the association between change in a risk factor 
and disease - produces biased results because of the phenomenon of regres-
sion towards the mean.15 The larger the effect of the regression towards the 
mean and the weaker the association between baseline and change, the 
more bias is introduced.16 In the study of Shibata et al., there was a significant 
cross-sectional association in an unadjusted model. Therefore, the association 
in their longitudinal analyses most likely results from the reported baseline 
association.
In both studies control for confounders may not have been adequate. 
Maes et al. used healthy controls and only adjusted for age, sex and LDL cho-
lesterol. Shibata et al. controlled for age, education, total cholesterol and total 
cholesterol minus HDL- cholesterol. Neither of the studies adjusted for smoking, 
cognitive function, social or dietary factors.
Finally, one could argue that our adjustment for nutritional behaviour and 
social factors is an over-correction. Possibly, the elderly who are widowed or 
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who cannot go shopping on their own get depressed due to poor vitamin E 
intake. The authors of the present study, however, prefer the interpretation 
that these factors are independently associated with depression and indicate 
a poor diet with a low vitamin E intake. Therefore, the fully adjusted model 
is the most adequate one. Antioxidant dietary intake as measured by the 
food frequency questionnaire is not included because it did not confound the 
relation between vitamin E levels and depression in the present study. This 
does not mean that there is no relation between intake and blood levels. The 
differences in normal nutritional intake may be too subtle to be detected with 
the method used in this study.17,18 
In summary, our findings do not support the hypothesis that depression 
and vitamin E levels are associated. In the present study, the observed dif-
ferences in vitamin E levels were largely due to confounding by biological 
factors and variables related to nutritional behaviour or social factors.
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ABSTRACT
Objective: The associations of vitamin B12, folate, and homocysteine with depression were 
examined in a population-based study.
Method: The authors screened 3,884 elderly people for depressive symptoms. Subjects with 
positive screening results had psychiatric workups. Folate, vitamin B12, and homocysteine 
blood levels were compared in 278 persons with depressive symptoms, including 112 with 
depressive disorders, and 416 randomly selected reference subjects. Adjustments were 
made for age, gender, cardiovascular disease, and functional disability.
Results: Hyperhomocysteinemia, vitamin B12 defi ciency, and to a lesser extent, folate 
defi ciency were all related to depressive disorders. For folate defi ciency and hyperho-
mocysteinemia, the association with depressive disorders was substantially reduced after 
adjustment for functional disability and cardiovascular disease, but for vitamin B12 this 
appeared independent.
Conclusions: The association of vitamin B12 and folate with depressive disorders may have 
different underlying mechanisms. Vitamin B12 may be causally related to depression, 
whereas the relation with folate is due to physical comorbidity.
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INTRODUCTION
Folate and vitamin B12 are involved in the one-carbon metabolism neces-
sary for the production of monoamine transmitters. Several case-control 
studies since the 1960s have shown high prevalences of folate and vitamin 
B12 deficiency in depression.
1 More recently, the total plasma homocysteine 
level was shown to be a sensitive marker of folate and vitamin B12 deficiency, 
and higher concentrations of homocysteine were observed in depressed 
patients.2 
Thus far we know of only one population-based study; that study3 con-
firmed that vitamin B12 deficiency was associated with depressive symptoms. 
However, folate deficiency and hyperhomocysteinemia were not related to 
depressive symptoms. The study was restricted to physically disabled women, 
and no clinical diagnosis of depression was made. In this study we examined 
the associations of folate, vitamin B12, and homocysteine with depression in 
community-dwelling elderly subjects in the Rotterdam Study who had a clini-
cal diagnosis of depression. 
METHOD
This study was conducted as part of the Rotterdam Study, a population-based 
study to which all inhabitants aged 55 years and over in a district of Rotter-
dam were invited in 1990–1993. In the third survey (1997–1999) we added 
assessments of depression to the study protocol. Of the 5,901 subjects who 
were invited, 4,730 participated in the home interview. Of these, 3,884 visited 
the research center and had overnight fasting blood samples drawn. Sub-
jects were screened for depressive symptoms during the home interview with 
the Center for Epidemiology Studies Depression Scale (CES-D Scale).4 This is a 
20-item self-report measure of symptoms experienced in the last week and is 
scored on a scale of 0 to 3 points. Subsequently, subjects with positive results 
in the screening (a score of 16 or higher) had a psychiatric workup with the 
Present State Examination. Psychiatric disorders were classified according to 
DSM-IV criteria. Of the subjects who visited the research center and had blood 
taken, 278 (7.0%) had positive screening results, and 262 (94.2%) of these 
were given psychiatric workups. Of these subjects, 112 fulfilled the diagnostic 
criteria for depression, i.e., major or minor depression or dysthymia. The sub-
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jects with depressive symptoms and disorders were compared with 416 com-
parison subjects randomly selected from the subjects with negative screening 
results. The study was approved by the Medical Ethics Committee of Erasmus 
University School. After complete description of the study to the subjects, writ-
ten informed consent was obtained. 
Serum folate and vitamin B12 levels were measured by using an immuno-
assay. The total plasma homocysteine level was determined with high-per-
formance liquid chromatography. To determine vitamin deficiency we used 
the following cutoffs, which correspond to the normal ranges of the assays 
and are described in the literature.3 Folate deficiency was considered present 
when the serum folate level was less than 11.4 nmol/liter and the homocyste-
ine level was higher than 13.9 mmol/liter. Vitamin B12 deficiency was defined 
as a level less than 258 pmol/liter. We defined hyperhomocysteinemia as a 
plasma level above 15.0 mmol/liter. 
The following variables were considered as confounders: age, gender, 
alcohol consumption, education, smoking, and cognitive function as mea-
sured by the Mini-Mental State Examination (MMSE). In additional analyses 
we also adjusted for functional status, blood pressure, and history of stroke 
and myocardial infarction. The latter were obtained through direct ques-
tioning and linkage with general practitioner records. Functional status was 
assessed with the Stanford Health Assessment Questionnaire.5 We used logis-
tic regression to assess the associations of hyperhomocysteinemia, vitamin B12 
deficiency, and folate deficiency with depressive disorders or symptoms. Fur-
thermore, differences in mean levels were tested with analysis of variance. 
Finally, we analyzed the relation between self-reported loss of appetite and 
vitamin deficiencies. For this the subjects’ score on the CES-D Scale item “I did 
not have any appetite” was entered in an age- and gender-adjusted model. 
RESULTS
The mean age of the study sample was 72.9 years (SD=7.1), 16% were smok-
ers, 11% had had a myocardial infarction, and 4% had had a stroke. The 
subjects with depressive symptoms were more likely to be female (73% versus 
58%, χ2=18.2, df=1, p<0.001), had a higher age-adjusted functional disabil-
ity score (mean=0.8, SD=0.6, versus mean=0.5, SD=0.4; F=47.7, df=1, 694, 
p<0.001), and had a lower MMSE score (mean=27, SD=2, versus mean=28, 
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SD=3; F=22.2, df=1, 694, p<0.001) than the nondepressed subjects. 
Among the 278 subjects with depressive symptoms and the 416 compari-
son subjects, hyperhomocysteinemia, vitamin B12 deficiency, and folate defi-
ciency were not associated with the presence of depressive symptoms (Table 
1). When we restricted the analysis to the 112 subjects fulfilling the DSM-IV 
criteria for depressive disorders, we found that subjects with vitamin B12 defi-
ciency were nearly 70% more likely than the comparison subjects to have a 
depressive disorder (Table 1). This association was independent of cardiovas-
cular factors and functional status. When adjusting for only age and gender, 
we also observed a significant association of hyperhomocysteinemia and 
a nonsignificant association of folate deficiency with depressive disorders. 
However, these associations disappeared after correction for cardiovascular 
factors and functional status. 
No substantial differences in mean levels of vitamin B12 and folate were 
observed between the subjects with depressive disorders or symptoms and 
the reference subjects (data not shown). The subjects with depressive disor-
ders had higher homocysteine levels (mean=11.7 µmol/liter, SD=5.9) than 
the reference subjects (mean=10.6, SD=3.7); the age- and gender-adjusted 
difference was 1.1 µmol/liter, and the 95% confidence interval (CI) was 0.3 
to 2.0 (p=0.01). However, adjustment for cardiovascular risk indicators and 
functional disability strongly decreased this difference, to 0.2 µmol/liter (95% 
CI=–0.7 to 1.1, p=0.66). 
Self-reported loss of appetite was not associated with vitamin B12 deficiency 
(odds ratio=1.03 per 1-point increase in symptom score, 95% CI=0.86 to 1.24, 
p=0.73), whereas it was significantly related to hyperhomocysteinemia (odds 
ratio=1.32, 95% CI=1.03 to 1.70, p=0.03); the relationship to folate deficiency 
fell short of significance (odds ratio=1.24, 95% CI=0.98 to 1.58, p=0.07). 
DISCUSSION
This population-based study shows that elderly persons with vitamin B12 
deficiency are more likely to have a depressive disorder. Furthermore, we 
observed a significant relationship of hyperhomocysteinemia and a nonsig-
nificant relationship of folate deficiency to depression that were due to physi-
cal comorbidity and cardiovascular risk factors in subjects with depression. 
Some methodological issues of the present study need to be considered. 
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First, this was a cross-sectional study; it cannot demonstrate whether the 
observed association with vitamin deficiencies precedes or results from the 
depression. Most important, lack of appetite is a cardinal feature of depres-
sion and could explain the association. Indeed, we observed a relationship 
of self-reported loss of appetite with hyperhomocysteinemia and folate defi-
ciency. However, no such relationship was found with vitamin B12 deficiency, 
and thus, appetite loss cannot account for the respective findings. Second, 
the prevalence of depressive symptoms (7.0%) was relatively low. However, it 
falls within the range (2.8% to 35%) reported in a review of the prevalence of 
depression among elderly people.6 A strength of this population-based study 
is the psychiatric workup of subjects who had positive screening results. There-
fore, misclassification of disease is unlikely to have influenced our results. 
The findings are consistent with the results of Penninx et al.3, who reported 
that physically disabled women with vitamin B12 deficiency were twice as 
likely to have severe depressive symptoms. However, they observed no 
association between homocysteine or folate and depression. The present 
study strongly suggests that the higher rates of depressive disorders in sub-
jects with low folate and high homocysteine levels are due to differences in 
cardiovascular factors and physical comorbidity. It is possible that earlier 
reports of a relation between folate deficiency and depression in psychiatric 
patients were confounded.1 The cardiovascular risk profile of the patients with 
depression might have been different from those of comparison subjects. On 
the other hand, it can be argued that adjustment for cardiovascular factors 
and functional disability is overcorrection. First, functional disabilities in daily 
activities, which include difficulties in shopping, may reduce the vitamin 
intake. It is plausible that depression develops thereafter as a consequence 
of low intake. Second, late-life depression might result from vascular diseases 
due to hyperhomocysteinemia. Adjustment for cardiovascular factors is 
appropriate only if one studies the direct effects of hyperhomocysteinemia 
that might be due to alterations in monoamine metabolism. In this case one 
should control for the fact that depression may also result from health impair-
ment or neuronal damage in patients with vascular disease. 
The effects of adjustment indicate that the associations of vitamin B12 and 
folate deficiency with depression have different underlying mechanisms. It 
has been reported3 that serum folate is more sensitive to nutritional intake 
than vitamin B12. Moreover, in the present study, folate but not vitamin B12 
deficiency was related to loss of appetite. In summary, this study suggests that 
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clinicians need to be aware of possible hyperhomocysteinemia in combina-
tion with cardiovascular factors or functional disability in depressed patients. 
Furthermore, vitamin B12 deficiency may be causally related to depression in 
the elderly. In view of the possible benefits of vitamin replacement, detection 
of this subgroup is important. 
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ABSTRACT
Background: Tetrahydrobiopterin is a cofactor in the synthesis of serotonin. Numerous small 
clinical studies investigated the association between biopterin and depression with con-
fl icting results. We studied the relation of plasma biopterin with depression in a population-
based study taking neopterin and folate levels into account. High neopterin levels may 
signal impaired biopterin biosynthesis. High folate levels increase biopterin biosynthesis.
Methods: We screened 3,884 adults aged 60 years and over for depressive symptoms and 
performed psychiatric interviews in screen-positives. Plasma pterins were determined in 
238 cases with depressive symptoms and 357 randomly selected non-depressed persons. 
Results: In the non-depressed the neopterin/biopterin ratio was negatively associated with 
folate (-0.21 per standard deviation (SD), 95% confi dence interval (CI)=-0.40, -0.02) but not 
in depressed subjects (0.01; 95%CI: -0.14, 0.17). Instead, in depressed persons high folate 
were accompanied by high neopterin concentrations (1.4 nmol/l per SD; 95%CI=0.41, 2.3). 
Furthermore, persons with low folate and a low neopterin/biopterin ratio had more depres-
sive symptoms (p=0.004 for interaction between folate and neopterin/biopterin ratio).
Conclusions: Our fi ndings suggest differences in pterin metabolism between depressed 
and non-depressed persons. Regulation of the biopterin homeostasis is complex and 
immunological, hormonal and genetic factors are involved. However, in some persons low 
folate levels probably cause depression in case of impaired pterin synthesis.
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INTRODUCTION
Tetrahydrobiopterin (BH4) is present in probably every cell or tissue of higher 
organisms. The best-established function of BH4 is that of a cofactor in the 
hydroxylation of phenylalanine, tyrosine and tryptophan.1 These are rate-
limiting steps in the synthesis of the monoamine neurotransmitters dopamine, 
serotonin and noradrenalin.  
Neurotransmitter metabolism in depression has been a major area of 
psychiatric research over the past 40 years. On the basis of experimental 
evidence from pharmacological, pathoanatomical and imaging studies in 
humans and animals monoamine theories of depression have been postu-
lated. According to the classic monoamine theory, functional deficiencies of 
catecholamines and serotonin in the brain play a crucial role in the patho-
genesis of depression.2,3 The theory has stimulated researchers to investigate 
the association of depression with potential markers of monoamine metabo-
lism.4 Against this background, numerous small clinical studies have tried to 
relate plasma concentrations of biopterins to depressive disorders in patients. 
However, the findings are conflicting; reduced and increased concentra-
tions of biopterin in depressed patients have been reported.5-10 More recently, 
neopterin and folates were investigated in this context.11,12 Increased neop-
terin may signal a failure to synthesize biopterin.13,14 Folates on the other hand 
increase the biosynthesis of biopterin and a salvage pathway for BH4 depends 
on dihydrofolate reductase.1,15
We examined the relation of biopterin and neopterin with depression in 
a large population-based sample of older adults. In particular, we sought 
to investigate whether this relation was dependent on folate levels. Demo-
graphic, clinical, and functional characteristics that may influence the report-
ing of depressive symptoms were controlled for.
SUBJECTS AND METHODS
Study population
This study is based on the third examination round of the Rotterdam Study, 
an ongoing population based cohort study in a district of Rotterdam.16 The 
Medical Ethics Committee of the Erasmus University approved the study and 
written informed consent was obtained from all participants. Measurements 
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took place between March 1997 and December 1999 and included a home 
interview and a visit to the research center. Of the 4703 persons over 60 years 
who participated in the home interview, 3,884 visited the research center, 
where blood was drawn. The 819 subjects who were not seen at the center 
were on average older (77.5 versus 72.3 years), more likely to be female 
(70 % versus 58 %) and had more depressive symptoms (12.2% versus 6.8%, 
overall prevalence 7.8%). From 3510 subjects blood samples were available 
for biochemical analysis. The 334 subjects in whom no or insufficient blood 
samples were available did not differ from the remainder in respect to age, 
gender and frequency of depressive symptoms. In the present analysis we 
compared plasma biochemical parameters between all non-demented sub-
jects with depressive symptoms and 357 randomly selected non-demented 
reference subjects.
Depression assessment
Depressive disorders were assessed using a two step procedure. First partici-
pants completed the Dutch version of the original Center for Epidemiologic 
Studies Depression scale (CES-D) during the home interview. The CES-D is a 20-
item self-reported measure of symptoms experienced in the last week includ-
ing a question on lack of appetite. Each item is scored on a scale of 0 to 3 
points. The criterion validity of the CES-D version is well established.17 We used 
a score of 16 as a cut-off, which had a very high sensitivity for major depres-
sion in elderly subjects in the Netherlands.18 Moreover, previous studies have 
verified that a score of 16 and above on the CES-D represents clinically signifi-
cant depressive symptoms.19 As a second step, screen positive subjects had a 
psychiatric work-up using the Dutch version of the Present State Examination 
(PSE-10), a semi-structured psychiatric interview included in the Schedules for 
Clinical Assessment in Neuropsychiatry.20 All interviews were conducted by 
one or other of two experienced clinicians. Psychiatric disorders were classi-
fied according to the Diagnostic and Statistical Manual of Mental Disorders-IV 
(DSM-IV) criteria with an algorithm based on the PSE-10 scores. The diagnos-
tic categories include major depression, dysthymia and minor depression as 
defined in the appendix of the DSM-IV.21
Of the 3510 subjects eligible for the present study, 243 (6.9 %) were screen-
positive on the CES-D. Five subjects with depressive symptoms were excluded 
because of dementia. The remaining 238 subjects were included in the analy-
sis of depressive symptoms. Of these, nine subjects refused the subsequent 
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psychiatric interview, and five screen positive subjects could not be reached. 
Psychiatric disorders were thus assessed in 224 (94 %) participants. Psychiatric 
work-up revealed that 91 cases had a depressive disorder as defined by the 
Diagnostic and Statistical Manual of Mental Disorders-IV. The remaining 133 
subjects were diagnosed as having depressive symptoms as part of anxiety 
or another psychiatric disorder (n=28) or did not meet criteria for an Axis I 
psychiatric disorder (n=105, subclinical depressive symptoms).
Selection of reference subjects
A sample of 357 participants ranging in age from 61 to 101 years, served as 
the reference group. They were randomly selected from the non-demented 
participants of the Rotterdam Study who were screen-negative for depression. 
We did not match on possible confounding variables in order to be able to 
study their effect on the relation between pterins (neopterin and biopterin) 
and depression. 
Blood specimens
Overnight fasting blood was collected under standardized conditions in a 10 
ml tube of ethylene diamine tetracetic acid (EDTA)-anticoagulated blood, put 
on ice directly and centrifuged at 2650g for 20 min. Plasma was separated, 
dispensed into two 1.5 ml aliquots and frozen within three hours at -80°C until 
analyzed. Plasma biopterin occurs as BH4 (active and main reduced form), as 
quinoid BH2 and oxidized biopterin. We measured total biopterin and neop-
terin (dihydroneopterin and neopterin) after acid oxidation of the reduced 
forms of both pteridines as described by Fukushima and Nixon (1980).22 
Plasma (0.4 ml) was oxidized in 0.1 ml 1 M trichloroacetic acid and 0.05 ml 
iodine solution (0.5% I2, 1%KI in 0.2 M trichloroacetic acid). After standing 60 
min under reduced light, excess iodine was reduced by the addition of 20 µl 
of 1% ascorbic acid solution and the mixture was centrifuged at 12 000 x g 
for 15 min at 4ºC. The supernatant (0.4 ml) was transferred to an amber glass 
vial and 10 µl was injected directly onto the analytical column using an HPLC 
system with an autosampler and a fluorescence detector as described previ-
ously.23 The intra-assay and interassay coefficients for neopterin were 2.4% 
and 3.8%, respectively, and for biopterin 2.1% and 2.8%, respectively.
The concentration of the serotonin metabolite 5-HIAA (5-hydroxyindole-
acetic acid) was analyzed by HPLC and electrochemical detection.24 Intra-
assay coefficient was 3.6% and interassay coefficient 4.2%.
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Serum folate concentrations measured by an immunoassay (Roche Diag-
nostics, Mannheim, Germany) were available in all participants but for four 
subjects with depressive symptoms and five reference subjects.25 
Other measurements
The following variables were considered as possible confounding variables: 
age, gender, level of education, history of stroke and myocardial infarction, 
cognitive function as measured by the Mini Mental State Examination, dis-
abilities in activities of daily living and cigarette smoking. Education was 
measured on an ordinal scale and later dichotomized at the median of the 
baseline sample into low and high education. A history of stroke or myocar-
dial infarction was obtained from all subjects through direct questioning and 
computerized linkage with general practitioner medical records. Cigarette 
smoking was scored in categories of current, former and never smoker. Dis-
abilities in activities of daily living were assessed using the score (continuous) 
of the Disability Index of the Stanford Health Assessment Questionnaire.26 This 
measure reflects the consequences of disease in terms of functional perfor-
mance and activities. 
Statistical analysis
First, we calculated the ratio between neopterin and biopterin. Subsequently, 
the associations of pterins, their ratio and 5-HIAA with depression were quan-
tified with logistic regression. We estimated odds ratios and 95 % confidence 
intervals (CI) for depressive symptoms and depressive disorders. The plasma 
concentrations and the ratio were entered into separate logistic regression 
models as continuous variables (divided by their standard deviation). 
Next, we included folate levels in our analyses of pterins and depression. 
First, we studied the association of folate with pterins and neopterin/biopterin 
ratio in depressed and non-depressed subjects using multiple regression 
analysis. Secondly, we examined whether there was an association between 
pterins and depression that depended on serum folate concentrations. For this 
aim, we entered folate concentrations and an interaction term between pter-
ins and folates into the models that already contained pterins. Primarily, this 
was done using the continuous variables and p-values for the multiplicative 
interaction term are reported. Because the interaction between two continu-
ous variables is difficult to interpret, we subsequently categorized folate con-
centration and compared neopterin/biopterin ratio with stratified analyses of 
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covariance. 
Age (continuous) and gender were controlled for in all analyses. To control 
for confounding we added all measured potential confounders to the basic 
model. Finally, all analyses were rerun and additionally adjusted for lack of 
appetite to check whether associations found were a consequence of poor 
dietary intake in depressed subjects.
RESULTS
The characteristics of the non-depressed persons and those with depressive 
symptoms and disorders are presented in table 1. Depressed subjects were 
more likely to be female, to have had a stroke or myocardial infarction, had 
higher levels of functional disability and lower cognitive scores.
Table 2 shows that in the unstratified analyses pterins, the neopterin/
biopterin ratio and 5-HIAA concentrations were not associated with depres-
TABLE 1: Characteristics of the study subjects 
Variables
Non-depressed
n=357
Depressive
symptoms†
n=238
Depressive
disorders†
n=91
Age, years, mean (range) 72.3 (61-101) 73.8 (61-93) 73.4 (61-97)
Gender, % female 59.4 73.5 72.5
Primary education only, % 50.1 55.9 57.1
MMSE-score, mean (SD) 27.8 (1.9) 27.1 (2.7) 26.7 (3.2)
History of stroke, % 2.2 6.3 8.8
History of MI, % 10.6 11.3 14.3
Smoking: current smoker, %
 ex-smoker, %
14.3
35.7
18.5
42.0
19.8
42.9
Functional disability score 0.5 (0.5) 0.7 (0.6) 0.8 (0.7)
Neopterin (nmol/l) 21.1 99.6) 21.6 (8.6) 22.7 (10.4)
Biopterin (nmol/l)  6.2 (1.4) 6.4 (2.5) 6.8 (3.9)
Neopterin/biopterin ratio  3.5 (1.7) 3.5 (1.4) 3.6 (1.6)
SD = Standard deviation, MMSE = Mini Mental State Examination, MI = myocardial infarction
† The category depressive symptoms includes all subjects with a Center of Epidemiological Studies 
Depression scale (CES-D) score ≥ 16.  The category depressive disorders includes only the cases with 
major or minor depression and dysthymia.
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sive symptoms or depressive disorders. The analyses presented were adjusted 
for age, gender, smoking, cognitive score, functional disability score, history 
of myocardial infarction and stroke. 
In both depressed and non-depressed subjects there was a trend for higher 
folate levels to be associated with higher biopterin concentrations (Table 3). 
However, the relation between folates and neopterin differed substantially 
between depressed and non-depressed persons. In subjects with depressive 
symptoms and depressive disorders higher folate levels were accompanied 
by higher neopterin concentrations, whereas this was not the case in the non-
depressed. In this group, higher folate concentrations were weakly related 
to lower neopterin levels. Finally, the neopterin/biopterin ratio was inversely 
related to folates in non-depressed but not in the depressed persons.
Next, we examined whether the relation between pterins and depression 
depended on serum folate concentrations. We found that in subjects with 
lower folate concentrations those with a lower neopterin/biopterin ratio were 
more likely to have a depression, whereas in subjects with higher folate levels 
a higher neopterin/biopterin ratio was associated with a higher risk of depres-
sion (p-values for interaction terms were 0.004 for depressive symptoms and 
0.04 for depressive disorders in fully adjusted models). Interaction with folate 
levels was also found for neopterin (p = 0.02 and p = 0.08, respectively) but 
TABLE 2: The association of pterins and 5-HIAA with depressive symptoms and depres-
sion, Rotterdam Study, 1997-1999
Depressive
symptoms*
(238 cases)
Depressive
disorder*
(91 cases)
Odds 
ratio
95% CI
Odds 
ratio
95% CI
Neopterin (per SD) 0.94 0.80, 1.10 1.02 0.83, 1,25
Biopterin (per SD) 1.02 0.90, 1.15 1.07 0.93, 1.23
Neopterin/biopterin ratio  (per SD) 0.93 0.77, 1.13 1.01 0.79, 1.29
 5-HIAA (per SD) 0.93 0.77, 1.12 1.05 0.82, 1.35
SD = standard deviation; CI = confi dence interval; 5-HIAA = 5-hydroxyindoleacetic acid
*The category ‘depressive symptoms’ includes all subjects who were screen positive, the category 
‘depressive disorder’ includes only the subjects with major or minor depression and dysthymia.
†Logistic regression analyses adjusted for age, gender, cognitive score, smoking, history of stroke 
and myocardial infarct; subjects (n=357) without depressive symptoms were used as the reference 
group. Infl ammation markers were analyzed as a continuous variable divided by one standard 
deviation.
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Figure 1: Association between plasma neopterin/biopterin ratio and depressive symptoms 
by tertiles of serum folate concentrations.
Mean plasma neopterin/biopterin ratio and upper limit of 95% confi dence intervals adjusted for age, 
gender, smoking, history of stroke and of myocardial infarction, cognitive score, and functional disabil-
ity score as calculated by analysis of covariance. Number of subjects with depressive symptoms were 
81, 70 and 83 in fi rst to third tertile and 111, 123 and 118 referent subjects, respectively.
Logistic regression was performed to test the interaction between neopterin/biopterin ratio and tertiles 
of folate on depressive symptoms, overall p=0.01.
not for biopterin (p=0.6 and p=0.9, respectively). 
Because the interaction between two continuous variables is difficult to 
interpret we categorized folate concentration and compared neopterin/
biopterin ratio with stratified analyses of covariance. We defined tertiles to 
have sufficient numbers of cases and referent subjects in each category. The 
interaction effects were tested with logistic regression and found to be com-
parable to the continuous model. Figure 1 shows that the neopterin/biopterin 
ratio between reference subjects and subjects with depressive symptoms dif-
fers in particular in subjects with low folate. Little differences were observed in 
the middle and upper tertile of folate concentration. The fully adjusted mean 
neopterin/biopterin ratios in the lower tertile were 3.5 and 4.1 for subjects 
with and without depressive symptoms, respectively, mean difference was 
0.6, 95% confidence interval (CI): 0.1, 1.2, p=0.04. The respective results for 
depressive disorders (figure 2) were 4.1 and 3.3, adjusted mean difference = 
0.8, 95% CI: 0-1.6, p=0.06. 
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Subsequently, we investigated whether 5-HIAA concentrations between 
subjects with and without depression differed according to folate levels. No 
differences were observed in the middle and upper tertile of folate concentra-
tion. Subjects with depressive symptoms and folate levels in the lower tertile 
had slightly lower 5-HIAA concentration than the reference subjects (4.1 
log (nmol/L) vs 4.0 log (nmol/L), mean difference 0.08; 95% CI: -0.01, 0.18, 
p=0.08, values were logtransformed to achieve a normal distribution).
Finally, all analyses were rerun with additional adjustment for appetite. 
Results did not change. 
DISCUSSION
In this large population-based study no association was found between 
plasma levels of pterins and depression. However, the relation between pter-
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Figure 2: Association between plasma neopterin/biopterin ratio and depressive disorders 
by tertiles of serum folate concentrations.
Mean plasma neopterin/biopterin ratio and upper limit of 95% confi dence intervals adjusted for age, 
gender, smoking, history of stroke and of myocardial infarction, cognitive score, and functional disabil-
ity score as calculated by analysis of covariance. Number of subjects with depressive disorders were 
37, 26 and 27 in fi rst to third tertile and 111, 123 and 118 referent subjects, respectively.
Logistic regression was performed to test the interaction between neopterin/biopterin ratio and tertiles 
of folate on depressive disorders, overall p=0.03.
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ins and folate concentrations was different for depressed and non-depressed 
persons. In depressed subjects higher folate concentrations were accompa-
nied by higher neopterin concentrations, whilst in the non-depressed partici-
pants folate was negatively associated with the neopterin/biopterin ratio. The 
difference between the two groups was most obvious at relatively low folate 
levels. Persons with low folate and a lower neopterin/biopterin ratio were 
more likely to have depressive symptoms than those with a higher ratio.
The strengths of this study are the large number of elderly people partici-
pating and its population-based design. The size of the study enabled us to 
detect interactions. A methodological limitation is the cross-sectional design. 
It is not possible to conclude whether depression follows or precedes the 
altered pterin metabolism. Furthermore, we determined pterin concentra-
tions in plasma and not cerebrospinal fluid. Because of the blood brain bar-
rier our observations reflect peripheral biopterin metabolism much more than 
brain metabolism. However, lumbar punction is not feasible in a population 
based study. 
Previous research on pterins and depression yielded conflicting results. 
High and low plasma biopterin levels as well as high and low plasma 
neopterin/biopterin ratios in depressed patients have been reported.5-10,12 
Other investigators interested in immunological aspects of depression have 
focussed on neopterin measurements only.27-29 Neopterin is released by acti-
vated macrophages and considered a marker of cell-mediated immunity. 
Some of these authors have reported increased plasma levels in patients as 
compared to normal controls.27,29
We found a relation between pterins and depression, but only when folate 
concentrations were taken into account. This may explain the conflicting 
observations on biopterin and neopterin/biopterin ratio in psychiatric research 
reported to date; interaction with folate concentrations was not considered. 
Previous studies examined the correlation between blood folate concentra-
tions and urinary or cerebrospinal liquor biopterin in depressed patients.10,30,31 
However, an association between plasma neopterin or neopterin/biopterin 
ratio and folates in community dwelling persons has, to our knowledge, not 
been investigated. 
Tetrahydrobiopterin (BH4) dependent enzymes include the phenylalanine, 
tyrosine, and tryptophan hydroxylases, the latter two being the rate-limiting 
enzymes for catecholamine and 5-hydroxytryptophan (serotonin) biosynthe-
sis.1 In the last ten years the molecular basis of biosynthesis and regeneration 
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of BH4 has been unraveled.
32 The de novo biosynthesis of BH4 is illustrated in 
figure 3. The first enzymatic step is the major controlling point for the biosyn-
thesis (see 1 in figure 3). The activity of the involved enzyme (can be stimu-
lated up to 100-fold.1 The figure also shows some of the many regulators of this 
enzyme, e.g. BH4 inhibits its activity (endproduct feedback).
33 The next step 
is rate-limiting because the activity of the involved enzyme in humans is low 
(see 2 in figure 3). Folates are closely related to the pterin metabolism. Tetra-
hydrofolate is required to form the starting molecule of the biosynthesis (not 
shown). Furthermore, a salvage and a regeneration pathway for BH4 exist. 
These are essential because de novo synthesis is not sufficient for controlling 
hepatic phenylalanine and brain monoamine neurotransmitter homeostasis.1 
The salvage pathway forms another link of folates with pterins as it depends 
on dihydrofolate reductase. In the brain dihydrofolate reductase concentra-
tions are low and hence regeneration dominates. However, the location of 
BH4 biosynthetic enzymes has not been studied extensively at the cellular 
level.1,13 Experimental evidence also supports the importance of folates. Some 
patients with BH4 deficiency benefit from folinic acid supplementation and 
BH4 synthesis in vitro is stimulated by tetrahydrofolate addition.
13,15 Experi-
mental studies suggest that a raised neopterin/biopterin ratio may imply a 
failure to synthesize BH4.
14 Furthermore, decreased biopterin levels have been 
described in the cerebrospinal fluid of Alzheimer and Parkinson patients.13
Our observations in non-depressed persons are compatible with the regu-
lation of peripheral BH4 homeostasis. In case of low folate levels de novo syn-
thesis may be insufficient and the activity of the salvage pathway enzyme 
limited.1 Consequently, biosynthesis would be stimulated via upregulation of 
the first enzyme. This increases the neopterin/biopterin ratio because the fol-
lowing enzymatic step is rate-limiting. However, we did not observed this in 
persons with depressive symptoms and disorders. Instead, the neopterin con-
centrations increased with higher folate levels. This suggests that low folate 
limit the biosynthesis of pterins in the depressed and that synthesis generally 
is upregulated as compared to the non-depressed.
Different explanations for an impaired or altered pterin metabolism in 
depressed subjects are possible. Many cell- and tissue-specific substances 
regulate the enzyme activity of biopterin synthesis at transcriptional, post-
transcriptional level or via an interacting protein.33 In humans pterin bio-
synthesis is controlled by hormones, cytokines and certain immune stimuli. 
Pro-inflammatory cytokines activate, whereas hormones such as corticoste-
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roids inhibit biosynthesis.1,33,34 Both the hormone and the immune system are 
implicated in the pathophysiology of depression.35,36 Hence, the dysregula-
tion of these systems could maintain or even precipitate a monoamine defi-
ciency if folate levels are low. The subtle differences in 5-HIAA concentrations 
between depressed and non-depressed subjects with low folates in our study 
are compatible with this interpretation. We may not have found differences 
in plasma biopterin concentrations between depressed and non-depressed, 
because decreased BH4 concentrations were concealed by normal total biop-
terin levels.7
Alternatively, an impaired regulation could signal a genetic disorder in 
pterin metabolism. Various rare, genetically determined abnormalities of the 
biopterin synthesis have been described.13 The 6-pyruvoyl-tetrahydropterin 
synthase deficiency for example is characterized by extremely high neop-
terin and low biopterin concentrations. However, little is known about any 
polymorphisms associated with biopterin levels in the normal range. Clini-
cal research has concentrated on identifying recessive traits in homozygote 
patients with extreme biopterin deficiencies. 
Our findings could shed light on the association between low folate status 
and depressive disorders. A large number of clinical studies since the 1960s 
reported a high prevalence of serum folate deficiency in depressed patients, 
though the nature of this association has remained obscure.37 Further, the 
association was not observed in this nor another population-based study after 
adjusting for confounders.25,38 The present results suggest that the interaction 
between folate and pterin metabolism may be relevant in depression. Effects 
of low folate could be diluted in many populations because deficiencies 
become a problem only if pterin synthesis is impaired. 
The findings provide initial evidence that there are differences in pterin 
metabolism between depressed and non-depressed persons. In some people 
depression could be due to insufficient biopterin synthesis when folate levels 
are relatively low. However, regulation of the biopterin homeostasis is com-
plex and different mechanisms may underlie impaired metabolism. Modula-
tions of enzymes by hormones or cytokines as well as genetic disorders need 
to be investigated in depressed persons.
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This thesis presents evidence on the role of biological factors in late life depression. All studies described in this work were based on the Rotterdam 
Study. This is an ongoing population-based cohort study among 7983 persons. 
In 1990 to 1993 all inhabitants aged 55 years or over living in a suburb in 
Rotterdam were invited to participate in the baseline examination. Screening 
for depressive symptoms was first performed in the second (1993-1995), but 
a psychiatric-work-up with a diagnostic interview was introduced only in the 
third examination (1997-1999). In total, 5901 persons of the baseline popu-
lation were alive and invited for this third round. Of these, 4,730 (response 
rate 80%) participated in the home interview and 4603 (97%) persons com-
pleted the screening for depressive symptoms. Subsequently, 4214 persons 
underwent physical examinations at the research centre. In additional home 
visits one or the other of two experienced clinicians assessed the symptoms 
of screen-positive subjects. Of the 363 persons with depressive symptoms, 337 
(93%) had a psychiatric interview. 
The merits and limitations of the studies in this thesis have been described 
in the previous chapters. In the general discussion I will elaborate only the 
most salient methodological issues pertaining to the research. Then I will sum-
marise the main findings. Finally, I will give a broad outlook on future studies 
needed.
1. STUDY DESIGN AND METHODOLOGICAL CONSIDERATIONS
1.1. Definition and measurement of depression
The criteria for depression of the American Psychiatric Association’s Diag-
nostic and Statistical Manual of Mental Disorders (DSM) have become the 
lingua franca for clinical research.1 Nevertheless epidemiological research 
frequently fails to adequately assess depression, in particular when psycho-
logical factors are not the primary outcome under study.2-4 Differences in 
definition have hampered comparison of results. Furthermore, comparability 
is difficult to achieve even when the well-defined and operationalised DSM 
criteria are employed. The diagnosis can be based on self-report, interview or 
observation and different instruments are available.5 
In the current study we used a two-step procedure to assess depressive 
disorders. We screened participants with the Dutch translation of the origi-
nal Center for Epidemiologic Studies Depression scale (CES-D). This version 
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includes items about positive emotions although these are not part of current 
concepts of depression.6 Besides, two items produce a gender bias.7 However, 
the CES-D is a frequently chosen self-report measure of symptoms and we 
were able to use an established cut-off score.8
Next, subjects with depressive symptoms had a psychiatric interview. We 
chose a semi-structured psychiatric interview, the WHO’s Schedules for Clini-
cal Assessment in Neuropsychiatry (SCAN).9 As opposed to a fully structured 
interview this instrument retains the features of a clinical examination. The 
psychometric properties of the SCAN have been studied in Dutch patients. An 
excellent agreement on the syndrome level and a substantial test-retest reli-
ability were found.10
Our approach enabled us to classify psychiatric disorders according to 
DSM criteria. In all our analyses we combined the diagnostic categories major 
depression, dysthymia and in addition, minor depression (as defined in the 
appendix of the DSM-IV). In the elderly, these syndromes have similar prog-
nosis and consequences for well-being and disability.11,12 Furthermore, the 
syndromes are difficult to delineate in the elderly; the validity of diagnostic 
criteria in this age group and certain standardised interviews can be ques-
tioned.13
The psychiatric interview made it possible to exclude subjects from our 
analyses in whom no depressive but an anxiety or another psychiatric dis-
order was diagnosed. Subjects who did not fulfil criteria for an Axis I disorder 
but had clinically relevant depressive symptoms could also be analysed. 
However, there is a confusion of terminology – the terms subthreshold or 
subclinical depression/depressive symptoms are used – and the group has 
an even more heterogeneous clinical presentation than the group of persons 
with depressive disorders.14 Even more importantly, the concept is linked to 
particular screening instruments used mainly in population-based studies.
1.2. The population-based approach
Numerous population-based surveys and cohort studies have looked at the 
prevalence, determinants and course of depressive disorders.15 However, 
biological parameters were rarely measured. Further, the large cohort stud-
ies with detailed physical examinations mostly included only very limited 
psychological assessments.3 The present study is one of the first attempts to 
investigate the relation of biological factors with depressive disorders in a 
population-based sample; so far they have been studied mostly in clinical 
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populations. Some differences between the two approaches will be high-
lighted in the following.
Firstly, the reference group is easier to define in population-based studies. 
We chose all non-depressed subjects or a random selection of these as the ref-
erent group. In clinical psychiatric epidemiology, the commonly chosen con-
trol group is the medical staff or healthy volunteers. The possibility of selection 
bias is obvious, but this is not a trivial problem to overcome. The lack of case-
control studies of depression that refer to a well defined study base is illustra-
tive of this design problem. Selecting an appropriate reference populations in 
clinical studies is a major challenge for psychiatric epidemiology. 
Secondly, the depressive disorders encountered in clinical or population-
based studies might differ. In the Netherlands, only 50% of cases with major 
depression receive some form of treatment in the course of 12 months,16 in 
the US around 30%.17 It is generally found that community cases have less 
severe disorders than those in treatment. That clinical severity is related to 
treatment is, of course, not surprising. However, in psychiatry the argument is 
taken further. For example, the US Substance Abuse and Mental Health Ser-
vice Administration decided that treatment of community cases with mental 
illness according to DSM criteria may not be a medical necessity because 
many are not severely ill.18 The question arises whether this has implications 
for research or reflects only a policy-oriented interpretation of epidemiologi-
cal data. The aetiology of depression might be different in community dwell-
ing persons. 
We conducted a psychiatric work-up that enabled us to study cases 
with more severe depressive symptoms separately. In all studies we ran 
analyses that were restricted to cases with DSM-IV depressive disorders and 
non-depressed reference subjects. The results were consistent for all but one 
possible risk factor (the vasomotor reactivity of cerebral arteries). We found 
stronger associations along the worsening spectrum of depressive symptoms. 
It cannot be ruled out, but seems unlikely, that the observed associations do 
not exist in subjects with even more severe depression. Furthermore, we were 
able to replicate most associations found in clinical studies. That some asso-
ciations disappeared after careful adjustment does not mean that the aetiol-
ogy differs between community dwelling and clinical populations. Rather, it 
makes it more likely that some clinical studies were flawed. Thus our results 
can probably be generalised to clinical populations.
Thirdly, the size of the study population is generally larger in population-
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based settings. Although not inherent to the design, clinical studies mostly 
do not exceed 50 depressed subjects, whereas the present population-based 
study included more than 250 subjects with clinically relevant depressive 
symptoms. 
1.3. Confounding
Confounding is by far the most likely cause of spurious associations.19 In 
essence, confounding is a problem of comparability.20,21 It can arise when 
there are differences in the comparison populations other than the determi-
nant under study. Any factor that correlates to the biological determinant and 
might have a different distribution between the depressed and non-depressed 
is a potential confounder. We did not match on any demographic variable 
or risk indicator in order to be able to study the effect of various variables 
on the relation between risk factors and depression. We did, however, select 
comparable groups. All participants were aged 60 and above and lived in 
one district of the city of Rotterdam. Further, we controlled for confounders by 
adjusting the data statistically. A comprehensive number of risk factors and 
indicators of depression were available for the analyses because the study 
was conducted in an ongoing cohort study. Nevertheless residual confound-
ing remains an issue in all observational research. Moreover, I will argue, the 
possibility of confounding is particularly present in studies of depression and 
what is a confounder or an intermediate may be less straightforward. 
The study on vitamin E (chapter 4.3) and depressive symptoms illustrates 
the complexity of confounding in psychiatric epidemiology. The relation 
between vitamin E and depressive symptoms was different in women and 
men and confounded only in the latter. Firstly, low cholesterol levels in 
depressed men biased the relation with vitamin E in plasma as this is bound 
to cholesterol. The smoking habits also differ between the non-depressed and 
depressed and had to be taken into account as they were related to vitamin 
concentrations. Next, we adjusted for frailty indicators such as functional 
disabilities and cognitive score, because depression and vitamin levels cor-
related with physical health. Finally, a third of the residual difference in 
vitamin E concentrations between depressed and non-depressed men could 
be explained by social factors. Widowhood and living alone, two markers 
of social support, were more frequent both in persons with depression and 
low vitamin E levels. Thus only by studying biological, social, demographic, 
medical and physiological factors could we control for confounding. 
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At the same time this example also shows the danger of overadjusting 
when one controls for confounding. Some factors could be an intermediate 
in the causal pathway between vitamin E and depression. Depression has 
reciprocal associations with many medical conditions and social variables. 
For example, there is some evidence that low vitamin E levels predispose to 
a number of somatic diseases (e.g. ischemic heart disease),22 which in turn 
cause depression. Adjusting for functional disabilities is thus debatable. To a 
certain extent this problem was also inherent to the cross-sectional design of 
our study (see also discussion of the cross-sectional design). 
Overadjustment can result not only from an intermediate. Bias through 
adjustment for confounders can also be introduced if a variable is causally 
related to the exposure but only correlated to the outcome.23 This is conceiv-
able in the current example. Functional disability could be a sequel of behav-
ioural changes accompanying depression (e.g. smoking). Some functional 
disabilities could also be related to depression because the proclivity to com-
plain may differ between depressed and non-depressed persons (information 
bias).
This kind of information bias is frequently discussed in observational studies 
on psychological factors and physical health. Very recently a study in Scot-
tish men was able to demonstrate it.24 The strong positive relation between 
psychological stress and coronary heart disease (as measured by hospital 
admissions for cardiovascular symptoms) disappeared when other outcome 
measures where used (cardiovascular mortality). In our study, we related 
depression to physiologic parameters only. These are considered objective 
measures of health status or health risk. Possible information bias is not likely 
to be due to the participants’ perceptions. One could argue, however, that our 
assessment of depression is biased, some persons complain more than others. 
On the other hand, this is part of the depressive syndrome. Thus in my view, 
measurement of the confounder is the most prominant problem related to this 
type of information bias. For example, there could be differential misclassifi-
cation of functional disability or poor cognitive score. This is another reason 
why adjustment is problematic.
Furthermore, what is judged to be confounding can occur by chance.25 
Strictly speaking this is not a problem of confounding bias. However, it is inti-
mately related to the way epidemiologists control for confounding. In most of 
our studies, we followed the approach recommended in standard epidemiol-
ogy textbooks and included only those variables that changed the measure 
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of association.26 If variables happened to decrease the strength of association 
by chance this selection biased the estimate. In our study we tested various 
other indicators of social support, nutritional behaviour or comorbidity. If the 
retained variables do not have the postulated causal association with depres-
sion our analyses were overadjusted. 
Finally, we may have missed potential confounders. This can never be 
ruled out in an epidemiologic study but it remains a pertinent issue in stud-
ies on vascular pathology, immunological activation and depression. All are 
related to countless chronic somatic conditions and residual confounding 
could explain our findings. However, even with complete data on all comor-
bid conditions it would be difficult to control for without means of data reduc-
tion.27 Including a large number of potential confounders leads to overfitted 
models and results cannot be generalized anymore.28 On the other hand, 
small effects of many confounders can add up (see again the example of 
vitamin E in men). 
1.4. Cross-sectional design
Cross-sectional studies have a poor reputation in epidemiological research. 
Rothman summarises the critique: “the cross-sectional approach can be 
viewed as a case-control study with an excessively large control group, with 
information from an inappropriate time period, and with a biased ascertain-
ment.”29 
The first point of criticism can be dealt with shortly. The present studies 
were conducted in the Rotterdam Study cohort. If assessment of biological 
factor was part of the routine examination in the third round we used all 
participating non-depressed subjects as reference. Otherwise, we restricted 
the analyses to depressed subjects and randomly selected referent subjects. 
Obviously, this is a more efficient, but not a more valid approach. Rather, a 
large control group can be an advantage if the confounding variables are 
substantially imbalanced.30 An adequate overlap of the confounding vari-
able will only be secured by matching or a large control group.
The current cross-sectional studies could be biased because subjects with a 
more chronic course of disease were more likely to be included as a case. The 
first step of our psychiatric work-up was based on an instrument screening for 
depressive symptoms in the last week. Thus subjects with short, self-limiting 
disease episodes and those treated successfully were included in the refer-
ence group. On the one hand, our results may be an underestimation of the 
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true association due to non-differential misclassification. We defined cases 
as those currently depressed and not asymptomatic subjects with a history 
of depression. In the first place a history of depression is difficult to establish. 
Secondly, this definition of depressive cases makes little sense if the risk factor 
is variable over time. 
On the other hand, the associations with biological factors could be overes-
timated in our study due to selection bias. Chronically depressed cases were 
overrepresented. However, we aimed to investigate whether the associations 
differed in the less severely depressed by performing separate analyses. The 
subthreshold groups included many subjects with shorter episodes of depres-
sion. Moreover, one can consider this more a problem of external validity. 
Our results apply to the typical late life depression which frequently is chronic 
or characterised by long periods with residual symptoms. 
Next, and most importantly, cross-sectional studies cannot demonstrate 
the temporal relation between risk factor and outcome, which is one of the 
most important criteria for causality.31 Ideally, the association between bio-
logical factors and depression should be studied prospectively in a cohort 
free of depression at baseline. In the present cross-sectional study temporal 
sequences had to be inferred very cautiously. Firstly, because the outcome 
may have influenced by the determinant. Depression brings about major 
behavioural and physiological changes. Secondly, some of the determinants 
of interest may be very variable in a subject over time. Then it becomes dis-
putable whether we can assume a cumulative effect caused the depressive 
symptoms.32
Both considerations most obviously bear on our studies that relate nutrient 
blood levels to depressive disorders. The respective findings will therefore be 
discussed examplarily. Reduced appetite is a symptom of depression and 
thus low folate, vitamin B12 or vitamin E levels may be a consequence of poor 
intake in the depressed. There is little longitudinal data on vitamin levels, but 
individual levels probably are not very stable.33 
As was discussed before, part of the association between vitamin E and 
depressive symptoms in men disappeared after adjustment for nutritional 
behaviour and social factors. This gave some indication of the temporal 
relation underlying the relation. Depression probably preceded a reduced 
intake. 
The nature of the association between depression and folate deficiency is 
less clear. In our study higher rates of depressive disorders were found in sub-
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jects with folate deficiency but this was due to differences in cardiovascular 
factors and physical comorbidity between the groups. In fact, this does not 
rule out that folate deficiency precipitates depression. However, other causal 
and temporal relations may seem likely. Folate deficiency could cause mor-
bidity, which in turn was prior to depressive symptoms. Alternatively, the 
reduced folate intake might be a result of disabilities that included difficulty 
to go shopping. Of course, depression could also have preceded a reduced 
intake of folates and morbidity. 
Adjusting for disability or comorbidity did not change the strong relation of 
vitamin B12 deficiency with depressive symptoms. This suggests that different 
mechanisms underlie the associations with depression. It makes it also more 
plausible that vitamin B12 deficiency directly caused depression than that 
folate deficiency did.
In the ongoing data-collection the incidence of depressive episodes is 
ascertained and we aim to prospectively study biological factors in depres-
sion. However, I would like to stress that a longitudinal design may not be 
able to give simple answers either. Firstly, depression is an episodic disorder 
and as many as half of the incident cases will have had prior depressive 
episodes.12 These prior episodes may have preceded and even caused the 
determinant of interest. It is hardly possible to exclude these subjects as a 
history of depression is difficult to establish in the elderly.34 On the other hand, 
it may not be necessary if one wants to study what maintains depression or 
causes recurrences in late life. Secondly, it is a big challenge to determine 
incident cases and in particular the incidence time of depression. Few longi-
tudinal studies were able to follow a sample intensively.12,35 Frequent remea-
surements or information from the interval period are exceptional. Thirdly, as 
noted before, many of the factors may not directly give rise to the depressive 
disorders. A common pathological process may underlie both depression and 
the biological factor, the causal pathway may be bi-directional or the depres-
sive symptoms secondary to physical disease that affected the variable of 
interest. In all instances, the temporal relation will be insufficient to establish 
a causal relationship. 
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2. MAIN FINDINGS
2.1. Frailty and depression
Population-based studies of depression mostly rely on self-reported measures 
of physical health. Frequently, functional limitations and the number of 
chronic conditions are assessed by asking patients explicitly whether they 
have certain problems.36,37 The result may be biased and more objective mea-
sures should be use to measure physical health.24 In our study we quantified 
physical health by constructing a study-specific frailty index. A multivariate 
score function was derived using baseline information from the Rotterdam 
Study on all available variables related to mortality. Demographic factors, 
medical problems, functional disabilities and indicators of health service use 
were included. However, most variables used were based on physiologic 
measurements. The score function was then employed to assess the physi-
cal health of depressed and non-depressed persons with data from the third 
examination round. 
We found a strong association between physical health and depressive 
symptoms in community dwelling older adults even when subjective mea-
sures of health were excluded. The frailty score of depressed persons was only 
moderately lower than that of persons with a history of a stroke. There was no 
indication that poorer health was related to more severe depressive disorders 
nor that a depressed subpopulation without somatic comorbidty can be dis-
tinguished in community-dwelling elderly. We concluded that a frailty index 
is an appropriate tool to study the health, defined as the mortality risk, and 
probably the etiology of late life depression. 
2.2. Vascular factors and late life depression
Several lines of evidence suggest that vascular disease may predispose to 
depression in late life. This vascular depression hypothesis is supported by 
the strong association of symptomatic and silent brain infarcts to subsequent 
depression.38 Subtle white matter and deep grey matter abnormalities were 
also found more frequently in depressed than in non-depressed persons.39 
Furthermore, prospective studies have reported that a prior history of depres-
sion is related to the subsequent development of ischaemic heart disease.40,41 
While generalised atherosclerosis remains the most likely explanation of these 
findings, a clear demonstration that depression is associated with vascular 
changes is still required.42 In this thesis we studied the association of hemo-
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dynamic changes in the brain, atherosclerosis and arterial stiffness at differ-
ent locations in the body with depression. To our knowledge none of these 
parameters has been studied in relation to depressive disorders in community 
dwelling subjects. Additionally, we studied cerebral small vessel disease as 
measured by MRI scanning of the brain. This was a longitudinal study of an 
association reported in several cross-sectional studies.4,43
• Generalised atherosclerosis – Subjects with atherosclerosis were more likely 
to be depressed. We found that a combined measure of extracoronary ath-
erosclerosis was related to both depressive symptoms and depressive dis-
orders although at some of the different locations the association was only 
moderate and non-significant. Further, we observed a substantial relation 
of severe coronary and aortic calcifications with depressive disorders.
Many clinical studies have been performed in patients with pre-exist-
ing vascular disease. These studies generally show a high risk of comorbid 
depression on survival after a cardiovascular event.44 To our knowledge 
the present study is the first to examine the relation between measures of 
atherosclerosis and depressive disorders in community dwelling subjects. 
Although it cannot establish the causal role of atheroscleroris it provides 
strong evidence that a generalized atherosclerotic process accompanies 
late life depression. Depression in late life and ischaemic heart disease 
could to a certain extent be manifestations of a common pathological 
process. 
• Arterial stiffness – Our study showed an association between arterial stiff-
ness and depression in the elderly. Persons with decreased distensibility of 
the carotid artery and those with increased carotid-femoral pulse wave 
velocity were more likely to have depressive symptoms. The association 
with arterial stiffness was stronger for depressive disorders meeting DSM-
IV criteria. Control for atherosclerosis, as measured by the ankle-to-bra-
chial index or presence of plaques in the carotid artery, did not change 
the associations. Neither correction for carotid plaques nor correction for 
peripheral arterial disease changed the point estimates. Only the adjust-
ment for aortic calcifications reduced the observed association between 
arterial stiffness and depressive symptoms. However, the presence of 
atheromatous plaques in the aorta is strongly correlated with decreased 
aortic distensibility. Adjusting for carotid plaques and peripheral arterial 
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disease was probably adequate to control for the effect of atherosclero-
sis. Thus our data suggest that the relation between vascular factors and 
depression may partly be caused by arterial stiffness.
• Cerebral hemodynamics – We found that depression in late life is associ-
ated with cerebral hemodynamic changes as assessed by transcranial 
Doppler ultrasonography. Subjects with depressive symptoms had a 
lower blood flow velocity and less CO2-induced vasomotor reactivity in 
the middle cerebral artery. Low blood flow may reflect an intrinsic prop-
erty of the vascular smooth muscle or cerebral metabolism. Metabolic 
autoregulation determines the flow velocity changes during cognitive 
activity.45 As reduced cognitive activity is a well-recognized symptom of 
depressive disorder, the low blood flow velocity in our study could be due 
to the diminished demand in depressive states and does not necessarily 
support the vascular hypothesis. Vasomotor reactivity, on the other hand, 
is a good indicator of microangiopathy.46 Less vasomotor reactivity signals 
that the cerebral arterioles are unable to dilate in order to compensate 
increased demand. Hence, vasomotor reactivity is a possible causal factor 
for depressive symptoms. 
• Cerebral small vessel disease – A total of 1077 non-demented elderly indi-
viduals underwent MRI images of the brain and assessment of depressive 
symptoms as part of the Rotterdam Scan Study in 1995 to 1996.43 Brain 
infarcts as well as the periventricular and subcortical white matter lesions 
visible on the MRI were rated. All persons were continuously monitored 
for mortality and major morbidity including depression. In 1999 to 2000, a 
total of 787 subjects were re-examined at the research centre.
This made it possible to examine longitudinally whether cerebrovas-
cular disease contributes to the pathogenesis of late-onset depression. We 
found that elderly people with brain infarcts, both symptomatic and silent, 
have a depressive disorder twice as frequently as those without infarcts. 
This suggests that ischaemic brain damage itself may lead to depressive 
symptoms. Brain infarcts on baseline MRI did not predict incident depres-
sive disorders in people without depressive symptoms at baseline, nor 
did periventricular white matter lesions. However, severity of subcorti-
cal white matter lesions predicted incident depressive disorders, both in 
persons with and without depressive symptoms at baseline. This supports 
HT5.indd   163 04-02-2003, 19:30:48
BIOLOGICAL FACTORS IN LATE LIFE DEPRESSION
164
the notion that vascular pathology plays an important role in the onset of 
late-life depression. 
2.3. Inflammatory, nutritional and metabolic factors in late life depression
Clinical and experimental studies suggest that depression is accompanied 
by immune dysfunction and more particularly by an enhanced production 
of pro-inflammatory cytokines.47,48 Cytokines modulate depressive symptoms, 
regulate the stress response and contribute to neurotoxicity. On this basis 
researchers have postulated a macrophage theory of depression and sug-
gested that cytokines are involved in the pathophysiology of depression.49 
This theory takes into account the altered levels of endocrine, nutritional and 
metabolic factors observed in depressed persons. We measured the inflam-
matory proteins interleukin-6 (IL-6), α1-antichymotrypsin (ACT) and C-reac-
tive protein as well as neopterin. Neopterin is produced by macrophages and 
considered an immune marker - apart from being related to the serotonin 
metabolism. Plasma fatty acid composition, which may influence the expres-
sion of immune markers was also determined. High n-6 polyunsaturated fatty 
acids (PUFA) concentrations can increase whereas high n-3 PUFA concentra-
tions may inhibit the formation of proinflammatory prostaglandines.    
• Inflammatory proteins – We investigated the relation of cytokine IL-6 and 
the acute phase proteins ACT and CRP with depression in the Rotterdam 
Study. Higher levels of IL-6 were observed in persons with depressive dis-
orders than in persons without depressive symptoms. This finding is in line 
with a previous population-based and a number of clinical studies.50,51 
Age- and gender-adjusted analyses of our data also suggested associa-
tions of ACT and CRP with depressive disorders, but these disappeared 
after adjustment for number of cigarettes smoked per day and stroke. 
For many years the finding that increased levels of acute phase proteins 
may occur in association with depression primarily emanated from one 
research group studying hospitalised patients and healthy controls.47,52 
Several confounding factors such as severity of symptoms, co-morbidity 
and tobacco dependence might have accounted for the heterogeneity in 
observations reported by other investigators. In the present study only IL-6 
was independently related to depression. Furthermore, part of this rela-
tion was explained by atherosclerosis. Most probably, not only a direct 
effect of cytokines in the brain plays a role, but inflammation is a marker 
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of a generalized pathophysiological process. Further analyses also dem-
onstrated that the association between inflammation markers and depres-
sion was not linear but suggested a threshold effect. This is compatible 
with observations in experimental studies that applied endotoxins intrave-
nously to stimulate an IL-6 response.53 Negative emotions were observed 
at IL-6 levels more than 20 times higher than those in our study, whereas 
moderately increased levels had a positive effect on mood. Thus there 
may be a threshold above which IL-6 has a negative effect on mood, and 
high concentrations could directly cause the depressed affect in a small 
group of community dwelling subjects. 
• Plasma fatty acid composition – We studied the plasma fatty acid compo-
sition in persons with depressive symptoms, including those with depres-
sive disorders, and randomly selected reference persons. In particular, we 
compared the n-3 and n-6 plasma polyunsaturated (PUFA) percentages of 
total fatty acids in blood and their ratio. Subjects with depressive disorders 
according to the DSM-IV criteria had a higher ratio of n-6/n-3 PUFAs, but 
differences in individual PUFAs were mostly small. So far fatty acid com-
position has been investigated only in a few small studies of depressed 
patients which reported large differences between depressed and non-
depressed persons.54,55 In our study we found that the relation between 
plasma fatty acids and depression depended on the level of inflammation 
marker CRP. The depressed subjects with normal CRP concentrations had 
much lower n-3 PUFA percentage and higher n-6/n-3 ratio as compared to 
the non-depressed subjects. There were no differences between depressed 
and non-depressed persons with high CRP. We assume that CRP indicates 
physical comorbidity and that differences may be easier to detect in a 
relatively healthy group. Three mechanisms could explain the importance 
of fatty acids. Fatty acid composition influences the biophysical properties 
of neuronal membranes. Via this pathway fatty acids have an impact on 
receptor function, neurotransmitter re-uptake and signal transmission.56 
Furthermore, a low ratio of n-6/n-3 PUFAs reduces the risk for vascular 
disease, presumably by affecting platelet aggregation, blood pressure or 
direct atherogenic effects.57 Finally, plasma fatty acids modulate immune 
activation.58 However, in our study adjustment for neither atherosclerosis 
nor CRP changed the results. This is most compatible with the postulated 
direct impact of fatty acid composition on mood.
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• Vitamin E – Vitamin E is a dietary compound that functions as an antioxi-
dant preventing lipid peroxidation. High levels of antioxidants have been 
reported to slow processes related to atherosclerosis, ageing, and selective 
neuronal damage.69 
Vitamin E levels in men with depressive symptoms were lower than in 
non-depressed men after adjusting for age, whereas no such difference 
was found in women participating in the Rotterdam Study. The association 
in men was weakened after controlling for biological factors such as cho-
lesterol. It disappeared after adjustment for nutritional behaviour such as 
supplement use and social factors such as marital status and living alone. 
In one previous study only men,70 in another women and men with low 
vitamin E status were more likely to be depressed.71 Probably, these were 
spurious findings because important confounders were not adjusted for.
• Vitamin B12, folate and homocysteine – Folate and vitamin B12 are involved 
in the one-carbon metabolism necessary for the production of monoamine 
transmitters. Several case-control studies since the 1960s reported a high 
prevalence of folate and vitamin B12 deficiency in depression.
67 More 
recently, total plasma homocysteine was shown to be a sensitive marker 
of folate deficiency and raised concentrations of homocysteine were 
observed in depressives.68
Similarly, we found that hyperhomocysteinemia, folate and vitamin 
B12 deficiency were more frequent in persons with depressive disorders. 
However, for folate deficiency and hyperhomocysteinemia the estimates 
were substantially reduced after adjustment for functional disability and 
cardiovascular disease, only for vitamin B12 the effect was independent of 
these factors. The association of vitamin B12 and folate with depressive dis-
orders may have different underlying mechanisms. Vitamin B12 could be 
causally related to depression, whereas the relation with folate was due 
to physical comorbidity.
• Pterins – Biopterin, neopterin and folate were studied in depressed and 
non-depressed persons participating in the Rotterdam Study. Tetrahydro-
biopterin (BH4) is a cofactor in the synthesis of the monoamine neurotran-
mitters dopamin, serotonin and noradrenalin.59 Neopterin, also considered 
an immune marker, may signal a failure to synthesise the active biop-
terin.60 Folates, on the other hand, increase the biosynthesis of biopterin 
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and a salvage pathway for BH4 depends on dihydrofolate reductase. Pre-
vious research on pterins and depression yielded conflicting results. Higher 
and lower plasma biopterin levels were found in depressed subjects as 
compared to controls.61-63 Other investigators reported higher and lower 
plasma neopterin/biopterin ratios in depression.64
We found that the relation between plasma pterins and folate con-
centrations was not the same in depressed and non-depressed persons. 
In depressed subjects higher folate concentrations were accompanied 
by higher neopterin concentrations. In the non-depressed the neopterin/
biopterin ratio was associated with folate levels. The differences between 
the two groups were most obvious at relatively low folate levels. Persons 
with low folate and a low neopterin/biopterin ratio were most likely to 
have depressive symptoms. This may explain the conflicting findings of 
other groups.
Further, our observations in the non-depressed are compatible with the 
regulation of peripheral BH4 homeostasis.
59 With lower folates concentra-
tion BH4 levels decrease and biosynthesis is stimulated via upregulation 
of an enzyme. Because the subsequent enzymatic step is rate-limiting the 
intermediary product accumulates. Neopterin is derived from this interme-
diary. Thus the neopterin/biopterin ratio rises. In persons with depressive 
symptoms and disorders this was not the case, which suggests an impair-
ment of the metabolism. This could be due to pathophysiologic regula-
tion of biopterin synthesis that is controlled by hormones and immune 
stimuli.65 Both the hormone and the immune system are implicated in the 
pathophysiology of depression. Hence, the dysregulation of these systems 
could maintain or even precipitate a monoamine deficiency especially if 
folate levels are low. Alternatively, an impaired regulation could signal a 
genetic disorder in pterin metabolism.66 
The findings provide initial evidence that there are differences in pterin 
metabolism between depressed and non-depressed persons. It is prema-
ture to speculate over a causal role of pterins in depression. The regula-
tion of the biopterin homeostasis is complex and different physiological 
mechanisms may underlie impaired metabolism. Modulations of enzymes 
by hormones or cytokines as well as genetic disorders need to be investi-
gated in depressed persons.
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3. OUTLOOK
This thesis was devoted to biological correlates of depression in community 
dwelling subjects. However, due to the cross-sectional design causality could 
only be inferred tentatively from the observed relationships. Prospective 
follow-up studies are, notwithstanding the possible problems inherent to stud-
ies on depression, a better tool to detect aetiologic mechanisms. 
A prominent issue in geriatric psychiatry in need of longitudinal research 
are vascular factors. Most studies in this field are associative rather than 
causal. Moreover, the few existing prospective studies suffer from the short 
follow-up time and were able to study the persistence of depressive symp-
toms only.72 If the evolving evidence on vascular depression is substantiated 
this has wide implications. It suggests the possibility of a treatment more akin 
to the management of cardiac disease or hypertension. 
The same holds for the nutritional factors studied in this thesis. They offer 
the chance to find new treatments or ways of prevention. Studies presented in 
this thesis suggest that nutritional factors may play a role in the onset or main-
tenance of depressive symptoms in the elderly. However, it is premature to 
speculate on clinical implications. Prospective population-based studies are 
needed to demonstrate the relation of vitamin B12, folate and polyunsaturated 
fatty acids with depression. Ultimately, only clinical trials can prove the effi-
cacy of supplements or dietary change. Even apparently robust findings from 
observational studies in nutritional epidemiology have not been confirmed 
by randomized clinical trials.33,73,74
Longitudinal studies are also necessary to show how depression increases 
the risk of cardiac morbidity and mortality. A number of epidemiological 
studies have reported a history of depression to be associated with sub-
sequent ischaemic heart disease.3 However, the nature of this association 
is unclear. The possible mechanisms include (1) depression is a marker of 
pre-existing, sub-clinical coronary disease, (2) side effects of antidepressant 
drugs, (3) poor adherence to medical treatment regimens, (4) behavioural 
changes that increase the effect of cardiac risk factors such as smoking or a 
poor diet, (5) depression is part of a pathological process encompassing gen-
eralised atherosclerosis or inflammation, (6) neuroendocrine function, and (7) 
altered autonomic tone. Of particular potential interest is cortisol excretion as 
an indicator of the hypothalamic-pituary axis. Both hypo- and hyperactivity 
has been reported but many studies were restricted to severely depressed 
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in-patients.75 The advance of saliva sampling made it easier for researchers 
to study the cortisol rhythm in community dwelling subjects.76 Another prom-
ising lead is altered autonomic tone. Depressed patients display signs, such 
as elevated heart rate, decreased heart rate variability, and increased physi-
ological reactivity to environmental stressors, which may indicate a predispo-
sition to cardiovascular disease.77 Furthermore, thyroid function must also be 
considered as an integral part of the neuroendocrine system and thus studied 
out of aetiologic and prognostic interest.78,79
For many decades psychiatric and social epidemiologists considered only 
a limited number of biological variables such as stress hormones.80 Since the 
beginning of the 1990s this has changed, vascular factors, immunological 
markers and metabolic parameters are reconsidered. However, it is still a 
common mistake to regard one mechanism only. It is not unreasonable to 
try to measure all variables in one cohort study.3 Biological mechanisms must 
be studied jointly and only combined analyses will permit to assess what 
are independent or intermediate factors. Psychiatric researchers are finally 
conducting large studies in close collaboration with basic science, radiology, 
medicine, and epidemiology. 
Neuroimaging is becoming increasingly important as a means to investi-
gate the pathophysiology of depresion. MRI has now been used in a number 
of population-based studies and the modern concept of vascular depression 
is intrinsically related to this technique.39,72,81,82 Structural imaging studies may 
be able to show volume loss or neuronal damage in specific brain areas 
of depressed persons. Functional MRI not only provides excellent spatial 
resolution but adds information on brain metabolism and blood flow.83 The 
procedures require considerably less cooperation than before from the study 
subjects, but so far the costs and time constraints preclude the use in large 
populations.84 Thus valid case-control designs are called for.
Genetics is perhaps the most frequently named area of future psychiatric 
research.85 The rapidly evolving field of genetic epidemiology, however, will 
struggle with the limitations that psychiatric nosology remains at a syndro-
matic level. Non-specific behavioural symptoms rather than pathophysiology 
define depressive disorders. Psychiatrists do not regard depressive disorders 
as a single entity, but no consensus exists which subgroups to differentiate.5 
Consequently, links between the broad spectrum of depressive syndromes 
and a single genetic polymorphism will be difficult to establish. I believe that 
behavioural genetic research in the elderly will book little progress unless 
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more sensitive designs are employed (e.g. population isolates and twin regis-
tries) or the limitations of psychiatric nosology are overcome.
Thus another challenge for future research lies in dealing with the het-
erogeneity of depressive syndromes. Different approaches are possible. One 
path traditionally pursued by biological psychiatrists is to employ physiologi-
cal variables as a marker of subgroups. Dexamethasone suppression test,86,87 
latency to rapid eye movement sleep88 and hypercortisolism have been 
used.89 This approach could be rewarding if scientists realized more than in 
the past that the underlying pysiological measures are continuous variables. 
Hence, sophistacted statistical methods may be needed to identify subgroups. 
Secondly, pure depressive disorder – persons without severe comorbidity 
– may be of particular interest not only in clinical trials.90 In the individual 
case it is pointless to allocate depressive syndromes exclusively to categories 
such as endogenous or reactive to a somatic condition. However, our study 
on frailty in late life depression suggested that somewhat more homogenous 
strata of community dwelling subjects can be defined. Thirdly, researchers 
may want to focus on specific behaviours and emotions.91,92 Thorough psy-
chiatric assessment permits analyses of subjects with melancholic features 
or psychomotor retardation. Finally, psychiatric co-morbidity could be taken 
into account more. Depression frequently coexists with anxiety, somatization 
or sleeping disorders.90 Depression with these co-occuring disorders has dif-
ferent risk factors and takes a different course.93 It may have been fruitless to 
define a distinct clincal category of mixed anxiety-depressive disorder, but 
one could investigate biological factors related to anxiety-depression comor-
bidity.94 
In any case, none of the suggested approaches can be pursued without 
adequately assessing depression and related psychiatric disorders. Further-
more, researchers should also use DSM categories to ensure comparibility, 
although in the past the success of this classification system may have obfus-
cated the search for causes. Epidemiological research will otherwise allow 
no meaningful interpretation. Unfortunately, investigators have introduced 
conditions which are not clearly related to current psychiatric concepts. They 
were termed vital exhaustion,95 hopelessness,2 depressive traits,96 compli-
cated grief97 or lack of emotional well-being.98 All of these conceptions are 
characterized by symptoms of depression. However, the investigators failed to 
adequately assess depression, because it was not the primary psychological 
risk factor studied.
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EPILOGUE
More than anything the studies presented in this thesis have generated 
hypotheses for future research. Some biological factors emerged as intriguing 
candidates for etiologic research. Our studies made out possible risk factors 
for depression. However, I regard it as equally important that we demon-
strated a complex or confounded relation between other biological factors 
and depression. We also proved that a population-based approach is of value 
for biological psychiatry. There is no question that large studies are needed 
to integrate physiological findings with social and psychological variables. 
Thus in the ongoing follow-up round of the main study we collect longitudinal 
data on depression and biological variables and additionally assess other 
psychiatric disorders, social support, quality of life, functional disability and 
grief in late life. 
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6.1 SUMMARY
Depression in late life is emerging as a major health problem. Because of the 
increase in the proportion of elderly in the population and the high preva-
lence of depression it imposes a severe burden on public health. Biological 
factors are closely related to depression in the elderly and have been studied 
for more than hundred years. Clinical studies showed that factors such as vas-
cular pathology, immune activation or nutritional deficiencies play a role in 
the aetiology and pathogenesis of late life depression. The aim of the present 
thesis was to examine the associations between biological factors and depres-
sion in a large sample of community-dwelling elderly. The basic idea of this 
thesis is that it is possible to learn something about possible causes and con-
sequences of depression in the elderly by well controlled studies of correlates. 
To investigate these issues, we used data from the third examination in the 
Rotterdam Study. This is a large ongoing population-based study of the total 
population aged 55 years and over in the district of Ommoord in Rotterdam.
In chapter 2, we constructed a quantitative measure to assess physical 
health in the elderly. A study-specific frailty score was calculated using base-
line information from the Rotterdam Study on all variables related to mortality. 
We showed that physiological measurements, which can be assessed more 
objectively, generally performed better in mortality risk assessment than self-
reported information. Using the frailty score we found a strong association 
between physical health and depressive symptoms in community dwelling 
older adults even when subjective measures of health were excluded. The 
frailty score of depressed persons was only slightly lower than that of persons 
with a history of a stroke. 
In chapter 3, studies of the relation between vascular factors and depres-
sion are described. Chapter 3.1 shows that subjects with atherosclerosis were 
more likely to be depressed. We found that an overall measure of extra-
coronary atherosclerosis was related to depressive disorders. Further, we 
observed a strong relation of severe coronary and aortic calcifications with 
depressive disorders, the relative risks of depressive disorders were 2.0 and 
3.7, respectively. Although this study cannot establish the causal role of ath-
erosclerosis it provides evidence that a generalised atherosclerotic process 
accompanies late life depression. In chapter 3.2 the results pertaining to 
associations between arterial stiffness and depressive disorders in the elderly 
are presented. Persons with decreased distensibility of the carotid artery and 
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those with increased carotid-femoral pulse wave velocity were more likely 
to have depressive symptoms. The association with arterial stiffness was 
stronger for depressive disorders meeting DSM-IV criteria. Control for athero-
sclerosis, as measured by the ankle-to-brachial index or presence of plaques 
in the carotid artery, did not change the associations. In the following we 
examined depressed and non-depressed persons with functional and struc-
tural imaging techniques of the brain. A study of cerebral hemodynamics 
as assessed by transcranial Doppler ultrasonography is presented in chapter 
3.3. We found that depression in late life is associated with cerebral hemody-
namic changes. Subjects with depressive symptoms had a lower blood flow 
velocity and less CO2-induced vasomotor reactivity in the middle cerebral 
artery. However, the low blood flow may reflect reduced cognitive activity 
and does not necessarily indicate vascular pathology in depressed persons. 
Low vasomotor reactivity, on the other hand, is a good indicator of microan-
giopathy and signals that the cerebral arterioles are unable to dilate in order 
to compensate increased demand. We also investigated cerebral small vessel 
disease in a large group of persons who underwent MRI images of the brain 
and were followed up to assess incident depression. This study is presented 
in chapter 3.4 and shows that elderly people with brain infarcts, both symp-
tomatic and silent, have a depressive disorder twice as frequently as those 
without infarcts. This suggests that ischaemic brain damage itself may lead 
to depressive symptoms. Furthermore, we found that severity of subcortical 
white matter lesions predicted incident depressive disorders, both in persons 
with and without depressive symptoms at baseline. The studies in chapter 3 
all support the notion that vascular pathology plays an important role in the 
onset of late-life depression. 
Chapter 4 contains fives studies in which the relation of inflammatory, 
nutritional and metabolic factors with late life depression is examined. First, 
we investigated the plasma levels of cytokine interleukin-6 (IL-6) and the 
acute phase proteins α1-antichymotrypsin and C-reactive protein (CRP) in 
depressed and non-depressed persons. A current theory suggests that depres-
sion may be precipitated by an immune dysfunction. In chapter 4.1 we report 
that only IL-6 was independently related to depression, whereas the relation 
between acute phase proteins and depression disappeared after adjustment 
for number of cigarettes smoked per day and stroke. Furthermore, part of the 
relation between IL-6 and depression was explained by atherosclerosis. Most 
probably, cytokines are a marker of a generalised pathophysiological process 
HT6.indd   180 05-02-2003, 14:25:46
181
and do not only signal a direct immune activation in the brain of depressed 
persons. Next, we studied the plasma fatty acid composition in persons with 
depression and randomly selected non-depressed persons. In chapter 4.2, we 
compared the n-3 and n-6 plasma polyunsaturated (PUFA) percentages of 
total fatty acids in blood and their ratio in depressed and non-depressed per-
sons. Plasma fatty acid composition can influence the expression of immune 
markers. We found that persons with depression had a higher ratio of n-6/n-
3 PUFAs than the non-depressed, but differences in individual PUFAs were 
mostly small. Further, we observed that depressed subjects with normal CRP 
concentrations had a much lower n-3 PUFA percentage and higher n-6/n-3 
ratio as compared to the non-depressed subjects with normal CRP levels. We 
assume that CRP indicates physical comorbidity and that differences may 
be easier to detect in a relatively healthy group. In chapter 4.3 we describe 
the relation of plasma vitamin B12, folate and homocysteine with depression. 
Folate and vitamin B12 are necessary for the production of monoamine neu-
rotransmitters, whereas total plasma homocysteine is a sensitive marker of 
folate deficiency. Like other investigators before, we found that hyperhomo-
cysteinemia, folate and vitamin B12 deficiency were about twice as frequent 
in persons with depressive disorders as in the non-depressed. However, for 
folate deficiency and hyperhomocysteinemia the estimates were substantially 
reduced after adjustment for functional disability and cardiovascular disease, 
only for vitamin B12 the effect was independent of these factors. This suggests 
that vitamin B12 could be causally related to depression, whereas the relation 
with folate is due to physical comorbidity. In chapter 4.4 we focus on another 
nutritional factor, vitamin E. This is a dietary compound that functions as an 
antioxidant. High levels of antioxidants possibly slow processes related to 
atherosclerosis, ageing, and selective neuronal damage. The plasma vitamin 
E levels in men with depressive symptoms were lower than in non-depressed 
men participating in our study, whereas no such difference was found in 
women. However, the association in men was weakened after controlling 
for biological factors such as cholesterol and disappeared after adjustment 
for nutritional behaviour such as supplement use and social factors such as 
living alone. This strongly suggests that the association previously observed 
in men was a spurious finding. In chapter 4.5 the relation between plasma 
concentrations of biopterin, neopterin and folate with depression is examined. 
Tetrahydrobiopterin (BH4) is a cofactor in the synthesis of the monoamine neu-
rotransmitters. Neopterin may signal a failure to synthesise the active biop-
SUMMARY
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terin, whereas folates increase the biosynthesis of biopterin. We found that 
the relation between plasma pterins and folate concentrations was not the 
same in depressed and non-depressed persons. In depressed subjects higher 
folate concentrations were accompanied by higher neopterin concentrations. 
In the non-depressed only the neopterin/biopterin ratio was associated with 
folate levels. Our observations in the non-depressed are compatible with the 
regulation of peripheral BH4 homeostasis. However, in persons with depression 
this was not the case, which suggests an impairment of the metabolism. This 
could be due to an altered regulation of biopterin synthesis, which is con-
trolled by hormones and immune stimuli, in depressed persons. 
In chapter 5, the general discussion, some of the methodological issues 
involved in the studies are discussed. The chapter focuses on the assessment 
of depressive symptoms in population-based studies, the design and possible 
bias by confounding. Furthermore, our findings are reviewed. The last part 
of this chapter provides a more general view on opportunities for population-
based studies of late life depression. Particular emphasis lies on the limita-
tions and chances of future research that includes assessment of biological 
factors.
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6.2 SAMENVATTING
Depressie op oudere leeftijd is een toenemend gezondheidsprobleem. Omdat 
het percentage ouderen in de bevolking stijgt en depressie veel voorkomt bij 
ouderen, drukt depressie steeds zwaarder op de gezondheidszorg. Biologische 
factoren zijn vaak in verband gebracht met depressie op oudere leeftijd en de 
relatie wordt al meer dan honderd jaar onderzocht. Klinische studies hebben 
aangetoond dat factoren zoals vasculaire pathologie, immuun activatie, 
of voedingsdeficiënties een rol spelen in de etiologie en pathogenese van 
depressie op oudere leeftijd. Het doel van dit proefschrift was om het verband 
te bestuderen tussen biologische factoren en depressie in een grote steekproef 
van ouderen in de algemene bevolking. Het uitgangspunt is dat men iets kan 
leren over mogelijke oorzaken en gevolgen van depressie op oudere leeftijd 
door correlaties te bestuderen. Hiertoe maakten wij gebruik van gegevens uit 
de derde onderzoeksronde van de Erasmus Rotterdam Gezondheid en Oude-
ren (ERGO) studie. Dit is een grootschalig, langlopend bevolkingsonderzoek 
onder de totale bevolking van 55 jaar en ouder in de wijk Ommoord te Rot-
terdam.
In hoofdstuk 2 wordt de constructie beschreven van een kwantitatieve 
maat om de fysieke toestand van ouderen vast te stellen. Een ‘frailty score‘ 
werd berekend op basis van alle beschikbare determinanten binnen de 
ERGO studie die gecorreleerd waren aan mortaliteit. We konden aantonen 
dat fysiologische maten, welke objectief vastgesteld kunnen worden, beter 
waren in het voorspellen van het mortaliteits risico dan zelf gerapporteerde 
informatie. Met behulp van deze ‘frailty score’ vonden we een sterk verband 
tussen fysieke gezondheid en symptomen van depressie in ouderen, ook als 
subjectieve gezondheidsmaten werden geëxcludeerd. De ‘frailty score’ van 
depressieve personen was slechts iets lager dan die van personen die een 
herseninfarct hadden doorgemaakt.
In hoofdstuk 3 worden studies naar de relatie tussen vasculaire factoren 
en depressie beschreven. In hoofdstuk 3.1 wordt aangetoond dat personen 
met arteriosclerose een grotere kans hebben om depressief te zijn. We vonden 
dat een gecombineerde maat voor extracoronaire arteriosclerose gerelateerd 
was aan depressieve stoornissen. Verder zagen we een sterke relatie tussen 
ernstige coronaire en aorta calcificaties en depressie: relatieve risico’s op een 
depressieve stoornis waren 2.0 en 3.7, respectievelijk. Hoewel deze studie niet 
een causaal verband kan aantonen, levert het wel bewijs dat een gegenera-
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liseerd atherosclerotisch proces samengaat met depressie op oudere leeftijd. 
In hoofdstuk 3.2 worden de resultaten gepresenteerd betreffende de associ-
atie tussen vaatwandstijfheid van slagaders en depressieve stoornissen bij 
ouderen. Personen met een afgenomen distensibiliteit van de halsslagader en 
degenen met een toegenomen polsgolfsnelheid tussen de halsslagader en de 
liesslagader hadden een grotere kans op het hebben van depressieve symp-
tomen. De associatie met vaatwandstijfheid was sterker voor een depressieve 
stoornis volgens de DSM-IV criteria. Correctie voor arteriosclerose, bepaald 
door de enkel-arm index of de aanwezigheid van plaques in de halsslagader, 
gaf geen verandering in de associatie. Vervolgens onderzochten we depres-
sieve en niet-depressieve personen met behulp van functionele en structurele 
beeldvormende technieken van de hersenen. Een studie naar de hemody-
namica van de hersenen, gemeten door transcraniële Doppler echografie, is 
beschreven in hoofdstuk 3.3. We vonden dat depressie op oudere leeftijd is 
geassocieerd met hemodynamische veranderingen in de hersenen. Personen 
met depressieve symptomen hadden een lagere stroomsnelheid van het 
bloed en een mindere CO2-geinduceerde reactivatie van de middelste cere-
brale arterie. Echter, de verminderde doorstroming kan een afname in cogni-
tieve activiteit weerspiegelen en is niet noodzakelijkerwijs een indicatie voor 
vasculaire pathologie bij depressieve personen. Anderzijds, een afgenomen 
reactivatie is een goede voorspeller voor microangiopathie en duidt op een 
onvermogen van cerebrale arteriolen om te verwijden ter compensatie van 
een toegenomen vraag. Tevens hebben we afwijkingen in de kleine bloed-
vaten van de hersenen onderzocht binnen een grote groep personen die een 
MRI scan hadden ondergaan en vervolgens in de tijd werden vervolgd op 
het optreden van depressie. Deze studie, beschreven in hoofdstuk 3.4, toont 
aan dat personen met een herseninfarct, zowel symptomatisch als niet-symp-
tomatisch, twee maal zo vaak een depressieve stoornis hebben als personen 
zonder herseninfarct. Deze bevinding suggereert dat ischemische schade 
aan de hersenen op zichzelf tot depressieve symptomen kan leiden. Verder 
vonden we dat de ernst van subcorticale witte stof afwijkingen voorspellend 
is voor het optreden van een depressieve stoornis, zowel in personen met als 
zonder depressieve symptomen aan het begin van de studie. Alle studies in 
hoofdstuk 3 ondersteunen het idee dat vasculaire pathologie een belangrijke 
rol speelt bij depressie op oudere leeftijd. 
Hoofdstuk 4 bevat vijf studies waarin de relatie tussen ontsteking, voe-
ding, metabole factoren, en depressie op oudere leeftijd wordt bestudeerd. 
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Ten eerste onderzochten we de bloedspiegels van de cytokine interleukine-6 
(IL-6) en de acute fase eiwitten α1-antichymotrypsine en C-reactief proteïne 
(CRP) in personen met en zonder depressie. Een huidige theorie suggereert 
dat depressie wordt onderhouden door een immuun stoornis. In hoofdstuk 4.1 
rapporteren we dat alleen IL-6 onafhankelijk gerelateerd was aan depressie, 
terwijl de relatie tussen acute fase eiwitten en depressie verdween na correc-
tie voor roken en het doorgemaakt hebben van een herseninfarct. Daarnaast 
kon een deel van de relatie tussen IL-6 en depressie worden verklaard door 
arteriosclerose. Waarschijnlijk zijn cytokines een uiting van een gegenerali-
seerd pathofysiologisch proces en niet een kenmerk van selectieve immuun 
activatie in de hersenen van depressieve personen. Vervolgens bestudeerden 
we de samenstelling van vetzuren in plasma van personen met depressie en 
een willekeurig geselecteerde groep niet-depressieve personen. In hoofdstuk 
4.2 vergeleken we het percentage n-3 en n-6 meervoudig onverzadigde 
vetzuren (MOVZ) ten opzichte van het totale vetzuur gehalte en hun ratio in 
depressieve en niet-depressieve personen. De samenstelling van vetzuren in 
het plasma kan de expressie van immuun eiwitten beïnvloeden. We vonden 
dat personen met depressie een hogere n-6/n-3 MOVZ ratio hadden dan niet 
depressieven, maar verschillen in individuele MOVZ waren klein. Ook zagen 
wij dat depressieve personen met een normale CRP concentratie een veel 
lager n-3 MOVZ gehalte en een hoger n-6/n-3 ratio hadden in vergelijking 
met niet-depressieve personen met een normaal CRP gehalte. We veronder-
stellen dat CRP een indicatie is voor fysieke comorbiditeit en dat een verband 
makkelijker aan te tonen is in een relatief gezonde groep. Hoofdstuk 4.3 
beschrijft de relatie tussen plasma vitamine B12, foliumzuur en homocysteïne, 
en depressie. Foliumzuur en vitamine B12 zijn noodzakelijk voor de productie 
van monoamine neurotransmitters, terwijl homocysteïne een gevoelige indi-
cator is voor foliumzuur deficiëntie. Evenals andere onderzoekers vonden wij 
dat veel homocysteïne en een tekort aan foliumzuur en vitamine B12 ongeveer 
twee maal zo vaak voorkwamen bij personen met een depressieve stoornis 
als bij niet-depressieve personen. Echter, in het geval van foliumzuur defi-
ciëntie en hyperhomocysteïne werd deze risico schatting beduidend zwakker 
na correctie voor functionele stoornissen en cardiovasculaire aandoeningen, 
terwijl alleen voor vitamine B12 het effect onafhankelijk was van deze fac-
toren. Dit suggereert dat vitamine B12 mogelijk causaal gerelateerd is aan 
depressie, terwijl de relatie met foliumzuur het gevolg is van comorbiditeit. 
In hoofdstuk 4.4 richten we ons op een andere voedingsfactor, vitamine E. 
SAMENVATTING
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Dit is een voedingsbestanddeel met een anti-oxidatieve werking. Een hoge 
concentratie anti-oxidanten kan mogelijk processen als arteriosclerose, ver-
oudering, en selectieve neuronale schade vertragen. Het vitamine E gehalte 
in mannen met depressieve symptomen bleek lager te zijn dan in mannen 
zonder depressie, terwijl geen verschil werd gevonden bij vrouwen. Echter, 
de associatie bij mannen werd zwakker na correctie voor dieet gedrag, zoals 
het gebruik van supplementen, en sociale factoren, zoals alleen wonen. Dit 
is een sterke aanwijzing dat de eerder beschreven associatie bij mannen een 
onjuiste bevinding was. In hoofdstuk 4.5 is depressie onderzocht in relatie tot 
het plasma gehalte aan biopterine, neopterine en foliumzuur. Tetrahydrobiop-
terine (BH4) is een cofactor in de synthese van monoamine neurotransmitters. 
Neopterine duidt op een stoornis in de vorming van het actieve biopterine, 
en foliumzuur verhoogt de biosynthese van biopterine. Wij vonden dat de 
relatie tussen plasma concentraties van pterines en foliumzuur niet hetzelfde 
waren in depressieve en niet-depressieve personen. In personen met depres-
sie gingen hogere foliumzuur concentraties gepaard met hogere neopterine 
concentraties. In niet-depressieven was alleen de neopterine/biopterine ratio 
geassocieerd met het foliumzuur gehalte. Onze observaties bij niet-depressie-
ven zijn in lijn met de regulatie van het BH4 homeostase. Echter, dit was niet 
het geval bij personen met een depressie, wat een stoornis in dit metabolisme 
suggereert. Dit zou het gevolg kunnen zijn van een verstoorde regulatie van 
biopterine synthese, welke gecontroleerd wordt door hormonen en immuun 
stimuli, bij depressieve personen.
Hoofdstuk 5 bevat de algehele discussie van het proefschrift waarin enkele 
methodologische aspecten van de studies worden besproken. Het hoofdstuk 
richt zich op de diagnostiek van depressieve symptomen in bevolkingson-
derzoeken, het ontwerp van de studie, en mogelijke bias door confounding. 
Verder worden alle bevindingen samengevat. Het laatste deel van dit hoofd-
stuk geeft een bredere kijk op de mogelijkheden van bevolkingsonderzoek 
naar depressie op oudere leeftijd. De nadruk ligt hierbij op de beperkingen 
en uitdagingen voor toekomstig onderzoek op het gebied van biologische 
factoren.
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